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Abstract 
 
Chemokines are extracellular signalling molecules which function as 
chemoattractants for leukocytes by directing their migration towards sites of 
inflammation as part of the immune response. On epithelial cells chemokine 
receptor expression is normally low or absent. However during cancer 
progression, chemokine receptors can become overexpressed on cancer 
cells, whilst chemokines are frequently present at sites of metastasis. 
Consequently aberrant chemokine signalling is associated with both 
metastasis and a poor prognosis in cancer patients. The chemokine signalling 
network is therefore consider a potential therapeutic target for cancer 
treatment. The aim of the research undertaken in this thesis was to identify 
novel therapeutic targets involved in chemokine downstream signalling in 
cancer cells. 
To investigate the chemokine downstream signalling pathway, a number of 
different chemokines and small molecules were used with their effects on 
cellular intracellular calcium signalling and migration of different leukemic and 
carcinoma cells assessed. 
The findings from the screen identified a role for CCL2 and CCL3 signalling in 
the migration of PC-3 and MCF-7 cells respectively. In MCF-7 cells, CXCL12 
intracellular calcium signalling was shown to be dependent on Gαi, Syk/Src, c-
Raf, DOCK1/2/5 and Arp2/3. With DOCK1/2/5 also shown to be essential for 
CCL3 and CXCL12 intracellular calcium signalling in both MCF-7 and THP-1 
cells, as well as for CXCL12 chemotaxis of Jurkat cells. For Arp2/3 its 
importance in chemokine signalling was specific to MCF-7 cells, whilst the 
roles of the microtubules and FAK were dependent on both the chemokine and 
cell type. 
In this thesis DOCK1/2/5 was identified as a novel target for blocking leukemic 
T-cell migration (Jurkats) in response to CXCL12. In addition, Arp2/3 and the 
microtubules were implicated in chemokine signalling and therefore would 
warrant further investigation to establish their importance in cancer cell 
migration.  
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1.0     Introduction 
 
1.1 Cellular Signalling 
Cells are considered the most basic unit of life and as such perform 
fundamental biological processes including growth, migration and respiration. 
Within the cell, proteins interact with one another and other molecules giving 
rise to biochemical pathways which regulate these biological processes [1].  
For these biological functions to be possible a cell must respond to the 
chemical, physical and biological composition of its external environment [2]. 
To achieve this cells have evolved the ability to communicate with their 
surroundings through a mechanism known as cellular signalling allowing the 
cell to not only detect changes in their surroundings but also influence them 
[3, 4]. 
In principle cellular signalling is when an external molecule (ligand) binds and 
activates a protein (receptor) on or within the cell [4, 5]. Signals at the cellular 
membrane can be relayed inside the cell by non-protein molecules such as 
nucleotides or ions and are commonly referred to as secondary messengers. 
These secondary messengers can activate various intracellular proteins to 
initiate signal transduction [6]. Alternatively the cytosolic side of the receptor 
can also interact with intracellular proteins to activate signal transduction. 
These activated proteins act as effectors to either reduce or increase 
enzymatic activity and/or gene transcription. The end result of the signalling 
pathway is a cellular response which often involves a physiological change, 
such as migration, division or death (apoptosis) [3-5] (figure 1.1). 
Due to the importance of cellular signalling, many of the molecular 
mechanisms involved have been conserved through evolution [7-10]. 
Nonetheless, a variety of different signalling pathways present in cells has 
arisen, with each pathway encompassing its own distinct set of proteins, 
molecules and function [11, 12]. These differences can also depend on the 
organism type, such as between prokaryotes and eukaryotes [13] or plants 
and animals [14], and most likely reflects their diverging needs.  
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Within the animal kingdom, cells have four main types of signalling pathways 
according to the receptor type: ion channels, enzyme linked receptors, guanine 
nucleotide-binding protein (G-protein) coupled receptors and intracellular 
receptors [3, 4]. 
 
`    
Figure 1.1. Overview of a general transmembrane cellular signalling 
pathway. 
 
1.2 G-protein Coupled Receptors 
1.2.1 Structure 
The G-protein-coupled receptor family (GPCRs) are the largest group of 
receptors in mammalian cells numbering above 800 [15]. GPCRs are 
characterised by their distinct seven transmembrane α-helical domains (7TM), 
which are connected by three extracellular and three intracellular loops. On 
the extracellular face is the N-terminal tail which varies in length depending on 
the receptor. Whilst the C-terminal tail resides on the cytosolic side of the 
receptor [16] (figure 1.2).  
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Figure 1.2. The general structure of GPCRs (image taken from [17]). 
 
The extracellular residues of the GPCR are important for ligand-receptor 
interactions, with the N-terminal tail a common site for ligand binding. The 
extracellular loops are also key for ligand binding, as well as receptor activation 
[18, 19]. Receptor activation induces a conformational change in the 7TM, 
which  recruits the G-protein to the intracellular loops for downstream signalling 
[18]. One particularly important G-protein binding site is the highly conserved 
Asp-Arg-Tyr motif on the second intracellular loop (IL2), known as the DRY 
motif. The arginine in the DRY motif forms an ionic salt-bridge with the 
glutamate on the third intracellular loop (IL3), to stabilise the receptor’s inactive 
conformation [20]. Upon receptor activation, the conformational change allows 
the DRY motif to become a main binding site for the G-protein [21]. Following 
receptor activation, the serine/threonine residues on the C-terminal tail 
become phosphorylated by the G-protein-coupled receptor kinase (GRK), 
which desensitises the receptor to ligand stimulation. These phosphorylated 
serine/threonine residues recruit β-arrestin to promote receptor internalisation 
and thereby regulate receptor signalling [22].  
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1.2.2 Classification 
Despite the universal 7TM, GPCRs display considerable variability in both their 
amino acid sequences, as well as, the N-terminal tail structures, and therefore 
can be further categorised into six discreet classes: A, B, C, D, E and F.  
The vast majority of GPCRs are class A receptors (80%), known as rhodopsin-
like receptors, and have an 8th α-helix and a palmitoylated cysteine on the C-
terminal tail [23]. In the receptors inactive state, the Phe residue of the 8th α-
helix, forms a hydrophobic bond with the Tyr in the NPxxY motif on the 7th α-
helix. This 8th α-helix has shown to be important for receptor signalling [24].  
Examples of class A GPCRs include chemokine receptors, opoid receptors 
and β-adrenergic receptors. Class B GPCRs, known as the Secretin receptor 
family, feature a 120 amino acid long N-terminal tail, which is stabilised by 
disulphide bonds. Class C receptors, have a long 600 amino acid, distinctive 
clam shaped, N-terminal tail and are commonly referred to as metabotropic 
glutamate receptors. The other remaining GPCR classes, are the class D: 
fungal mating pheromone receptors, class E: cyclic adenosine 
monophosphate (cAMP) receptors and class F: frizzled/smoothened [23]. 
 
1.2.3 Heterotrimeric G-protein Signalling 
GPCRs are coupled to the heterotrimeric G-protein, which consist of the Gα, 
Gβ and Gγ subunits. In its inactive state the Gα subunit of the G-protein is 
bound to guanosine diphosphate (GDP) [25]. Upon GPCR activation, the G-
protein is recruited to the intracellular loops, which catalyses the exchange of 
GDP for guanosine triphosphate (GTP), to activate the G-protein. GTP binding 
reduces Gα affinity for the Gβγ subunits, causing the G-protein to dissociate 
into the Gα and Gβγ subunits, which are then free to bind and activate various 
effectors [26] (figure 1.3). The Gα subunit is divided into four main classes: 
Gαs (stimulatory), Gαq, Gαi (inhibitory) and G12: each of which has its own 
distinct mode of signalling (figure 1.3) [26].  
Gαs activates adenylate cyclase (AC) to generate the secondary messenger: 
cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP), 
whilst Gαi has the oppositie effect to Gαs and inhibits AC activity. Hence, Gαs 
   
 
24 
 
is referred to as stimulatory, whilst Gαi as inhibitory [25]. For Gαq and G12 their 
known downstream effectors are phospholipase C (PLC)-β and Rho guanine 
exchange factor (RhoGEF) respectively [27]. Gαq activation of PLC leads to 
the mobilisation of calcium ions (Ca2+) from the intracellular stores through the 
cleaving of phosphatidylinositol 4,5-biphosphate (PIP2): to produce inositol 
1,4,5-triphosphate (IP3). IP3 opens the IP3 channels present on the intracellular 
calcium stores [28].  
Receptor coupling of different Gα classes is not mutually exclusive and GPCRs 
can activate more than one type of Gα subunit [27]. This allows GPCRs to 
activate multiple different signalling pathways, thereby producing a variety of 
cellular physiological changes in response to the stimuli. Besides the Gα 
subunit, the Gβγ heterodimer is also able to mediate its own separate 
signalling pathways by directly interacting with a variety of different effectors 
including phospholipase Cβ2 (PLC2), phosphoinositide 3-kinase (PI3K)γ, 
GRK, AC and Ca2+ ion channels  [26, 29] (figure 1.3). 
The Gα subunit has an intrinsic GTPase activity and eventually hydrolyses 
GTP to GDP, allowing the Gα and Gβγ subunits to reassociate into their 
inactive state, as a means of self-regulation. This process is facilitated by 
GTPase activating proteins (GAPs) [26, 30]. 
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Figure 1.3. Overview of heterotrimeric G-protein signalling (Image 
adapted from [31, 32]). (a) Ligand binds to the GPCR which recruits the G-
protein to the intracellular loops to facilitate the exchange of GDP for GTP on 
the Gα subunit of the G-protein [25]. (b) The activated G-protein then 
dissociates into the Gα and Gβγ subunits. The four different Gα subunit 
classes: Gαs, Gαq, Gαi and G12, each activate their own separate intracellular 
signalling pathway. The Gβγ is also able to directly activate several effectors, 
such as PLC and PI3K [26]. 
 
1.3 Chemokine Receptors  
Chemokine receptors are members of the class A, rhodopsin-like family of 
GPCRs [33], of which 23 have been discovered in humans [34]. Amongst the 
23 chemokine receptors, 4 are classified as atypical chemokine receptors 
(ACKR) and cannot signal via the heterotrimeric G-protein due to an absent or 
altered DRY motif [35]. For “typical” chemokines receptors, they are primarily 
coupled to the Gαi/βγ heterotrimeric G protein and thus are sensitive to 
pertussis toxin (PTX) [36-39] which specifically blocks Gαi/βγ signalling 
through the attachment of an ADP-ribose onto the cysteine residue of the Gαi 
subunit [40]. Nonetheless, despite this sensitivity to PTX, incidences of 
chemokine receptors signalling via Gαq have also been observed [41, 42]. 
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1.4 Chemokines 
Chemokines are small extracellular cytokines (8-11 kDa in size), which are 
synthesised and secreted by cells [43]. Chemokines were first discovered in 
1987 [44, 45], with at least 50 identified in humans since [46]. As there are 50 
chemokines and only 20 chemokine receptors, many chemokine receptors can 
be activated by several different chemokines. In addition, a large number of 
chemokines also display similar levels of promiscuity for receptor binding 
(figure 1.4). This overlapping of ligand-receptor binding originally led many 
researchers to postulate that there was a high level of functional redundancy 
involved in chemokine signalling [47].  
 
 
Figure 1.4. Chemokines and their respective cognate receptors (Image 
adapted from [48]). Chemokines and receptors are also grouped according 
to their main biological activity.  
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1.4.1 Chemokine Families 
Chemokines are grouped into four families: CL, CCL, CXCL and CX3CL, 
according to the spacing of the cysteine residues at the N-terminus end of the 
protein. The X in the motif corresponds to another amino acid besides cysteine, 
whilst C and L are abbreviations for cysteine and ligand respectively [49]. 
These cysteine residues are able to form disulphide bonds with other 
cysteines, to maintain the chemokines 3D tertiary structure (figure 1.5a) [50]. 
Most chemokines belong to either the CCL or CXCL families with only two 
chemokines belonging to CL and one CX3CL [43]. Chemokine receptors are 
also categorised into the same four families as their corresponding chemokine 
ligand. R in the chemokine receptor nomenclature corresponds to receptor 
[49]. The CXCL family can also be further categorised into two separate 
subfamilies, according to the presence or absence of the ELR motif (Glu-Leu-
Arg): ELR+ and ELR- respectively, which lies before the first cysteine residue 
of the CXC sequence [43, 51] (figure 1.5b).  
 
 
 
Figure 1.5.  The four chemokine families and their respective motifs 
(Image taken from [52]). (A) The cysteine motifs of the four separate 
chemokine families: C, CC, CXC and CX3C. (B) The presence of the ELR motif 
in the CXCL family. 
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1.4.2 Chemokine Structure 
Chemokines are comprised of a short N-terminal tail, followed by an extended 
loop, and three β strands, and one α-helix present at the C-terminal tail [50]. 
The N-terminal tail is conserved amongst chemokines and is essential for 
receptor activation and affinity [53]. The extended loop is less conserved and 
displays greater variability amongst the different chemokines. The extended 
loop is important for chemokine receptor specificity as well as affinity [53, 54]. 
The three β strands and one α-helix provides structural stability to the 
chemokine [53, 55] (figure 1.6). 
Chemokines have been proposed to bind to chemokine receptors in two steps. 
The first step involves the N-loop of the chemokine binding to both the N-
terminal tail and extracellular loops of the receptor. In the second step the N-
terminus of the chemokine interacts with the transmembrane domain for 
receptor activation [51, 53, 56-58]. This two-step binding model gives 
chemokines a broad binding site on the receptor.  
Another key structural/functional component of chemokines is their ability to 
attach to glycosaminoglycans (GAGs) [53] which is largely facilitated through 
the electrostatic interactions between the basic residues of the chemokine and 
the GAGs acidic residues [50, 59]. 
 
 
Figure 1.6. The general structure of a chemokine: an N-terminal loop, 
three β strands and the C-terminal α-helix (Image taken from [55]). The 
disulphide bonds (yellow) stabilise the N-terminal loop. The α-helix is folded 
over the β strands. 
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1.5 Gαi\βγ Downstream Signalling 
As previously mentioned, chemokine receptors are mainly coupled to and 
signal via the Gαi class of the Gα subunits. Unlike Gαs, Gαi is an inhibitor of AC 
and blocks cAMP production [25]. Alternatively, in the canonical Gαi 
downstream signalling pathway: Gαi activates the tyrosine kinase Src 
(sarcoma non-receptor tyrosine kinase) [60], which modulates the activity of 
several kinases, including focal adhesion kinase (FAK) [61, 62], mitogen 
activated protein kinases (MAPK) [63, 64] and PI3K [65-67]. Each of these 
kinases is a regulator for a specific downstream signalling pathway which 
ultimately leads to cellular responses such as proliferation, survival and 
migration [12, 68, 69] (figure 1.7). Despite belonging to their own distinct 
pathway, cross-talk between these pathways is possible, such as, through the 
binding of FAK and PI3K [70-72] or the downstream activation of MAPK by 
FAK [73]. 
The Gβγ subunit on the other hand, binds and activates PLC2 at the cellular 
membrane [74, 75]. PLC2 is a phosphodiesterase and cleaves PIP2, to 
produce two secondary messengers: IP3 and diacyl-glycerol (DAG). IP3 is 
hydrophilic, allowing it to detach from the membrane and bind the IP3 channels 
on the endoplasmic reticulum (ER). This opens the IP3 channels, causing an 
influx of calcium ions from the intracellular calcium stores and into the cytosol 
[51]. Calcium ions are key secondary messengers and alongside DAG activate 
protein kinase C (PKC) through binding to the C2 and C1 domains respectively 
[76] (figure 1.7). PKC activation, leads to the phosphorylation of 
serine/threonine residues on multiple downstream proteins, including c-Raf 
[77, 78] and MAPK/Erk kinase (MEK) [79] for the regulation of the MAPK 
signalling pathway. In addition to MAPK, PKC is also thought to regulate PI3K 
signalling [80-82], whilst the Gβγ subunit has been shown to be a director 
activator of PI3Kγ [83]. This again reaffirms the possibility of cross-talk 
downstream of the Gαi and Gβγ activation. Ultimately, the activation of both 
PKC and PI3Kγ is often important for promoting cell migration [84-87]. 
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Figure 1.7. Canonical Gαi/βγ signalling pathway downstream of 
chemokine receptor activation (Image based on [88]). The Gαi signalling 
involves signal transduction through Src leading to FAK, PI3K and MAPK 
activation to induce various cellular responses. The Gβγ pathway activates 
PLC at the cell membrane to cleave PIP2 to produce IP3 and DAG. IP3 opens 
the IP3 channels on the endoplasmic reticulum releasing Ca2+ into the cytosol, 
which alongside DAG can activate PKC to promote cell migration [88]. 
 
1.6 Biased Signalling 
G-protein signalling is ubiquitous for GPCRs however alternate modes of 
intracellular signalling involving Janus-family tyrosine kinase-Signal 
transducer and activator of transcription (JAK-STAT) [89-91] and β-arrestin 
have also been observed. β-arrestin signalling occurs following GPCR 
endocytosis whereby β-arrestin can act as a scaffold to mediate either 
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Extracellular signal-regulated kinase (ERK) [92] or Jun N-terminal kinase 
(JNK) [93] activation to initiate the MAPK signalling pathway [22].  
The ability to utilize different signalling modes has allowed GPCRs to display 
a phenomena known as biased signalling. Signalling biases arise when a 
ligand induces a conformational change in the receptor which causes a 
particular signalling pathway to be preferentially activated over another 
pathway [94] (figure 1.8). Biased signalling has been detected in a numerous 
GPCRs such as chemokine, β-adrenergic and angiotensin receptors, with the 
β-arrestin and G-protein pathways most commonly investigated [95, 96]. No 
studies have explored the involvement of JAK-STAT in the biased signalling of 
GPCRs.  
Signalling bias can be influenced by either the ligand, receptor or cell type [94] 
(figure 1.8). Many examples of different signalling biases have been provided 
from studies involving chemokine receptors, due to their large number of 
shared ligands and receptors [96, 97]. The chemokine receptor CCR7 is a 
particularly useful model for studying ligand bias as it has two known cognate 
ligands: CCL19 and CCL21 [94]. Activation of CCR7 by CCL19 in Human 
embryonic kidney-293 (HEK293) cells has been shown to exhibit greater β-
arrestin 2 recruitment and receptor desensitisation compared to CCL21 [98]. 
In T-lymphocytes CCL21 was able to induce a greater chemotactic response 
than CCL19 [99], although in dendritic cells the opposite was shown, 
suggesting the presence of cell specific bias for both CCL19 and CCL21 as 
well [100]. Aside from receptor sharing chemokine receptors such as CXCR4 
and ACKR3 (previously known as CXCR7) share ligands i.e. CXCL12, which 
allows the possibility for biases in receptor signalling to be observed. One such 
example is CXCL12s ability to  recruit both β-arrestin and Gαi/βγ upon CXCR4 
activation [101] whilst for CXCL12-ACKR3 activation only β-arrestin is 
recruited [102].  
Biased signalling is a relatively new concept with most evidence provided from 
in vitro assays and often in heterologous cell expression systems, therefore 
the exact physiological relevance of biased signalling in vivo is not fully 
understood. It is likely that biased signalling enables tissues to exert a greater 
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degree of control over cellular responses thereby ensuring tighter spatial and 
temporal regulation [94, 97].  
Improved understanding of the biological significance of biased signalling and 
its role in disease pathogenesis in vivo will allow the opportunity to develop 
drugs which can disrupt specific disease related pathways whilst 
simultaneously leaving normal pathways unaltered. This approach would 
therefore reduce the possibility of adverse side effects and at the same time 
maximise the therapeutic benefit [94, 97, 103]. 
 
 
Figure 1.8. Outline of the three possible signalling biases for GPCRs: 
ligand, receptor and tissue (Image taken from [94]). Arrows (grey) highlight 
the preferentially activated G-protein or β-arrestin pathway. 
 
1.7 Chemokine and Chemokine Receptor Oligomerisation 
Although chemokines are monomeric proteins they are known to frequently 
form homodimers, as well as tetramers and even heterodimers. This coupling 
of chemokines is facilitated through interactions between β-strands, with dimer 
orientation dependent on the chemokine family [50]. Chemokine dimerization 
has been shown to influence biological effects such as CXCL12 monomers 
promoting colonic carcinoma cell migration whilst CXCL12 dimers inhibiting 
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this same migration despite both forms of CXCL12 activating CXCR4 [104]. In 
addition to chemokine dimerization, chemokine receptors can also exist as 
hetero and homodimers which can also impact on the downstream signalling 
pathway [105]. In HEK293 cells CXCR4/CXCR7 heterodimerisation amplified 
intracellular calcium signalling and regulated ERK activation in response to 
CXCL12 stimulation compared to HEK cells expressing CXCR4 alone [106]. 
Therefore the presence of chemokine and receptor oligomerisation provides 
an additional level of complexity to the biological nature of chemokines. 
 
1.8 Chemokine Biological Activity 
Chemokines are a chemoattractant for cells expressing chemokine receptors, 
often leukocytes and endothelial cells. This chemotaxis serves two broad 
functions in the human body: inflammation or homoeostasis [107].  
During inflammation and/or infection, chemokines are secreted by stromal and 
epithelial cells in response to the presence of pro-inflammatory cytokines, 
lipopolysaccharides and viral particles within the tissue microenvironment 
[108-110]. Secreted chemokines attach to GAGs present on surface of 
endothelial cells to form a local concentration gradient within the tissue 
microenvironment [111]. This concentration gradient traffics neighbouring 
leukocytes towards these sites of infection and/or inflammation to mount an 
effective immune system response [109]. Chemokines associated with 
inflammation tend to exhibit greater receptor promiscuity which was originally 
presumed to ensure a robust immune response to disease [47]. The 
importance of a robust response is particularly pertinent when considering the 
molecular mechanisms deployed by viruses to mimic and manipulate the 
chemokine signalling network to avoid immune cell detection [112].  However 
notwithstanding receptor redundancy, chemokine receptors can be 
differentially expressed on leukocytes with CCRs commonly located on 
monocytes, T cells, eosinophils and basophils and play a key role in chronic 
inflammation [113, 114]. Whilst members of the CXCR family in particular 
CXCR1/2 are expressed on neutrophils and therefore are considered more 
important for acute inflammation [51, 114]. 
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For homeostasis chemokines are constitutively secreted by stromal cells to 
promote leukocyte basal migration as part of the immunosurveillance process 
[115]. Homeostatic chemokines commonly traffic leukocytes to peripheral sites 
in the body such as the blood brain barrier, skin, lymph nodes, thymus and 
spleen, with the secondary lymphoid organs also involved in lymphocyte 
maturation [114, 116, 117]. Aside from immunosurveillance chemokines 
CXCL12, CXCL14 and CX3CL1 are also expressed within the brain where they 
regulate neurogenesis [116]. Furthermore CXCL12 is also present at high 
levels in the bone marrow for the homing of hematopoietic stem cells to support 
the bone marrow stem cell niche [118].   
These two inflammatory and homeostatic roles however are not always 
mutually exclusive and can vary depending on the tissue or disease state [119, 
120]. Aside from inflammation and homeostasis chemokines also regulate 
angiogenesis, apoptosis [121], and phagocyte activation [122]. In 
angiogenesis the presence of ELR motif in the CXCL family determines 
whether the chemokine inhibits or promotes endothelial cell migration [123]. 
ELR+ chemokines: CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and 
CXCL8 promote endothelial migration and proliferation primarily through 
CXCR2 activation [43, 124]. Whilst, ELR- chemokines: CXCL4, CXCL9, 
CXCL10, CXCL11 and CXCL17 inhibit endothelial migration and proliferation 
often via CXCR3B [43]. There is however one notable exception CXCL12, 
which can promote endothelial migration through activation of both CXCR4 
and ACKR3 even without ELR [43, 125, 126].  
As chemokines play a vital role in regulating the migration of immune cells, 
dysregulation in chemokine signalling has been implicated in a range of 
autoimmune and inflammatory disorders including rheumatoid arthritis and 
multiple sclerosis [127] as well as atherosclerosis [128]. Moreover chemokine 
receptor overexpression has been identified in numerous different cancer 
types with the chemokine acting as a chemoattractant to promote cancer cell 
invasion and metastasis [48, 129-131]. Consequently the targeting of the 
chemokine signalling network to block abnormal cell migration in both immune 
and cancer cells is a highly sought area of research to treat inflammatory and 
immune associated diseases [132, 133].  
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1.9 Cell Migration 
Cell migration can be defined as the ability of a cell to navigate through their 
surrounding external environment and includes responding to extracellular 
cues for directing movement (chemotaxis). Cell migration is particularly 
important in the evolution of multicellular organisms whereby cellular 
movement is tightly regulated both spatially and temporally for tissue and 
organ formation during early stages of development [134]. Cell migration is 
also crucial for other homeostatic processes, such as wound healing [135] and 
the immune system response [136] with the latter having been previously 
described. As coordinated cell migration is involved in a diverse range of 
biological processes it often takes place within differing tissue 
microenvironments and involves various different cell types [135-137]. This 
has therefore given rise to distinct modes of cell migration which can vary 
according to the cell type, external environment and even disease state, such 
as in cancer [138].  
 
1.9.1 Cell Migration Modes 
Cells suspended in aqueous environments such as leukocytes, have the 
tendency to migrate in an ‘amoeboid’ mode through the formation of actin 
filament (F-actin) rich protrusions known as pseudopods [139]. ‘Amoeboid’ 
migrating cells have a weak adherence to the external substrate and therefore 
migrate rapidly. In contrast mesenchymal cells such as fibroblasts reside in 
firmer and more stable environments and so adhere more strongly to the 
external substratum [140]. Mesenchymal cells migrate slower than ‘amoeboid’ 
cells despite also forming pseudopods (figure 1.9 and table 1.1). However 
unlike ‘amoeboid’ cells which migrate individually mesenchymal cells can 
migrate collectively as clusters [141]. Nonetheless despite differences in the 
migratory modes both involve the remodelling of the F-actin cytoskeleton and 
as such there is a significant overlap in some of their underlying molecular 
events [138].  
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Figure 1.9. Two of the main modes of cell migration: amoeboid and 
mesenchymal (Image taken from [142]). 
 
Table 1.1. Differing cellular characteristics between the amoeboid and 
mesenchymal migration modes 
 Amoeboid Mesenchymal 
Migration speed Fast, around 10 
μm/min 
Slow, ˂ 1 μm/min 
Polarity Defined front and rear Multiple lamellipodia 
Migration mode Squeezing through 
gaps in the ECM  
Generate traction by 
adhering to the ECM 
Adhesion Weak, mostly interior. Strong 
Actin cytoskeleton 
organisation 
Thick dendritic F-actin 
at the front and 
surrounding actin 
cortex elsewhere 
Dendritic F-actin in 
lamellipodia. Thinner 
F-actin in the 
lamellum. Stress fibers 
inside cell.  
Common receptors type 
used for chemotaxis 
GPCRs Receptor tyrosine 
kinases 
Example cell type Leukocytes Fibroblasts 
 
Table adapted from [142]. ECM refers to extracellular matrix. 
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1.9.2 Actin Polymerisation 
In eukaryotic cells monomeric G-actin is a highly abundant protein, where it 
serves as a building block for actin filament (F-actin) formation. F-actin 
formation is the main process which drives both ‘mesenchymal’ and 
‘amoeboid’ migration and is comprised of three steps: nucleation, elongation 
and steady state [143] (figure 1.10).  
F-actin polymerisation begins with the aggregation of at least three G-actin 
monomers to form a stable actin nucleus structure known as nucleation. The 
actin nucleus can be then be further extended through the addition of G-actin 
monomers to the barbed (+) end for unidirectional F-actin polymerisation. F-
actin polymerisation is directed towards and against the cell membrane 
causing the membrane to extend outwards to create pseudopods [144]. To 
maintain polymerisation G-actin monomers are removed from the pointed (-) 
end and added to the barbed (+) end at an equal rate thereby keeping F-actin 
polymerisation at a steady state or tread milling [143] (figure 1.10 below). 
 
 
Figure 1.10. The three stages of actin polymerisation (Image adapted 
from [145, 146]). The process of F-actin formation is initiated by the 
aggregation of three G-actin monomers to form a nucleus. G-actin monomers 
are then added to the barbed end which extends the F-actin. During 
treadmilling the G-actin monomers are added and removed at an equal rate 
from the barbed and pointed ends respectively. 
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F-actin polymerisation is facilitated by formin, a dimeric protein which forms a 
ring like structure at the barbed end with its FH2 domains. Formin both 
removes and blocks protein capping to promote nucleation and polymerisation 
[147]. The FH1 domain of formin recruits profilin to the barbed end of the F-
actin. Profilin binds and catalyses the exchange of ADP for ATP on the G-actin 
monomer which promotes F-actin stability, before trafficking the G-actin 
monomer to the barbed end to promote extension [148, 149] (figure 1.11a). 
Beside actin polymerisation at the barbed end, actin filaments can also be 
formed at a 45° angle at the sides. This F-actin branching is mediated by the 
actin related protein 2/3 (Arp2/3) which binds to the F-actin sides to initiate 
nucleation and polymerisation [145]. F-actin branching by Arp2/3, is dependent 
on both ATP and the recruitment of nucleation-promoting factors Wiskott-
Aldrich syndrome protein (WASP) and WASP-family verprolin-homologous 
(WAVE) [150] (figure 1.11b).  
 
 
Figure 1.11. The molecular mechanisms facilitating F-actin 
polymerisation (Image adapted from [145]). (a) Formin’s FH2 domain 
surrounds the barbed end of the F-actin, with the FH1 domain binding the 
profilin-G-actin associated complex. (b) The VCA (or WCA) domain of N-
WASP binds both G-actin and Arp2/3 to initiate F-actin branching. 
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1.9.3 Leading Edge (Extension) 
In migrating cells actin polymerisation occurs at the cellular membrane of a 
cells leading edge to form two types of pseudopods: lamellipodia and filopodia 
[140, 151, 152]. The formation of both the lamellipodia and filopodia are 
dependent on F-actin polymerisation, however, aside from this both their 
functions and molecular mechanisms differ [153-156]. 
 
1.9.3.1 Filopodia 
Filopodia are thin structures around 100-300 nm in diameter and consist of 
between 10-30 parallel actin filaments. Filopodia are the sensors of the cell to 
the external environment and express higher levels of cell adhesion proteins 
such as integrins and cadherins [153, 154] (figure 1.12). Filopodia formation is 
regulated by Cdc42, a member of the Rho GTPase family, which together with 
PIP2, activates WASP and N-WASP by disrupting interactions between the 
VCA and CRIB domains which cause WASP autoinhibition. The VCA domain 
of WASP is then free to interact with Arp2/3 to promote F-actin branching [157] 
(figure 1.11b). Formin and another actin binding protein enabled/vasodilator-
stimulated phosphoprotein (ENA/VASP) are also present at the filopodia to 
block barbed end capping and promote F-actin extension [153]. Other proteins 
also involved in filopodia development are fascin, an F-actin cross linker for F-
actin bundling and the insulin-receptor substrate p53 (IRSp53), an adaptor 
which localises Cdc42, WASP and ENA/VASP to the F-actin and also assists 
in membrane deformation [153, 157, 158]. 
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1.9.3.2 Lamellipodia 
Lamellipodia are large flattened cellular sheets which act as the mechanical 
force to propel the cell forward [155] (figure 1.12). Lamellipodia formation is 
regulated by another Rho GTPase Rac as well as Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), both of which recruit and activate WAVE2 at the leading 
edge [155, 156]. WAVE2 activation is facilitated by IRSp53 which has a Rac 
binding domain at the N-terminus and a Src-homology-3 (SH3) domain to bind 
WAVE2 at the C-terminus [155, 159]. Similar to WASP, WAVE2 then activates 
Arp2/3 using its VCA domain to promote F-actin branching [155]. 
 
1.9.3.3 Cellular Polarity 
In order for pseudopods to only form at the leading edge the molecular events 
between the cells leading and trailing edges must differ. Hence migrating cells 
display substantial cellular polarity according to their signalling pathways [160-
162] (figure 1.12).   
PI3K is an important facilitator of cellular polarity through the phosphorylation 
of PIP2 to produce PIP3 which acts a binding site for proteins which have a 
pleckstrin homology domain e.g. guanine exchange factors (GEF), Akt and 
WAVE2 [155, 162]. Experiments using GFP-labelled Akt have demonstrated 
the localisation of PI3K/PIP3 at the leading edge of migrating fibroblasts [163], 
neutrophils [164] and Dictyostelium [165], with the pharmacological blockade 
of PI3K shown to inhibit the chemotaxis of neutrophils [166] and Dictyostelium 
[167]. Interestingly phosphatase and tensin homolog (PTEN) which acts in 
opposition to PI3K by dephosphorylating PIP3 to generate PIP2 is preferentially 
located at the trailing edge of the cell [162].  
PIP3 acts as a localisation point for GEF at the leading edge of the cell for Rho 
GTPase activation and subsequent F-actin polymerisation [168]. Also as PIP2 
is able to bind profilin and block profilin-G-actin interactions [169], higher levels 
of PIP3 at the leading edge could result in greater levels of profilin present in 
the cytosol which aids F-actin formation.  
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However despite evidence of PI3K being important for chemotaxis, one 
comprehensive study using 5 separate PI3K and one PTEN knockout in 
Dictyostelium showed no effect on chemotaxis [170]. This lead to the 
conclusion that off-target effects of the PI3K inhibitor LY294002 may have 
contributed to some of these chemotaxis defects [170]. This also suggests that 
in Dictyostelium there are other signalling mechanisms involved in chemotaxis 
which may include phospholipase A2, cyclic guanosine monophosphate and 
RasC [171]. Nonetheless the same authors did identify a role for PI3K in 
cellular speed confirming some importance of PI3K for cell migration [170]. 
Aside from the PIP3, calcium ion levels are also polarised within migrating cells 
with low calcium ion levels present at the leading edge whilst higher levels 
found towards the rear [161] (figure 1.12) . Low levels of calcium increases the 
cells sensitivity to pulses of calcium at the boundary between the lamellipodia 
and lamella at the leading edge. These calcium pulses arise from either the 
ER or calcium channels on the cell surface which can activate various effectors 
including calmodulin and PKC [161, 172]. Calmodulin can activate the myosin 
light chain kinase (MLCK) which in turn phosphorylates myosin II to induce 
contraction. Myosin II contraction causes the F-actin to be pulled towards the 
cell interior, a process known as retrograde flow which regulates F-actin 
treadmilling [161]. Activation of PKC is able to modulate cell migration through 
the regulation of fascin, myosin II and p115RhoGEF for remodelling the actin 
cytoskeleton [173-175]. 
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Figure 1.12.  The molecular mechanisms involved in forward cellular 
migration (Image adapted from [176]). Cdc42 is important for the formation 
of filiopodia and nascent focal adhesions (small pink circles) [153, 177]. Whilst 
Rac1 is important for lamellipodia formation as well as nascent focal adhesions 
[155, 178]. Rho promotes the conversion of nascent focal adhesions to mature 
focal adhesions (long purple circles) [179]. Stress fibers connect mature focal 
adhesions within the cell for cellular contraction [155, 180]. During forward 
migration PIP3 is present at higher levels at the leading edge whilst at the 
trailing edge Ca2+ levels are higher instead [161, 171]. 
 
1.9.4 Focal Adhesions (Traction) 
During migration cells generate traction by adhering to the extracellular matrix 
(ECM) through the assembling of macromolecular structures on their cell 
surface known as focal adhesions (FAs) (figures 1.12 and 1.13). FAs are sites 
of adherence and actin polymerisation and function to counteract the F-actin 
retrograde flow caused by myosin II contraction [181, 182]. The activation of 
various transmembrane receptors including chemokine receptors are known 
to promote focal adhesion assembly [183-186]. 
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1.9.4.1 Integrins 
Cellular adherence often involves integrins, a group of transmembrane 
receptors which exist as αβ heterodimers [187]. Cells express a particular set 
of integrin subunits depending on the extracellular environment encountered. 
In the presence of collagen, cells express α1β1 and α2β1, whilst for laminin 
the α2β1, α3β1 and α6β1 subunits are expressed instead [188]. These distinct 
combinations of integrin subunits are able to activate specific signalling 
pathways which allows the cell to exert a greater flexibility and specificity over 
both its adherence and migration in response to its surroundings [188-190] 
ECM and integrin binding causes the integrins to cluster which recruits talin to 
the cytoplasmic side of the β subunits. Upon arrival, talin disrupts the 
interaction between the α and β cytoplasmic tails of the integrin which shifts 
the integrin into a high ligand affinity state and enhances ECM binding [191]. 
Talin is often considered as an initiator of FA formation by recruiting FAK, 
vinculin and α-actinin (F-actin binding protein) [188]. Though this model was 
disputed by a separate study which alternatively identified FAK as being 
essential for talin recruitment and not the other way round [192]. However one 
review proposed a comprise between these two studies, in which at nascent 
FAs, talin recruitment is dependent on FAK, whilst at mature FAs,  FAK is 
dependent on talin for retention [193].  
 
1.9.4.2 Focal Adhesion Kinase 
FAK recruitment to the FA is central to both FA assembly and its signal 
transduction, and is trafficked to the integrin’s via its FAT (focal adhesion 
targeting) domain where it can bind both talin and paxillin [194] (figure 1.13). 
At the FA, the FAK FERM (four-point-one, ezrin, radixin, moesin) domain was 
originally thought to interact with the cytoplasmic tail of the β integrin subunit 
to cause a conformational change in FAK leading to Tyr397 
autophosphorylation and the subsequent activation of FAK [68]. However 
more recently an alternative model has been suggested in which FAK is 
activated at the FA by neighbouring PIP2 molecules instead [195-197].  
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Nevertheless the autophosphorylation of Tyr397 acts as a binding site for 
proteins with the SH2 (Src Homology 2) such as Src, PI3K, PLC-γ and Ras 
GTPase activating protein (GAP) [194, 198]. The recruitment and activation of 
Src by Ty397 is a particularly important event as Src is able to phosphorylate 
the Tyr576 and Tyr577 residues on the activation loop of FAKs kinase domain 
which initiates FAKs tyrosine kinase activity [199]. Both Src and FAK are then 
able to phosphorylate two FA adaptor proteins paxillin and p130cas which can 
form binding sites for CT10 sarcoma oncogene cellular homolog (Crk) [194, 
200]. Crk is an effector for the atypical GEF, dedicator of cytokinesis 1 
(DOCK1) which in turn can activate Rac to promote cell migration, survival and 
membrane ruffling, with the latter being a precursor to migration [201-203]. 
Besides paxillin and p130cas, FAK is also able to phosphorylate N-WASP to 
promote migration, possibly by blocking its nuclear localisation [204]. 
Besides Tyr397, Tyr576 and Tyr577, other FAK phosphorylated tyrosine 
residues are Tyr861 and Tyr925 which enhance SH3 and SH2 binding of 
p130cas and growth factor receptor-bound protein 2 (Grb2) respectively [194]. 
Grb2 is another adaptor protein which is able to activate Ras and initiate the 
MAPK signalling cascade [194]. Additionally FAK can directly regulate GEFs 
and GAPs to either promote or suppress Rho GTPase activity respectively, as 
a means of regulating F-actin formation [200]. Thus FAK localisation to the 
integrins is not only important for FA assembly but also for integrin signal 
transduction to regulate F-actin polymerisation. This allows the cell to 
coordinate an appropriate cellular response according to the ECM 
encountered. 
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Figure 1.13. The (general) molecular composition of focal adhesions 
(Image taken from [194]). 
 
1.9.4.3 Focal Adhesion Maturation 
Nascent FAs are small structures which are formed at the leading edge of the 
cell and provide significant traction for cellular migration [205, 206]. The vast 
majority of these nascent FAs are disassembled, however a few can undergo 
maturation by elongating in the opposing direction to cellular migration where 
they become more important for cellular adherence [181] (see figure 1.12).  
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FA maturation involves the Rho GTPase RhoA, an effector of Rho-dependent 
protein kinase (ROCK) and formin activity. Among ROCKs downstream targets 
are myosin II light chain and LIM kinase both of which enhance stress fiber 
formation [179]. Stress fibers consist of 10-30 parallel F-actin bundles which 
span across the transverse, dorsal and ventral sides of the cell and often 
connect separate FAs (figure 1.12). Stress fiber contraction by myosin II is 
particularly important for FA maturation [180] and as such stress fiber 
formation is particularly characteristic of mesenchymal migration [140] (table 
1.1). Overtime mature FAs will undergo either disassembly or remain to 
become sites for α5β1 integrin and tensin clustering. These sites are known 
as fibrillar adhesions and are found within the cell interior to promote stable 
adherence [207].  
 
1.9.5 Trailing Edge (Retraction) 
Cells migrate in a unidirectional manner and as such during migration the 
trailing edge of a cell needs to be retracted. This cellular retraction requires the 
focal adhesions located at the cellular edge to undergo disassembly [208]. The 
molecular mechanisms involved in FA disassembly are not as well understood 
as those involved in its assembly, however, several proteins associated with 
FA disassembly have been uncovered.  
Although FAK is well known to be involved in FA formation many studies have 
shown that FAK is also important for FA disassembly [209-211]. At the FA site, 
FAK recruits dynamin to its FERM domain to initiate integrin endocytosis by 
either clathrin or caveolin [212, 213]. Dynamin endocytosis is also facilitated 
by the presence of Src which phosphorylates the Tyr231/597 residues of 
dynamin to enhance its GTPase activity [214]. At the FA, FAK may also 
activate p21-activated kinases to inhibit MLCK activity and thereby reducing 
FA stability [211]. Moreover the microtubules are also shown to be crucial for 
FA disassembly by trafficking endocytic related proteins to the FA [213]. 
As mentioned earlier (section: 1.8.3.3), calcium ion levels are higher at the 
trailing edge and as such Ca2+ modulated proteins are often associated with 
cellular retraction [215, 216]. Two particularly notable Ca2+ activated proteins 
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involved in FA disassembly are calpain and calcineurin. Calpain is a proteinase 
which cleaves FA adaptor proteins talin [216], FAK [217] and paxillin [218], 
whilst calcineurin facilitates intergrin endocytosis [215]. Furthermore, the 
presence of calcium ions at the trailing edge is thought to promote FAK 
retention at the FA [219] and interesting FAK can also bind calpain directly to 
promote FA turnover [220]. 
Both FA assembly and disassembly at the respective leading and trailing 
edges are key for cell migration with integrin endocytosis and recycling 
occurring at both edges to promote and maintain cell migration [221]. Moreover 
this recycling of integrins is also considered to be essential for the invasion of 
cancer cells [222, 223] with regulators of integrin activity such as FAK and Src, 
frequently dysregulated in cancer cells [224-226]. This therefore makes the FA 
signalling pathway a worthwhile area of study in cancer. 
 
1.10 Cancer Metastasis 
Cancer is a heterogeneous genetic disease characterised by uncontrolled 
cellular proliferation which gives rise to an abnormal cluster of cells known as 
a tumour [227]. The most widely accepted paradigm for metastasis is, over 
time some cancer cells within a primary (benign) tumour can acquire additional 
mutations allowing them to detach from their primary (tumour) site and invade 
the surrounding tissue to access the body’s circulatory system. Once in 
circulation these cancer cells can travel to other sites within the body [227, 
228]. Upon arriving at a new site, the cancer cell adheres to the blood vessel 
walls and migrates through the extracellular gaps between the endothelial 
cells, known as extravasation. The cancer cell then invades the new tissue site 
and grows to form a secondary tumour. This formation of a second tumour is 
termed metastasis [227, 228] (figure 1.14). 
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Figure 1.14. The sequence of events involved in cancer metastasis 
(Image taken from [228]). Tumour vascularization at the primary site is one 
of the first steps in cancer dissemination by suppling nutrients for tumour 
growth, as well as allowing the cancer cell access to the body’s vascular 
system. Occasionally cancer cells detach from the primary tumour and enter 
the vascular system by intravasation. Circulating cancer cells can then attach 
and extravasate through the blood vessel walls and form a second tumour at 
a new site within the body [228].  
 
Metastasis is the leading cause of fatality in cancer patients and is considered 
to be responsible for 90% of all cancer related mortality worldwide [229]. Its 
deadliness is further emphasised when comparing the five year survival rates 
between patients with stage IV (metastatic) tumours and those with stage I 
(benign) tumours. In the UK, breast cancer patients diagnosed with a stage I 
tumour have a 99% chance of surviving after five years whilst at stage IV this 
drops to just 15% [230]. Similar downward trends in survival rates for patients 
diagnosed with stage IV tumours is prevalent amongst other types of cancer 
as well (see table 1.2). This emphasises the need to block cancer metastasis 
as a strategy for improving the survival rates of cancer patients.
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Table 1.2. List of carcinoma types and their common metastatic sites. 
The five year survival rates were for adults (15-99 years old) diagnosed 
with different stages of cancer in England and Wales 
 
Information about the main sites of metastasis was obtained from the National 
Cancer Institute [231]. The five year survival rate data was from the Former 
Anglia Cancer Network, 2002-2006 [230] except for pancreatic cancer. The 
five year survival rate for pancreatic cancer was provided by the London 
School of Hygiene and Tropical Medicine, 2010-2011 [232]. All data on the five 
year survival rates were obtained for both sexes except for breast and prostate 
cancer which were from women and men only respectively. Data on Kidney 
cancer excludes the renal pelvis. UA corresponds to unavailable. 
 
One of the reasons for the low survival rates for metastatic cancers is the 
cancers resistance to chemotherapy and/or radiotherapy as well as more 
targeted treatments [233]. This drug resistance can often arise as a result of 
mutations caused by the intrinsic genomic instability present in cancer cells 
due to their uncontrolled cell proliferation and defective DNA repair pathways 
[234-237]. Besides therapeutic agents and radiotherapy, for patients with solid 
tumours surgery is still the main treatment option [238, 239]. Nevertheless its 
efficacy is often limited to early-stage cancers as once the cancer has invaded 
the surrounding tissue and metastasised, removing all the cancerous tissue 
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using surgery alone is difficult [240-242]. Hence there is a greater likelihood of 
cancer recurrence in patients with higher stage tumours following surgery 
[241-243].    
Due to the multiple mutational events required for a cancer to metastasize, 
many of the molecular mechanisms involved are not properly understood. 
Nevertheless, one feature common amongst all cancer types is their distinct 
pattern of metastasis. In prostate cancer the bone is the most common 
metastatic site (90% of cases) [244]. For pancreatic cancer it is the liver (85% 
of cases) [244]. Whist, in breast cancer there are a range of common sites 
including the bone, lung, liver and brain, although the bone is still the most 
frequent site (48% of cases) [244]. Some of this metastatic pattern can be 
partly explained by anatomy, such as blood flowing from the pancreas to the 
liver via the portal vein [245, 246]. However for more distant metastatic sites 
like the brain or site specific metastasis such as bone metastasis in breast 
cancer, this cannot be completely explained in terms of physiology alone and 
thus other contributing factors must be involved.  
This has given rise to the ‘seed and soil’ hypothesis which was first proposed 
in 1889 by an English surgeon named Stephen Paget and was based on his 
observations of the non-random pattern of metastasis from the autopsy 
records of 735 women with breast cancer [247]. In this analogy the cancer cell 
is the seed whilst the pre-metastatic site is the soil. Therefore as certain seeds 
flourish within a particular type of soil the same concept is thought to occur for 
metastasis [248].  
Within the pre-metastatic environment there are a myriad of different signalling 
molecules, such as growth, pro-survival, adhesion, proangiogenic factors and 
cytokines including chemokines. Many of which are considered crucial to the 
seeding of cancer cells for metastasis [249]. 
 
  
   
 
51 
 
1.11 Chemokines and Cancer Metastasis 
Cancer aetiology has identified inflammation as a key promoter of cancer 
progression [250] through two possible pathways: an extrinsic and an intrinsic 
pathway. The extrinsic pathway is caused by continuous exposure to toxic 
exogenous sources e.g. excessive alcohol intake or tobacco smoke which 
leads to persistent tissue damage and chronic inflammation within the tissue 
microenvironment [251]. Whilst the intrinsic pathway is instead a result of an 
accumulation in genetic abnormalities within a cell which causes oncogenesis 
and/or tumour suppressor loss leading to an upregulation in pro-inflammatory 
pathways [251, 252]. Both of these pathways can lead to elevated levels of 
chemokines and chemokine receptors through the increase in transcriptional 
activity of  nuclear factor kappa light chain enhancer of activated B cells [253-
258], hypoxia inducing factor [258-260] and activator protein 1 [256, 257]. 
The importance of chemokine overexpression in cancer metastasis was first 
discovered in 2001 from the seminal nature paper by Muller et al. (2001) [130]. 
In this study chemokines CXCL12 and CCL19/21 were found to be 
overexpressed at common sites of metastasis such as liver, lung, brain and 
lymph nodes whilst their respective cognate receptors CXCR4 and CCR7 were 
overexpressed on various breast cancer cells [130]. Since then CXCR4 
overexpression has been further identified in at least 23 different cancer types 
and is often associated with a poor prognosis for cancer patients [261]. In 
addition to CXCL12 other particularly well-studied chemokines within the 
cancer research field are CCL2 [262], CCL5 [263] and CCL19/21 [264] with 
emerging chemokine signalling axis of interest involving CXCL9/10/11-CXCR3 
[265] and CXCL8-CXCR1/2 [266]. 
Within the tumour microenvironment chemokines are commonly secreted by 
cancer associated fibroblasts, endothelial cells and tumour infiltrating 
leukocytes for the trafficking of immunosuppressive leukocytes such as 
regulatory T-cells and myeloid derived suppressor cells as well as endothelial 
cells to the tumour site [131, 267-269]. This helps to create an 
immunosuppressive environment and encourages blood vessel formation both 
of which support tumour survival and growth [131] (figure 1.15). At the pre-
metastatic site chemokines also act as a chemoattractant for circulating cancer 
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cells which overexpress chemokine receptors [115, 130, 270]. In 
haematological cancers, the homing of leukemic cells to the bone marrow and 
lymph nodes by chemokines is thought to contribute to survival and drug 
resistance [271-273]. In cancer cells, chemokine signalling has also been 
shown to promote invasion, proliferation, survival, adhesion, and the secretion 
of vascular epidermal growth factors and matrix metalloproteinases [274-279]. 
 
 
Figure 1.15. The various roles of the chemokine signalling axis in cancer 
progression (Image taken from [131]). Chemokines secreted at the primary 
tumour (yellow) are able to recruit leukocytes and endothelial cells to 
encourage tumour growth and vascularisation. Chemokine signalling also 
increases the production of growth factors at the tumour site. Chemokines 
expressed in the lymph nodes can recruit cancer cells from the primary tumour 
site and aid metastasis (pictured as the lungs). (TAM = Tumour associated 
macrophages, NK = Natural killer cells, MDSC = Myeloid derived suppressor 
cells, Th1 = Type 1 helper T-cells, CD8 T = CD8 T-cells and Treg = Regulatory 
T-cells) [131].
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1.12 Chemokine Signalling:  A Therapeutic Target for Cancer 
Treatment 
GPCRs are the largest family of receptors in humans and their dysfunction 
underlies the pathogenesis of many diseases [280, 281]. To date, around 34% 
of all US Food and Drug Administration (FDA) approved drugs target GPCRs 
[282].  
Successive preclinical in vitro and in vivo cancer models have demonstrated 
the therapeutic benefit in targeting chemokine signalling in several cancers 
including breast [130, 283-286], prostate [287, 288] and leukaemia [289, 290]. 
Hence there has been considerable interest from the pharmaceutical industry 
to develop and bring drugs which target the chemokine signalling network to 
clinical trial as a form of targeted treatment against cancer progression [291, 
292]. 
 
1.12.1 Small Molecules Targeting Chemokine Signalling in 
Cancer Patients  
CXCR4 is the most widely studied chemokine receptor in cancer, therefore it 
is unsurprising that most small molecules undergoing clinical trials are 
antagonists for CXCR4.  
Currently the only licensed CXCR4 small molecule inhibiter used in cancer 
treatment is AMD3100 (licensed name plerixafor) which was approved in 2008 
by the FDA to treat non-Hodgkin lymphoma and multiple myeloma (MM) [293]. 
AMD3100 is administered together with the granulocyte-colony stimulating 
factor for the mobilisation of hematopoietic stem cells into the blood stream for 
autologous stem cell transplantation following chemotherapy [294]. Since 
2008, AMD3100 has undergone clinical trials in combination with different 
chemotherapy agents to enhance the treatment for acute myeloid leukaemia 
(AML) by blocking the retention of leukemic cells in the bone marrow [273]. 
Results from these studies demonstrated the successful mobilisation of 
leukemic cells into the circulatory system as well as improved remission rates 
[273, 295]. Other CXCR4 antagonists which have also completed phase II 
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clinical trials are Burixafor (previously known as TG-0054) and POL6326 both 
as alternatives to AMD3100 for the mobilisation of hematopoietic stem cells for 
MM and both non-Hodgkin’s and Hodgkin’s lymphoma [296, 297]. The results 
from both trials showed successful hematopoietic stem cell mobilisation and 
drug safety [296, 297]. 
Besides haematological cancers POL6326 also completed a clinical trial in 
combination with Eribulin for metastatic breast cancer however no results have 
been released (Trial registration ID: NCT01837095). Another CXCR4 inhibitor 
which has undergone clinical trials for solid tumours is the LY2510924 for small 
cell lung carcinoma, although no significant anti-tumour effect alongside 
carboplatin/etoposide was observed [298]. Whilst a clinical trial involving MSX-
122 also for solid tumours was suspended with no reason given for the 
suspension (Trial registration ID: NCT00591682). Similarly, two other trials 
with LY2510924 in solid tumours (Trial registration ID: NCT02737072) and 
renal metastasis (Trial registration ID: NCT01391130.) were also cancelled, 
with the latter due to low efficacy [299]. However the clinical trial for AML with 
LY2510924 is still actively recruiting (Trial registration ID: NCT02652871). 
Aside from the CXCL12-CXCR4 signalling axis another pathway being 
targeted is CXCL8-CXCR1/2 using the dual CXCR1 and CXCR2 inhibitor 
Reparixin. Reparixin is still in phase II clinical trial for triple negative breast 
cancer in combination with Taxol (Trial registration ID: NCT02370238) 
following a phase I study which reported favourable pharmacokinetics and no 
serious adverse effects or interference on Taxol anti-tumour activity [300]. 
 
1.12.2 Antibodies and Peptides Targeting Chemokine 
Signalling in Cancer Patients  
Mogamulizumab is the only licensed monoclonal antibody used to target a 
chemokine receptor in cancer treatment. Mogamulizumab was first approved 
in 2012 by the Japanese Pharmaceuticals and Medical Devices Agency to 
target CCR4 positive adult T-cell leukaemia (ATL) in relapsed or refractory 
patients [301]. In 2018 the USA FDA approved the use of mogamulizumab for 
Non-Hodgkin lymphoma [302]. Whilst in Europe the European Medicine 
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Agency designated mogamulizumab as an orphan drug in 2016 and approved 
its use in 2018 also for the treatment of the cutaneous T-cell lymphoma 
subtype of Non-Hodgkin lymphoma [303].  
For targeting CXCR4 the current leading antibody is MDX-1338 (or BMS-
936564), developed by Bristol-Myers Squibb Co. MDX-1338 completed two 
phase I clinical trials, one as a monotherapy for treating patients with relapse 
AML and three subtypes of B-cell leukaemia (Trial registration ID: 
NCT01120457), and another as both a monotherapy and in combination with 
lenalidomide/dexamethasone or bortezomib/dexamethasone for relapse MM 
(Trial registration ID: NCT01359657). Both trials aimed to establish MDX-1138 
safety and tolerability in these patients [304] however neither has disclosed 
any results since.  
The CCL2-CCR2 signalling axis is another therapeutic target which has 
enjoyed preclinical success with antibodies [287, 305, 306]. As a result this 
lead to the development of two antibodies: carlumab and MLN1202. Carlumab 
(CNTO888) is a high affinity antibody for CCL2 developed by Centocor and 
has completed two separate phase I clinical trials for advanced solid tumours 
and one phase II trial for metastatic prostate cancer as both a monotherapy 
and in combination with chemotherapeutic agents. Carlumab was well 
tolerated in patients but there was no significant improvement in the disease 
state [307-309]. Furthermore, in both of the carlumab trials, despite the initial 
reduction in CCL2 levels these levels rebounded following a week of treatment, 
which could have been a contributing factor for the lack of anti-tumour activity. 
Possible reasons provided for lack of robust reduction in CCL2 levels by 
carlumab were poor affinity for CCL2 in humans, low clearance rate of the 
carlumab-CCL2 complex and an increase in CCL2 secretion in response to 
carlumab [307-309]. 
An alternative strategy for blocking CCL2-CCR2 signalling was using the 
CCR2 antibody MLN1202 developed by Millennium Pharmaceuticals, which 
was in a phase II clinical trial involving solid tumours with bone metastasis 
(Trial registration ID: NCT01015560). MLN1202 was shown to be safe as well 
as 32% of patients displaying a reduction in urinary N-telopeptide (a bone 
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reabsorption and metastasis marker), suggesting some possible therapeutic 
benefit though this has yet to be confirmed [310]. 
Aside from antibodies, other biological therapeutic agents include nanobodies 
and peptides. Nanobodies consist of a single heavy chain and thus are much 
smaller than regular antibodies making them more soluble and easier for drug 
delivery [311]. This has led the biotech company Ablynx to develop the first 
CXCR4 nanobody ALX-0651 which was used for phase I clinical trial in healthy 
patients (Trial registration ID: NCT01374503). Although this trial was 
terminated the proof of principle was listed as having been established. There 
has been no further news on the status of ALX-0651 since. 
Alternatively a CXCR4 peptide antagonist, CTCE-9908, underwent a phase I/II 
trial for solid tumours in which it demonstrated drug safety and a potential anti-
tumour effect in ovarian cancer [312]. Nonetheless since these findings (2007) 
there appears to be have been no further development with CTCE-9908 in the 
clinic. Although CTCE-9908 is still actively used in preclinical models [313-315] 
and has apparently been granted orphan drug status by the FDA for 
osteogenic sarcoma [316]. 
 
1.12.3 Challenges in Targeting Chemokine Signalling  
Despite nearly a decade of research into the therapeutic targeting of the 
chemokine signalling system for cancer treatment only two drugs worldwide 
have been licensed: AMD3100 and mogamulizumab, with only 
mogamulizumab used as a direct therapeutic agent against cancer 
progression.  
Several published review articles have discussed the challenges surrounding 
the blocking of the chemokine signalling system for the therapeutic treatment 
of inflammatory diseases including cancer [291, 292, 317, 318]. One of the 
most commonly cited reason for clinical failure is the redundancy thought to 
underpin chemokine signalling [319, 320], which could be particularly 
problematic for targeting chemokine signalling axis associated with 
inflammation (figure 1.4) [48, 321].  
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Evidence from the immunostaining of cancers has shown that cancer cells 
often overexpress multiple different chemokine receptors [130, 322, 323] whilst 
within the tumour microenvironment a multitude of different chemokines can 
be expressed at any given time [320, 324-326]. This therefore renders the 
targeting of a particular chemokine or receptor ineffective as alternative 
chemokine receptors present on the cancer cells can become activated 
instead.  
Nevertheless not all chemokines display promiscuity especially chemokines 
which are involved in more homeostatic roles, with many having cognate 
receptors also expressed on cancer cells e.g. CXCR4, CCR7 and CCR9 [115, 
130, 327]. However receptors such as CXCR4 are widely expressed amongst 
leukocytes [328] whilst CCR7 is expressed on both dendritic cells [329] and T-
lymphocytes [330]. Therefore their pharmacological blockade could provoke 
unwanted and toxic side effects especially when considering many immune 
cells like T-cells, natural killer cells and M1 macrophages play an important 
role in anti-tumour activity [331-333]. Thus disturbing some of these 
chemokine signalling axis may be particularly detrimental for the treatment of 
solid tumours [267, 324].  
Aside from redundancy, other explanations have included inappropriate target 
selection, off-target effects and poor pharmacokinetics [133, 317, 319]. 
Regarding inappropriate target selection, some of the contributing factors 
could involve inter-tumour heterogeneity as a few studies have reported 
chemokine receptor expression being associated with a more favourable 
prognosis in certain cancers [334-337]. Therefore as some clinical trials 
involve a range of solid tumours this approach may not be the most effective 
method to establish a therapeutic benefit. Moreover most preclinical models 
rely on immunodeficient mice as a proof of concept for targeting chemokine 
signalling in cancer [284, 285, 287, 338]. Which as previously mentioned, as 
chemokine receptors are expressed on anti-tumour immune cells the lack of 
anti-tumour leukocytes in vivo could over exaggerate the efficacy of chemokine 
blockade on cancer progression and hence would not translate into the clinic. 
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In the case of small molecule inhibitors their off-target effects maybe a result 
of their allosteric binding inside the receptor transmembrane domain [132], as 
the transmembrane domain is more conserved amongst chemokine receptors 
and as such this may cause off-targeting and possibly reduce clinical efficacy 
[319].   
As discussed in this section, despite the wealth of preclinical evidence for 
targeting chemokine receptors for cancer treatment this strategy has thus far 
been mainly unsuccessful, particularly for solid tumours [298, 299, 307-309]. 
Hence there is still an urgent need to identify alternative approaches to block 
chemokine driven progression of cancer. One option are dual receptor 
inhibitors such as Repaxirin which may offer a way of overcoming some 
receptor redundancy though this has not yet been proven in the clinic. 
Combination therapies involving checkpoint inhibitors is another possibility 
with mogamulizumab currently undergoing several such clinical trials (Trial 
registration ID NCT03309878 and NCT02476123). 
Another therapeutic strategy is to target specific proteins which are acting 
downstream of chemokine signalling to promote cancer cell migration. 
However one obstacle to this approach is that many of these downstream 
signalling pathways are not particularly well understood, with the few published 
studies on these cell signalling pathways tending to focus on the CXCL12-
CXCR4 signalling axis and often in breast cancer [339-343]. Nonetheless a 
few key proteins such as Src, PI3K, protein tyrosine kinase 2, Casitas B-
lineage Lymphoma, ELMO (Engulfment and Cell Motility), FAK and SH2-
containing phosphatase 2 have been identified as being important for breast 
cancer cell migration in response to CXCL12 [339-344]. Some of these 
findings are from single studies, with a few deriving their results from only one 
breast cancer cell model. Therefore these results do not always account for 
cell specific differences as despite the limited amount of studies investigating 
the downstream signalling pathways of chemokines evidence of cell specific 
biases have been observed [89, 340, 345].  
In the breast cancer MCF-7 cells, CXCL12 migration was shown to be 
dependent on PKC signalling [340] whilst in another breast cancer model,  
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MDA-MB-231 cells this was not the case [342, 343]. Similar differences in the 
role of PKC in CXCL12 signalling have also been observed between the 
migration of the leukemic Jurkat cells and MCF-7 cells [340]. However one 
potential drawback when comparing some of these different cell types was the 
different approaches used to measure cellular migration i.e. the wound healing 
assay and chemotaxis. Which may have also influenced the molecular 
mechanisms involved in cell migration. Notwithstanding cell specific biases, it 
is also possible for different chemokine ligands to activate separate signalling 
pathways within the same cell type under very similar conditions. Such as the 
importance of Rac for CXCL12 but not CCL3 migration in MCF-7 and 
monocytic THP-1 cells [346], or Gβγ for CXCL11 but not CCL3 chemotaxis in 
THP-1 cells [347].  
These studies begin to demonstrate the possibility for significant differences in 
the molecular machinery for cellular migration between distinct chemokine and 
cell types. Which, when considering the vast number of chemokines and 
proteins involved in cellular migration provides both a substantial challenge but 
also a great opportunity to develop targeted treatments against cancer 
metastasis. As such there is a need to further explore the molecular 
mechanisms which are involved in cell migration. 
  
   
 
60 
 
1.13 Research Aim 
Chemokines are a large family of cytokines, which regulate leukocyte 
migration under both homeostatic and inflammatory conditions [107]. 
Dysregulation of the chemokine signalling network provides cancer cells with 
the opportunity to metastasize to other sites within the human body [115, 130]. 
As such chemokine receptor overexpression on cancer cells is often 
associated with a poor prognosis for cancer patients [115]. Despite many 
clinical trials attempting to block chemokine signalling to prevent cancer 
metastasis the vast majority have been unsuccessful [291]. With chemokine 
promiscuity and inappropriate target validation considered to be two of the 
main causes [317]. Consequently, there is still a need to find alternative 
strategies to successfully disrupt chemokine signalling for cancer treatment. 
In cancer cells, chemokine signalling activates a downstream pathway to 
promote cell migration and invasion [348]. As such, one alternative is to identify 
other viable therapeutic candidates downstream of the chemokine receptor 
which are also essential for cancer cell migration. However, very little is known 
about the downstream molecular mechanisms and furthermore these 
downstream signalling pathways can differ depending on the chemokine and 
cancer cell type [340, 346, 347]. Therefore this is still an area of cancer 
research which warrants further study and subsequently forms the basis of the 
PhD work presented in this thesis.  
To investigate the downstream signalling pathway, a pharmacological based 
approach was used to identify and assess the importance of particular proteins 
(commonly dysregulated in cancer) in chemokine driven cancer cell migration. 
The aim of this thesis was to initially identify chemokines signalling pathways 
important for carcinoma metastasis and thereafter use small molecules to 
interrogate their downstream molecular mechanisms to discover novel 
therapeutic targets. 
 
 
 
   
 
61 
 
The outline of the research objectives were as follows: 
 Chapter 3 
The aim of this chapter was to identify chemokine signalling pathways 
important for the metastasis of carcinoma cells. This was achieved by 
screening a range of chemokine ligands to determine their effect on the 
migration, actin cytoskeleton and release of calcium from the intracellular 
stores in different cancer cell types. 
 Chapter 4 
As chemokines signal via the heterotrimeric G-protein to induce 
chemotaxis [349]. The aim of this chapter was to explore the role of the 
heterotrimeric G-protein signalling pathway in the migration of leukemic 
and carcinoma cell types in response to two notable chemoattractants: 
CCL3 and CXCL12. To investigate the downstream signalling pathway 
several known Gαi/βγ effectors including FAK, PI3K and PLC were studied, 
due to their implication in the development of cancer [225, 350-352]. 
 Chapter 5 
Actin polymerisation is a principal driving force for both cell migration and 
cancer invasion [353, 354]. As such, in this chapter the involvement of 
cytoskeletal regulators DOCK, Arp2/3 and the microtubules in CCL3 and 
CXCL12 downstream signalling was investigated in different leukemic and 
carcinoma cell types. 
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Chapter 2.0 Materials and Methods 
 
2.1 Tissue culturing 
2.1.1 Reagents 
The Dulbecco’s Modified Eagle Medium (DMEM) and Rosewell Park Memorial 
Institute (RPMI) 1640 were supplied by Thermo Fisher Scientific 
(Loughborough, UK). Fetal Calf Serum (FCS) and glutamine were supplied by 
Life Technologies (Thermo Fisher Scientific), and non-essential amino acids 
by (Thermo Fisher Scientific). The G418 was obtained from Invitrogen 
(Thermo Fisher Scientific), with 500 µg/mL added to DMEM media for CHO-
CCR5 subculture.  
Adherent cell lines were harvested using 0.25% Tryspin/EDTA or Trypsin/PBS 
supplied by Life Technologies (Thermo Fisher Scientific) and 2 mM 
EDTA/PBS. Both the Ethylenediaminetetraacetic acid (EDTA) and phosphate 
buffered saline (PBS) (8.1 mM, Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, and 
2.7 mM KCL, with a pH 7.2) were obtained from Thermo Fischer Scientific.  
Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich (Poole, UK). 
 
2.1.2 Cell culture  
All the secondary mammalian cancer cell lines: MCF-7 (Michigan Cancer 
Foundation-7), MIA PaCa-2, MDA-MB-231, PC-3 (Prostate Cancer-3), Jurkat 
and THP-1 cells were obtained from American Type Culture Collection 
(ATCC), Teddington, UK.  
In addition, Chinese Hamster Ovary cells transfected with pcDNA3 encoding 
human CCR5 (CHO-CCR5) and antibiotic resistance gene to Geneticin (G418) 
were also used in this thesis. The CHO-CCR5 cells have been previously 
described and were provided by J. McKeating, Reading, UK [355]. 
MCF-7, MIA PaCa-2, MDA-MB-231 and CHO-CCR5 were cultured in DMEM, 
supplemented with 10% v/v FCS, 2 mM glutamine and 10X non-essential 
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amino acids. CHO-CCR5 were also cultured with the same DMEM 
composition previously stated, but also contained 500 µg/ml of G418.  
PC-3, THP-1 and Jurkat cells were cultured in RPMI 1640 Medium, 
supplemented with 10% v/v FCS, 2 mM glutamine and 10X non-essential 
amino acids.  
 
2.1.3 Cell culture protocol 
All cell lines were cultured in 75 cm2 (ThermoFischer Scientific) cell culture 
flask and incubated at 37°C, 5% CO2 and 100% humidity. All cell culture was 
performed under class 2 vertical laminar air flow cabinets at room temperature. 
All cell lines were subcultured as described in tables 2.1 and 2.2. 
For storing cell lines, cells were harvested and spun down (12000 revolutions 
per minute (RPM) for 5 mins) after reaching 90% confluency. Supernatant was 
removed and cells were resuspended in freezing media (10% v/v DMSO and 
FCS) for cryopreservation. 1 mL of cells were loaded into 1.8 ml sterile 
Cryotubes (BioSigma (Cona, Italy)), before wrapped within several layers of 
tissue to retain moisture and ease the freezing process to minimise cellular 
damage from crystallisation. The cells were then frozen overnight at -80°C, 
and then placed in liquid nitrogen at -196°C for long term storage. 
For defrosting cells, cells were quickly thawed and washed once in growth 
media (10 mL). Thereafter, cells were resuspended in growth media (10 mL) 
and seeded into a 25 cm2 cell culture flask (Thermo Fischer Scientific) before 
being incubated at 37°C, 5% CO2 and 100% humidity. Cells were harvested 
and reseeded into a 75 cm2 cell culture flask after reaching 90% confluency. 
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2.1.4 Description of cell lines and subculture methods used 
2.1.4.1 MCF-7 cells 
MCF-7 cells are a mammalian epithelial cell line originating from the breast 
tissue and obtained from the pleural effusion site of a 69 year old Caucasian 
women diagnosed with breast adenocarcinoma [356]. MCF-7 cells express 
both oestrogen and progesterone receptors [357, 358], but do not overexpress 
HER-2 [359]. Thus MCF-7 cells are used as an in vitro model to understand 
hormone sensitive breast cancers. MCF-7 cells were harvested with 2 mM 
EDTA/ PBS (4 ml) and subcultured in DMEM growth media (10% v/v FCS, 2 
mM glutamine and 10X non-essential amino acids). Cells were split 1:10, after 
reaching 95% confluency (every 3 to 4 days). 
 
2.1.4.2 MDA-MB-231 cells 
MDA-MB-231 cells are a mammalian epithelial cell line originating from the 
breast tissue and obtained from the pleural effusion site of a 51 year old 
Caucasian women diagnosed with breast adenocarcinoma [360]. MDA-MB-
231 cells are thought to be insensitive to either oestrogen or progesterone and 
do not overexpress HER-2 [357, 361]. Therefore they are considered a model 
for the triple negative breast cancer subtype. 
For harvesting MDA-MB-231 cells, cells were washed in PBS (5 ml), prior to 
the addition of 0.25% Trypsin/PBS or EDTA (1.5 ml). MDA-MB-231 cells were 
subcultured in DMEM growth media (10% v/v FCS, 2 mM glutamine and 10X 
non-essential amino acids) and split 1:10 after reaching 95% confluency (every 
2 to 3 days). 
 
2.1.4.3 MIA PaCa-2 cells 
MIA PaCa-2 cells are a mammalian epithelial cell line originating from the 
pancreatic tissue of a 65 year old Caucasian male diagnosed with pancreatic 
carcinoma [362]. 
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MIA PaCa-2 cells were harvested with 2 mM EDTA/ PBS (4 ml) and 
subcultured in DMEM growth media (10% v/v FCS, 2 mM glutamine and 10X 
non-essential amino acids). Cells were split 1:10, after reaching 95% 
confluency (every 3 to 4 days). 
 
2.1.4.4 PC-3 cells 
PC-3 cells are a mammalian epithelial cell line originating from the bone of a 
62 year old Caucasian male diagnosed with grade IV metastatic prostate 
adenocarcinoma [363]. PC-3 cells express lower levels of the androgen 
receptor [364, 365] and are used as a model for the androgen insensitive 
prostate cancer subtype. 
PC-3 cells were harvested with 0.25% Trypsin/EDTA (3 ml) after reaching 90% 
confluency (between 3-5 days) and split 1:10. PC-3 cells were subcultured in 
RPMI 1640 growth media (10% v/v FCS, 2 mM glutamine and 10X non-
essential amino acids).  
 
2.1.4.5 CHO-CCR5 cells 
CHO-CCR5 cells are a mammalian epithelial cell line originating from the ovary 
of a female Chinese hamster. CHO cells are known for their ease of 
transfection and hence used to express recombinant genes and proteins [366]. 
The CHO cells were transfected with the pc3DNA plasmid which express 
human CCR5 and is resistant to G418 antibiotic. 
CHO-CCR5 cells were harvested with 2 mM EDTA/ PBS (4 ml) and 
subcultured in DMEM growth media (10% v/v FCS, 2 mM glutamine, 10X non-
essential amino acids and 500 µg/mL G418). Cells were split 1:10, after 
reaching 95% confluency (every 3 to 4 days). 
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2.1.4.6 THP-1 cells 
THP-1 cells are a mammalian monocytic cell line originating from the 
peripheral blood of a 1 year old human male infant diagnosed with acute 
monocytic leukaemia [367]. 
THP-1 cells were subcultured in RPMI 1640 growth media (10% v/v FCS, 2 
mM glutamine and 10X non-essential amino acids) and split either 1:2 or 1:3 
every 3 to 4 days after reaching a confluency above 70x104 cells mL-1. 
 
2.1.4.7 Jurkat cells 
Jurkat cells are a mammalian T-lymphocyte cell line originating from the 
peripheral blood of a human male diagnosed with acute T cell leukaemia [368]. 
Jurkat cells were subcultured in RPMI 1640 growth media (10% v/v FCS, 2 
mM glutamine and 10X non-essential amino acids) and split either 1:2 or 1:3 
every 2 to 3 days after reaching a confluency above 150x104 cells mL-1. 
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2.1.4.8 Summary of cell lines and subculture methods used 
Table 2.1. Adherent cells 
Cell line Origin Characteristics Cell subculture method 
MCF-7 Human: 
Caucasian 
Female, 69 
year old  
Oestrogen and 
progesterone 
positive breast 
adenocarcinoma 
- 4 ml of PBS/EDTA for 
harvesting cells. 
- Cells split (1:10) every 3 to 
4 days. 
MDA-MB-231 Human: 
Caucasian 
Female, 51 
year old 
Triple negative 
breast 
adenocarcinoma 
- Washed in 4 ml PBS (room 
temp), before harvesting with 
1.5 ml of 0.25% 
Trypsin/EDTA or PBS.  
- Cells split (1:10) every 2 to 
3 days. 
MIA PaCa-2 Human: 
Caucasian 
Male, 65 year 
old 
Pancreatic 
carcinoma 
- 4 ml of PBS/EDTA was 
used to harvest cells. 
- Cells split (1:10) every 3 to 
4 days. 
PC-3 Human: 
Caucasian 
Male, 62 year 
old 
Androgen 
negative, prostate 
adenocarcinoma, 
grade IV 
3 ml of 0.25% Trypsin/EDTA 
used to harvest cells. 
Cells split (1:10) every 3 to 5 
days. 
CHO-CCR5 Chinese 
Hamster 
Ovaries 
Overexpresses 
human CCR5  
- 4 ml of PBS/EDTA used to 
harvest cells. 
- Cells split (1:10) every 3 to 
4 days. 
 
Table 2.2. Suspension cells 
Cell line Origin Characteristics Cell culture method 
THP-1 Human: 1 
year old infant 
Acute monocytic 
leukaemia 
- Cells split (1:2 or 1:3) every 
3 to 4 days. 
Jurkat Human: Male Acute T-cell 
leukaemia 
- Cells split (1:2 or 1:3) every 
2 to 3 days. 
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2.2 Chemokines 
Chemokines: CCL2, CCL4, CCL5, CCL8, CCL23, CXCL8, CXCL9 and 
CXCL12 were obtained from Peprotech, London, UK. Chemokines were 
diluted in purified water and aliquoted into 10, 1 and 0.1 µM working stocks 
and stored at -20°C.  
CCL3 was a gift from a L.Czaplewski of British Biotech, and is the 
characterised CCL3 D26A isoform [369]. 
Pharmacological studies into chemokines has allowed the identification of 
some of the cognate receptors, cellular function and has also highlighted the 
potential for redundancy underpinning chemokine signalling. Improved 
understanding of chemokine pharmacodynamics allows the opportunity to 
explore the potential therapeutic benefits and feasibility in targeting the 
chemokine signalling network to treat inflammatory associated diseases.  
There is however still some discrepancy within the chemokine research field 
as to which chemokines can be considered an endogenous ligand for a 
particular chemokine receptor including the chemokine signalling axis 
presented in figure 1.4 [48, 113].  Consequently a literature search for 
published pharmacological studies on the chemokines used for this thesis was 
undertaken to identify some of the key cognate receptors. This list of 
chemokines and their respective cognate receptors was then used as a 
reference for the results presented in this thesis (see table 2.3).  
In table 2.4 is a list of all the small molecules which were used in this thesis 
and includes information on their respective protein targets, pharmacological 
properties, storage and concentrations used.
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Table 2.3. List of chemokines and their pharmacological properties for identified cognate receptors 
Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CCL2 
 
CCR2 
Receptor binding Ki= 0.1 nM in CHO-K1-CCR2 cells [96] 
Kd = 0.04 nM in THP-1 cells [370] 
GTPγS binding EC50 = 9 nM in CHO-CCR2B cells [370] 
Calcium flux EC50 = 0.7 nM in 300.19-CCR2 murine pre-B cells [371] 
EC50 = 6.31 nM in CHO-K1-CCR2 cells [96] 
EC50 = 3 nM in CHO-CCR2B cells [370] 
Chemotaxis EC50 = 2.2 nM in CD14+ monocytes [372]  
EC50 = 159 nM in primary hypothalamic neurons [373] 
EC50 = 1 nM in human primary monocytes [370] 
Dose response = 0.12-360 nM in HEK293-CCR2b cells [374] 
cAMP EC50 = 0.794 nM in CHO-K1-CCR2 cells [96] 
BRET β-arrestin2 
recruitment 
EC50 = 3.16 nM in CHO-K1-CCR2 cells [96] 
Internalisation EC50 = 15.3 nM in CHO-CCR2B cells [370] 
pERK phosphorylation EC50 = 0.106 nM in CHO-CCR2B cells [9] 
 
CCR3 
GTPγS binding EC50 = 1.1 nM in CHO-CCR3 cells [370] 
Internalisation EC50 = 4.1 nM in CHO-CCR3 cells [370] 
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Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CCL3 
 
CCR1 
Receptor binding Ki = 0.15 ± 0.07 nM in retinoic acid differentiated HL60 cells [375] 
Ki = 0.056 ± 0.013 nM in Ba/F3-CCR1 murine ProB cells [375]  
Kd = 4 ± 0.8 nM in HEK293-CCR1 cells [374]  
Kd = 5-9 nM in HEK293-CCR1 cells [376] 
GTPγS binding EC50 = 15 ± 25 pM in Ba/F3-CCR1 murine ProB cells [375] 
EC50 = 0.040 ± 0.04 nM in retinoic acid differentiated HL60 cells 
[372] 
Calcium flux EC50 = 0.1-0.3 nM for CCR1 in retinoic acid differentiated HL60 
cells [377] 
Chemotaxis EC50 = 0.2 nM in HEK293-CCR1 cells [378] 
EC50 = 0.1 nM for CCR1 in retinoic acid differentiated HL60 cells 
[375]  
Dose response = 0.012-360 nM in HEK293-CCR1 cells [374]  
Dose response = 0.12-120 nM in HEK293-CCR1 cells [376] 
  
CCR5 
GTPγS binding EC50 = 3.9 ± 2.4 nM in Ba/F3-CCR5 murine ProB cells [375]  
EC50 = 1.3 nM in CHO-CCR5 cells [355] 
EC50 = 2.3 nM in CHO-CCR5-CD4 cells [355] 
Calcium flux EC50 = 63.1 nM in CHO-K1-CCR5 cells [96] 
cAMP EC50 = 0.025 nM in CHO-K1-CCR5 cells [96] 
BRET β-arrestin2 
recruitment 
EC50 = 2.51 nM in CHO-K1-CCR5 cells [96] 
 
  Receptor binding IC50 = 7.4 nM in THP-1 cells [378] 
 Multiple Calcium flux EC50 = 4.7 nM in THP-1 cells [378] 
  Chemotaxis EC50  = 0.2 nM in THP-1 cells [378] 
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Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CCL4 
 
CCR1 
GTPγS binding EC50 = 11.9 ± 1.7 nM in Ba/F3-CCR1 murine ProB cells [375] 
EC50 = 17.1 ± 2.7 nM in retinoic acid differentiated HL60 cells 
[375] 
Calcium flux no response for CCR1 in retinoic acid differentiated HL60 cells 
[375] 
Chemotaxis no response for CCR1 in retinoic acid differentiated HL60 cells 
[375] 
agonist in Ba/F3-hCCR1 cells [375]  
weak agonist = 30 nM in HEK-293-CCR1 cells [376] 
 
CCR5 
Receptor binding Ki = 0.398 nM in CHO-K1-CCR5 cells [96] 
GTPγS binding EC50 = 5.8 ± 2.7 nM in Ba/F3-CCR5 murine ProB cells [375]  
EC50 = 3.4 nM in CHO-CCR5 cells [355] 
EC50 = 4.3 nM in CHO-CCR5-CD4 cells [355] 
Calcium flux EC50 = 6.31 nM in CHO-K1-CCR5 cells [96]   
cAMP EC50 = 0.794 nM  in CHO-K1-CCR5 cells [96] 
BRET β-arrestin2 
recruitment 
EC50 = 7.94 nM in CHO-K1-CCR5 cells [96] 
 
 
CCL5 
 
CCR1 
GTPγS binding EC50 = 1.4 ± 0.2 nM in Ba/F3-CCR1 murine ProB cells [375] 
EC50 = 2.2 ± 0.7 nM in retinoic acid differentiated HL60 cells [369]                                  
Chemotaxis EC50 = 0.6 nM in HEK293-CCR1 cells [378]   
Dose response = 6-360 nM in HEK293-CCR1 cells [376] 
  
CCR3 
Calcium flux ED50s  = 10 nM in AML14.3D10-CCR3 cells [379] 
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Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CCL5 
 
CCR5 
GTPγS binding EC50 = 0.27 ± 0.13 nM in Ba/F3-CCR5 murine ProB cells [375] 
EC50 = 3.4 nM ± 0.27 in HEK293T-CCR5 cells [380]  
EC50 = 0.33 nM in CHO-CCR5 cells [355]  
EC50 = 0.5 nM in CHO-CCR5-CD4 cells [355] 
Calcium flux EC50 = 2.3 nM in HEK293-CCR5 cells [380]  
EC50 = 80 nM in CHO-K1-CCR5 cells [96]                                         
cAMP EC50 = 0.0501 nM  in CHO-K1-CCR5 cells [8] 
BRET β-arrestin2 
recruitment 
EC50 = 7.94 nM in CHO-K1-CCR5 cells [96] 
 
  
Multiple 
Receptor binding IC50 = 1 nM in THP-1 cells [378] 
  Calcium flux EC50 = 13 nM in THP-1 cells [378] 
  Chemotaxis EC50 = 0.6 nM in THP-1 cells [378] 
 
CCL8 
 
CCR1 
GTPγS binding EC50 = 19.8 ± 2 nM in Ba/F3-CCR1 cells murine ProB cells [375] 
Chemotaxis Dose response = 0.012-360 nM in HEK293-CCR1 [374] 
 
CCR2 
Calcium flux EC50 = 15.4 nM in 300.19-CCR2 murine pre-B cells [371] 
Chemotaxis Dose response = 0.12-360 nM in HEK293-CCR2B [374] 
cAMP EC50 = 3.98 nM  in CHO-K1-CCR2 cells 
BRET β-arrestin2 
recruitment 
EC50 = 20 nM in CHO-K1-CCR2 cells [96] 
 
CCR3 
GTPγS binding  EC50 = 1.10 nM in CHO-CCR3 cells [370] 
Internalisation  EC50 = 3.1 nM in CHO-CCR3 cells [370] 
 
CCR5 
Receptor binding  Kd = 5 ± 2 nM in HEK293-CCR5 cells [381] 
GTPγS binding  EC50 = 5.5 nM in CHO-CCR5 cells [355] 
Calcium flux EC50 = 39.8 nM in CHO-K1-CCR5 cells  [96]                                       
Chemotaxis EC50 = 0.12 nM in HEK293-CCR5 cells [381] 
cAMP assay  EC50 = 0.631 nM  in CHO-K1-CCR5 cells [96]  
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Chemokine         Chemokine 
receptor 
Assay Pharmacological properties 
  BRET β-arrestin2 
recruitment 
EC50 = 100 nM in CHO-K1-CCR5 cells [96] 
CCL8 CCR5 Receptor binding Kd = 2 nM in human peripheral blood monocytes [374] 
 
CCL23 
 
CCR1 
Calcium flux EC50 = 3-10 nM for CCR1 in retinoic acid differentiated HL60 cells 
[375] 
Chemotaxis assay EC50 = 10-30 nM for CCR1 in retinoic acid differentiated HL60 cells 
[375] 
Receptor binding  Ki = 1 nM in HL-60-CXCR1 cells [382] 
Kd = 4.7 ±  0.095 nM in rat basophilic leukaemia-2H3-CXCR1 
[383] 
Kd = 1.2 ±  0.54 nM in rat basophilic leukaemia-2H3-CXCR1 [384] 
 
CXCL8 
 
CXCR1 
Calcium flux EC50 = 2 nM in HL-60-CXCR1 cells [382]  
EC50 = 1.5 ± 0.1 nM in human neutrophils [385] 
agonist at 10 nM in rat basophilic leukaemia-2H3-CXCR1[384] 
PI hydrolysis  Dose dependent response = 0.1-1000 nM in rat basophilic 
leukaemia-2H3-CXCR1 [384] 
Chemotaxis  EC50 = 0.814 nM in human neutrophils [386]  
EC50 = 3.1 ± 1.1 in rat basophilic leukaemia -2H3-CXCR1 [385] 
Dose dependent response = 0.01-100 nM in rat basophilic 
leukaemia -2H3-CXCR1 [384] 
Internalisation  100 nM induced 50% CXCR1 internalisation after 60 mins in rat 
basophilic leukaemia-2H3-CXCR1 [384] 
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Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CXCL8 
 
CXCR2 
Receptor binding  Ki = 1 nM in HL-60-CXCR2 cells [382]  
Kd = 2.49 ± 0.13 nM in rat basophilic leukaemia -2H3-CXCR2 [383] 
Kd = 1.02 ± 0.94 nM in rat basophilic leukaemia -2H3-CXCR2 [384] 
Calcium flux  agonist at 10 nM in rat basophilic leukaemia -2H3-CXCR2 [384] 
PI hydrolysis  Dose dependent response = 0.1-1000 nM in rat basophilic 
leukaemia-2H3-CXCR2 [384] 
Chemotaxis  EC50 = 3.8 ± 0.2 in rat basophilic leukaemia -2H3-CXCR2 [385]  
- dose dependent agonism 0.01-100 nM in rat basophilic leukaemia-
2H3-CXCR2 [384] 
Internalisation  100 nM induced 95% CXCR2 internalisation after 60 mins in rat 
basophilic leukaemia-2H3-CXCR2 [384] 
 
CXCL9 
 
CXCR3 
GTPγS binding  EC50 = 260 nM in CHO-CXCR3 cells [387] 
Calcium flux  EC50 = 22 nM in rat basophilic leukaemia-CXCR3 [387] 
Chemotaxis assay EC50 = 0.34 ± 0.05 nM in peripheral blood mononuclear cells from 
patients with chronic obstructive pulmonary disease [388] 
EC50 = 24.5 nM in H9 T lymphoma cells [387] 
 
 
 
 
   
 
75 
 
Chemokine Chemokine 
receptor 
Assay Pharmacological properties 
 
CXCL12 
 
CXCR4 
Calcium flux  EC50 = 1.6 nM in U87.CD4.CXCR4 cells [389] 
EC50 = ∼2 nM in Fetal bovine heart endothelial cells [126]  
EC50 = 17 nM in HEK-293-CXCR4 cells [390] 
Chemotaxis  EC50 = 10-20 nM in human endothelial cells [126] 
EC50 = 7.9 nM in T-lymphoblast CCL-119 cells [391] 
Wound healing  EC50 =  508 nM in H1299 cells (human non-small cell lung 
carcinoma) [392] 
Dynamic mass 
redistribution  
EC50 = 53 nM in Jurkat cells [390] 
EC50 = 73 nM in HEK-293-CXCR4 cells [390] 
S346/347-
phosphyorylation  
EC50 = 0.87 nM in HEK-293-HA-tagged CXCR4 cells [390] 
PRESTO-Tango β-
arrestin recruitment  
EC50 = 4.6 nM in HTLA cells [393] 
BRET β-arrestin 
recruitment assay 
EC50 = 242 nM in HEK293T-CXCR4 cells [394]  
 
ACKR3  
(previously known as 
CXCR7) 
Receptor binding  Kd = 0.4 ± 0.1 nM in A0.01-CXCR7 T-cells [395] 
BRET β-arrestin2 
recruitment 
EC50 = 30 nM in HEK293T-CXCR7 cells [394] 
β-arrestin2 
recruitment   
EC50 = 18 ± 7 nM in CHO-CXCR7 cells [396] 
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Table 2.4. Details of small molecules used 
Compound 
category 
Compound Protein 
target 
Pharmacological 
properties 
Supplier Vehicle Storage Stock 
conc 
Assay 
conc 
 
Chemokine 
receptor 
antagonists 
 
J113863 CCR1 
CCR3  
IC50 = 0.73 nM for  
CCL3 activation of CCR1 
[397] 
IC50 = 0.58 nM for  
Eotaxin binding of CCR3 
[397] 
TOCRIS  
Bioscience 
(Bristol, 
England) 
DMSO 4°C 
 
10 mM 10 nM 
Maraviroc CCR5 IC50 = 3.3 nM for  
CCL3 activation [398] 
Pfizer 
(Sandwich, 
UK) 
Ethanol Room 
Temp 
500 µM 10 nM 
AMD3100 CXCR4 CXCR4 IC50 = 5.7 nM  
Chemotaxis IC50 = 44 nM 
[396] 
Santa Cruz 
(Dallas, 
USA) 
DMSO -20°C 100 mM 1 μM 
 
Tyrosine 
kinase 
antagonists 
 
FAK14 FAK IC50 = 1 µM [399] TOCRIS  
Bioscience 
H2O -20°C 50 mM 1 µM 
PF562271 FAK IC50 = 5 nM [400] Abcam 
(Cambridge, 
UK) 
DMSO -20°C 10 mM 10 nM 
 Masitinib Lyn B IC50 = 510 ± 130 nM [401] Santa Cruz DMSO -20°C 100 mM 500 nM 
Bosutinib Src IC50 =  100 nM [402] Selleck  
Chemicals 
(Munich, 
Germany) 
DMSO 4°C 100 mM 250 nM-
25 nM 
MNS Src /Syk  IC50 =  29.3/2.5 µM [403] Santa Cruz DMSO -20°C 1000 mM 10 µM 
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Compound 
category 
Compound Protein 
target 
Pharmacological 
properties 
Supplier Vehicle Storage Stock 
conc 
Assay 
conc 
 
Serine/threonine 
kinase antagonists 
  
Y27632 ROCK ROCK1 Ki = 220 nM 
ROCK2 Ki = 300 nM 
[404] 
TOCRIS  
Bioscience 
H2O -20°C 2 mM 20 μM 
ZM336372 c-Raf IC50 = 70 nM [405] Santa Cruz DMSO -20°C 10 mM 1 µM 
 
Phosphodiesterase 
antagonists 
    
U73122 PLC/PIP2 IC50 = 1-5 µM [406] TOCRIS  
Bioscience 
DMSO -20°C 2 mM 1 μM-
50 nM 
 
ATPase pump 
antagonist 
   
Thapsigargin ER Ca2+ 
ATPase 
IC50 = 30 nM [407] Sigma Aldrich DMSO 4°C  1% 
 
Guanine nucleotide 
exchange factor 
antagonist 
  
CPYPP DOCK 
1/2/5 
DOCK 2 IC50 = 22.8 
μM [408] 
TOCRIS  
Bioscience 
DMSO -20°C 50 mM 5 mM- 
1 μM 
 
PI3K antagonists 
  
AS605240 PI3Kγ IC50 = 8 nM [377] Stratech  
Scientific 
(Ely, UK) 
DMSO -20°C 100 mM 2.5 µM 
LY294002 PI3K IC50 =  1.4 µM [409] Selleck  
Chemicals 
DMSO -20°C 25 mM 10 µM 
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Compound 
category 
Compound Protein 
target 
Pharmacological 
properties 
Supplier Vehicle Storage Stock 
conc 
Assay 
conc 
 
G-protein  
antagonists 
 
Gallein Gβγ IC50 = 241 ± 24 nM 
[410] 
TOCRIS  
Bioscience 
Ethanol -20°C 6 mM 10 μM 
 PTX Gαi IC50 = 158 ± 40 pg/ml 
[411] 
Sigma 
Aldrich 
H2O 4°C 0.1 µg/µL 100 
ng/mL 
EHT 1864 Rac Rac1 Kd = 40 nM 
Rac1b Kd = 50 nM 
Rac2 Kd = 60 nM 
Rac3 Kd = 230 nM [412] 
Cambridge  
Biosciences 
(Cambridge, 
England) 
H2O -20°C 10 mM 100 nM 
 
Cytoskeletal 
effectors 
 
CK666 Arp2/3 IC50 = 4 μM [413] TOCRIS 
Bioscience 
DMSO -20°C 100 mM 10 μM 
Nocodazole Microtubules αβII Kd = 0.52 ± 0.2 μM 
αβIII Kd = 1.54 ± 0.29 μM 
αβIV Kd = 0.29 ± 0.04 μM    
[414] 
TOCRIS 
Bioscience 
Ethanol -20°C 25 mM 3 μM 
Taxol Microtubules IC50 1-10 nM [415] Santa Cruz DMSO -20°C 100 mM 1 nM 
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2.3 Antibodies 
Table 2.5. Primary antibodies 
Antibody Protein 
Target 
Dilution 
factor 
Supplier Species 
raised in 
Storage 
MAB145 Human 
CCR1 
1:100  R&D 
systems 
Mouse -20°C 
HEK/1/85a/7a 
and 1/74/3j 
(abbreviated 
to 83a15j) 
Human 
CCR5 
1:500 Dr 
J.McKeating 
Rat 4°C 
 
Table 2.6. Secondary antibodies 
Antibody Antibody 
specificity 
Dilution 
factor 
Supplier Species 
raised 
in 
Storage 
Anti-mouse IgG 
Tetramethylrhodamine  
(TRITC) 
mouse 1:50  Sigma 
Aldrich 
Goat 4°C 
Anti-rat IgG Fluorescein 
isothiocyanate  
(FITC) 
rat 1:50 Sigma 
Aldrich 
Goat 4°C 
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2.4 Cellular migration experiments 
2.4.1 The wound healing assay 
Prior to cell seeding, 12 or 24 well plates were marked across the bottom with 
two parallel horizontal lines using a marker pen which served as a reference 
point for imaging the same scratches at different time points. Cells were 
seeded onto either a 12 or 24 well plate in 1 mL or 0.5 mL growth media 
respectively and incubated overnight at 37°C, 5% CO2 and 100% humidity to 
form a confluent (100%) cell monolayer. The following day, growth media was 
removed and the cells were covered with 0.5 ml or 1 ml simple media to reduce 
cell proliferation. Three scratches were induced across the monolayer per well 
with either a 200 or 1000 µl pipette tip. After scratch induction, media was 
removed to clear cellular debris and cells were washed twice with 200 µl or 
400 µl simple media. Each scratch was imaged using a Leica DMI6000 
inverted microscope and Leica application suite, version 2.8.1.The image 
settings were at 77.7 ms exposure time, 0.75 saturation, 0.89 Gamma and 
2.0X Gain and under 10x objective. After scratch imaging, chemokines and 
compounds were added to cells and incubated at 37°C, 5% CO2 and 100% 
humidity for the designated time period. Following incubation the same 
scratches were reimaged using the previous imaging specifications. At the final 
time point all media was removed and cells were covered with 200 µl or 400 µl 
PBS.  
To calculate cellular migration two approaches were used. The primary 
method involved measuring the scratch width before and after incubation using 
MS Powerpoint 2013. A ratio between the scratch width before and after 
incubation was taken to give a scale from 1 to 0. A value of 1 corresponded to 
no cellular migration, whilst 0 equated to full migration.  
The alternative method was using ImageJ 1.48v. For this method, all images 
were cropped to show the scratch only. The cropped images were then 
converted to an 8-bit grey scale image and sharpened, with the edges of the 
cells marked and identified. To remove some of the background noise, the 
image was despeckled. The image background was then subtracted using the 
light background setting, with the rolling ball radius set at 10 µm pixel size, as 
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the largest size for all objects in the foreground. To measure the cell coverage, 
the threshold was adjusted to identify all objects considered as cells, with all 
objects/cells with pixel size: 0-infinity and circularity: 0-1 were counted. Cells 
at the edge of images and holes within cells were counted. From the particle 
analysis data, the percentage area (of cells) before incubation was divided by 
the percentage area (of cells) after incubation, to give a ratio of change in cell 
coverage (%). The closer the ratio was to 0, the more cellular migration. 
 
2.4.2 Agarose spot assay 
To make the agarose spot, low-melting point agarose (Sigma Aldrich) was 
diluted in PBS, to give a 0.5% agarose solution. The 0.5% agarose solution 
was heated on a hot plate, to dissolve the agarose particles, before being 
cooled to 40°C. Chemokine was prepared into a 0.1% BSA/PBS stock, and 
then diluted in molten 0.5% agarose solution (40°C), to give a final 
concentration of 125 nM. For the control, 0.1% BSA/PBS was added to the 
0.5% agarose solution.  
Using a black marker, a line was marked across the middle, along the bottom 
of the 35 mm plate. One side was labelled as the control, whilst the other 
CXCL12 125 nM as shown in figure 2.1 (below). 
 
Figure 2.1. Agarose spot assay setup. Orange circles correspond to 
agarose spots. 
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2 mm was removed from the ends of 20 µl pipette tips, and two, 10 µl spots of 
either chemokine/agarose or PBS/agarose (control) were pipetted onto a 35 
mm sterile plate. The plate was then incubated at 4°C for 5 mins to cool the 
agarose spots. 
MDA-MB-231 cells were harvested with trypsin/PBS and prepared in 1 mL 
DMEM growth media, at a cell density of 17x104 per mL cells. Cells were 
incubated at 37°C, 5% CO2 and 100% humidity for 4 hrs allowing the cells to 
adhere to the base of the plate. After 4 hrs, DMEM growth media was removed 
and cells were covered with simple DMEM media, and then incubated at 37°C, 
5% CO2 and 100% humidity for 24 hrs. 
Following incubation the edges of all four agarose spots were imaged using a 
Leica DMI6000 inverted microscope and Leica application suite, version 2.8.1. 
Cells within each spot were counted with the cell number used as a 
measurement of cellular migration. 
 
2.4.3 Transwell migration assay 
2.4.3.1 Suspension cells 
Chemotaxis was measured using a microchemotaxis chamber (ChemoTx® 
System from Neuro Probe Inc.) with wells blocked with 30 µl of blocking buffer 
(1% BSA in simple RPMI) for 30 mins. Following blocking, 31 µl of chemokine 
diluted in working buffer (0.1% BSA in simple RPMI) or working buffer alone 
for controls, was added to each well. Cells were then harvested and adjusted 
to a concentration of 25x104 cells mL-1 and 50x104 cells mL-1 per well for 
Jurkats and THP-1 cells respectively, and resuspended in working buffer. Cells 
were then incubated with either vehicle or compounds for 30 mins at 37°C and 
5% CO2, prior to loading. 20 µl cells were then loaded onto a 5 μm pore 
polyvinylpyrollidone-free polycarbonate filter membrane and incubated for 4 
hrs at 37°C and 5% CO2 in a humidified chamber.  After 4 hrs, the 
polyvinylpyrollidone-free polycarbonate filter membrane was removed and 10 
µl was taken from the wells and loaded onto a Neubauer hemocytometer. Cells 
present in each well were counted, with the number of cells counted used as 
a measure of cellular chemotaxis. All conditions were performed in duplicates. 
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2.4.3.2 Adherent cells 
Similar to suspension cells: chemotaxis was measured using a 
microchemotaxis chamber (ChemoTx® System from Neuro Probe Inc.). All 
wells were blocked with 30 µl of blocking buffer (1% BSA in simple RPMI) for 
30 mins. Following blocking, 31 µl of chemokine diluted in working buffer (0.1% 
BSA in simple RPMI) or working buffer alone for controls, was added to each 
well. PC-3 cells were harvested with 3 ml of 0.25% Trypsin/EDTA and adjusted 
to a concentration of 10x104 cells per mL-1 per well. 20 µl of cells were then 
loaded onto a 8 μm pore polyvinylpyrollidone-free polycarbonate filter 
membrane and incubated for 24 hrs at 37°C and 5% CO2 in a humidified 
chamber. After 24 hrs, cells on the upper surface of the membrane were 
removed gently through swabbing with a cotton bud. Working buffer was 
removed from the wells and washed once with 31 μl of PBS. 31 μl of 4% 
paraformaldehyde was then added to the wells and the underside of the 
membrane was fixed for 5 mins. Following fixation, wells were washed with 
PBS (31 μl) and then 31 μl of crystal violet (Biocolor Ltd) was added. The 
underside of the 8 μm pore polyvinylpyrollidone-free polycarbonate filter 
membrane was stained for 30 mins. After 30 mins the membrane was washed 
with PBS to remove excess crystal violet. To account for the background 
staining from the crystal violet: a well which had been incubated with no cells 
was also fixed and then stained with crystal violet. To measure chemotaxis, all 
cells on the underside of the 8 μm pore polyvinylpyrollidone-free polycarbonate 
filter membrane were counted using a Leica DMI6000 inverted microscope 
with a 40x objective. The number of cells counted for each condition was 
subtracted against the number of cell shaped objects identified from the 
background stain, as a true measurement of cellular chemotaxis. 
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2.4.4 Time-lapse assay 
PC-3 cells were harvested with 1.5 mL of 0.25% Trypsin/EDTA. PC-3 cells 
were sparse seeded onto a 24 well plate by pipetting 10 μl of cells into 1 mL 
of RPMI growth media. Cells were then incubated overnight at 37°C, 5% CO2 
and 100% humidity. Following incubation, growth media was removed and 
cells were recovered in 200 μl of fresh RPMI growth media. Cells were then 
incubated in the presence or absence of CXCL12 and inhibitors for 10 hrs at 
37°C, 5% CO2 and 100% humidity. During incubation cells were imaged every 
4 mins with a Zeiss Axiovert 200M microscope and using AxioVision Rel 4.8 
software at a 10x objective. Cell migration was analysed using ImageJ 1.48v 
with all the images set at 1 µm for the z plane and either 1.023 or 0.645 µm as 
the scale for the x/y plane: hence all the data was normalised. The distance 
was manually tracked for a least 10 cells per condition and the cellular velocity 
calculated as the distance (µm)/time (hrs). 
 
2.5 Cellular signalling experiment  
2.5.1 Intracellular calcium flux assay 
Cells were harvested with appropriate agent and centrifuged at 12000 rpm for 
5 mins. Thereafter cells were washed twice and resuspended in calcium flux 
buffer (reagents: 137 mM NaCl, 5 mM KCl, 1 mM MgCl, 1.5 mM CaCl2, 10 mM 
Hepes and 25 mM D-glucose (pH 7.4)) (4°C). Cells were then incubated with 
4 µM of Fura-2 AM (Invitrogen, ThermoFischer Scientific) alongside vehicle or 
compounds for 30 mins in the dark, at 37°C, 5% CO2 and 100% humidity. For 
experiments involving PTX, MCF-7 cells were seeded and incubated overnight 
in two separate 25 cm2 cell culture flasks to reach a 95% confluency. After 
incubation growth media was removed and the cells were incubated for a 
further 16 hrs with PTX in simple DMEM (100 ng/mL) or simple DMEM alone 
as a control. Following 16 hrs the cells were detached and harvested as per 
usual. 
Cells were then washed twice with calcium flux buffer (4°C) to remove excess 
Fura-2 AM. 100 µl of cells were then added to each well of the 96 well black 
plate and loaded into the Fluorometer. The Fluorometer microinjector pump 
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was cleaned with H2O (room temperature) twice, both before and after 
chemokine priming. The Fluorometer ran under BMG Labtech FLUOstar 
OPTIMA/POLARstar program with the Gain threshold set at 30%. Cells were 
excited at both 340 and 380 nm and the emission was measured at 510 nm at 
1.46 secs intervals over a 73 secs assay running time. Chemokines were 
injected after 15 secs of the assay running time.  
The intracellular calcium levels were measured as a ratio between the relative 
fluorescent units (at 510 nm) of the calcium bound Fura-2 (340 nm) and 
unbound Fura-2 (380 nm). Intracellular calcium fluctuations were quantified 
using two approaches: one by subtracting the difference between the 340:380 
ratio prior to chemokine stimulation (background fluorescence) and the peak 
340:380 ratio after chemokine stimulation (maximal fluorescence). 
Alternatively the 340:380 ratio data points were all normalised to the first data 
point (0 secs) which was defined as 100%. GraphPad Prism 6 was then used 
to measure the Area under Curve with the baseline set at 100% and only peaks 
above this baseline measured. 
 
2.6 Cellular proliferation experiment 
2.6.1 MTS cytotoxicity assay 
Cells were seeded in growth media (200 μl) at the appropriate cell density onto 
either a round or flat bottomed clear 96 well plate (Sterilin Ltd, UK) depending 
on suspension or adherent cell type respectively. Control wells contained 
growth media only to measure background absorbance. 100 μl of PBS was 
added to surrounding wells to prevent loss of media during incubation. Cells 
were incubated in the presence or absence of compounds for the designated 
time at 37ºC, 5% CO2 and 100% humidity.  
After incubation 10 μl of MTS reagent (3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium from CellTiter 96 
AQueous Non-Radioactive Cell Proliferation Assay (Promega)) was added to 
each well and incubated for at least one h.  
   
 
86 
 
During incubation the NAD(P)H dehydrogenase in viable cells metabolises the 
MTS tetrazolium into formazan, which is a purple coloured compound soluble 
in media. The concentration of formazan can be quantified by measuring it’s 
absorbance at 492 nm using a BMG Labtech FLUOstar fluorometer. The 
absorbance readings are directly proportional to the number of viable cells 
allowing changes in cellular proliferation to be detected.  
After incubation the absorbance of the plate was read at 492 nm. Cellular 
proliferation was measured against the absorbance reading of the media 
(background) whilst compound cytotoxicity was assessed against the control 
(cells only). 
 
2.7 Cellular imaging experiments  
2.7.1 Immunofluorescence 
Cells were detached after reaching 90% confluency and seeded onto a glass 
coverslip in a 12 well plate containing growth media (1.5 ml) and incubated at 
37ºC, 5% CO2 and 100% humidity overnight. Following incubation growth 
media was removed and 500 μl of PBS (4ºC) was added. Cells were washed 
twice with PBS (4ºC) and incubated with the primary antibody for 1 h at 4°C, 
except for the control cells which were incubated with PBS (4ºC) only. After 
incubation the primary antibody was removed and the cells were washed twice 
with PBS (4ºC) and then incubated with the secondary antibody for 1 h at 4ºC 
in the dark. Following 1 h the cells were washed twice with PBS (4ºC) and fixed 
with 4% Paraformaldehyde and then mounted onto glass slide using DPX 
(Thermo Fisher Scientific) or alternatively fixed with glycerol and imaged 
thereafter. All cells were imaged using Leica DMI6000 inverted microscope 
and Leica application suite, version 2.8.1.  
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2.7.2 Phalloidin Staining 
Cells were harvested using the appropriate agent after reaching 90-95% 
confluency. MCF-7 and CHO-CCR5 cells were seeded onto a 12 well plate 
with glass coverslips whilst PC-3 cells were seeded onto a 12 well plate. All 
cells were grown in 1.5 ml growth media and incubated overnight at 37ºC, 5% 
CO2 and 100% humidity. After cells had reached 70-80% confluency the 
growth media was removed and cells were washed twice with simple media 
(400 µl). Chemokines and inhibitors were added to the cells and incubated for 
24 hours at 37ºC, 5% CO2 and 100% humidity. After 24 hrs the media was 
removed and cells were washed twice with 500 µl of PBS (4ºC), and fixed with 
100 µl of 4% Paraformaldehyde for 5 mins. After fixing cells were washed once 
more with 500 µl PBS (4ºC) and then permeabilized with 200 µl, 0.1% Triton x-
100 (FischerBiotech) for 10 mins. Following permeabilized, cells were washed 
with 500 µl PBS (4ºC) and stained with 200 µl Phalloidin CruzFluor TM594 
conjugate (Santa Cruz) (diluted 1:1500 in 1% BSA/PBS) and incubated for 30 
mins in the dark at room temperature. Cells were washed again with 500 µl 
PBS (4ºC) and either mounted with DPX onto glass slide or recovered with 500 
µl PBS in the 12 well plate. All fixed cells were imaged using a Leica DMI6000 
inverted microscope and Leica application suite, version 2.8.1.  
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2.7.3 Phalloidin Staining: ImageJ analysis 
All images were converted to 32-bit grayscale using ImageJ 1.48v and the 
contrast enhanced to 0.4% saturated pixels to identify cells easier. All clearly 
visible cells were drawn around using freehand selection and measured for 
area, shape descriptors, integrated density and mean gray value. The cellular 
fluorescence was calculated using the corrected total cell fluorescence (CTCF) 
equation:  
CTCF = integrated density of selected cell – (area of selected cell x mean       
fluorescence of background readings). 
Two background readings were taken for each image: a high and a low 
fluorescence reading. A mean was then taken from these two background 
readings. A minimum of six images for each condition was taken. 
 
2.8 Data and Statistical Analysis 
All data collected was analysed using GraphPad Prism 6 (GraphPad software). 
Post hoc statistical analysis was performed using one-way analysis of variance 
(ANOVA) or Kruskal Wallis test with the appropriate multiple comparison test 
applied as stated in figure legend. In appropriate cases datasets were 
compared using an unpaired Student’s t-test or Wilcoxon Signed Rank Test. 
95% was deemed a value for significance in all statistical tests performed with 
p-values ≤0.05 = *, ≤0.01 =**, ≤0.001= *** and ≤0.0001= ****. Dose response 
curves were fitted and analysed using a non-linear regression dose-
concentration response curve assuming a Hill coefficient of 1. All data was 
formatted to the mean and ± standard error of means (S.E.M.) for a minimum 
3 independent experiments unless stated otherwise.  
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Chapter 3.0 Screening for chemokine signalling 
pathways involved in carcinoma metastasis 
  
 
3.1 Introduction 
Chemokines are small extracellular proteins which are synthesised and 
secreted by cells upon detection of inflammatory, bacterial and viral molecules 
present in the tissue microenvironment [108-110]. Secreted chemokines have 
the ability to bind to GAGs on neighbouring stromal cells which retains their 
presence in the tissue microenvironment to form a local concentration gradient 
[416]. This chemokine concentration gradient serves as a chemoattractant for 
immune cells expressing chemokine receptors and forms the basis for 
mounting an immune system response towards the infection and/or tissue 
damage or alternatively for immunosurveillance as part of the body’s 
homeostasis [417]. This immune system response is vital for the survival of 
multicellular organisms and therefore tightly regulated. However over time 
aberrations within this process can occur caused by the dysregulation of 
upstream regulators of chemokine receptor expression or due to chronic 
inflammation from the external environment leading to chemokine 
overexpression. Both can give rise to inflammatory associated diseases such 
as rheumatoid arthritis, atherosclerosis and cancer metastasis [113].  
Clinical data from cancer patients has shown that chemokines are often 
overexpressed at the sites of metastasis such as lung, liver and brain [115], 
whilst chemokine receptors are overexpressed on metastatic cancer cells 
including breast [418, 419], pancreatic [420] and prostate [421]. Hence 
dysregulation in chemokine signalling is often associated with a poorer 
prognosis [115]. This has therefore generated much interest in targeting both 
chemokines and receptors to block cancer metastasis but to date this 
approach has been ineffective. There have been several reasons cited for the 
lack of clinical efficacy, with chemokine signalling redundancy considered as 
one of the main challenges [319, 320]. As cancer cells frequently overexpress 
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several chemokine receptors whilst sites of metastasis inhabit a variety of 
different chemokines. Therefore targeting just one receptor or chemokine is 
ineffective as alternative chemokine signalling pathways could become 
activated instead.  
However the extent of this chemokine redundancy is starting to be questioned 
due to the emergence of many studies identifying evidence of biased signalling 
in both chemokines and receptors [96, 97]. Biased signalling has been shown 
to give rise to differences in cellular physiology in a few notable examples. 
Such as for CCR2, whereby activation by CCL2 induces actin polymerisation 
whilst CCL11 activation blocks actin polymerisation [422] or CXCL8 inducing 
respiratory burst in neutrophils via CXCR1 but not CXCR2 [423]. Though 
biased signalling is not merely dependent on just the ligand and receptor, it 
can also be influenced by the cell type, commonly referred to as tissue bias 
[424]. Tissue bias has been recognised within the CCL19-CCR7 signalling axis 
whereby CCL19 induces chemotaxis in dendritic cells [100] but not to the same 
extent in T-lymphocytes [99].  
Despite a handful of examples demonstrating the role of biased signalling in 
normal cellular behaviour even less is known about the role it could play in 
disease states such as cancer metastasis. This evidence of biased signalling 
in chemokines could imply that the low clinical success rate in treating cancer 
is due to targeting inappropriate chemokine signalling pathways rather than 
any functional redundancy.  
Although many clinical studies have identified a variety of different chemokines 
associated with cancer metastasis, numerous published target validation 
studies have tended to focus on chemokines such as CCL2, CCL5, CCL19, 
CCL21 and especially CXCL12 particularly for breast cancer [425-427] and to 
a lesser extent prostate [262, 263, 421, 427] and pancreatic cancer [262, 420, 
428-430] amongst a family of 50 known chemokines. Consequently there are 
still many chemokines yet to be properly validated as therapeutic targets for 
blocking cancer metastasis.  
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3.2 Chapter Aim 
 Identify chemokine signalling pathways involved in carcinoma 
metastasis for therapeutic targeting. 
 
 Explore the extent of functional redundancy within chemokine 
signalling. 
 
3.3 Immunofluorescence staining for CCR5 and CCR1 in 
different carcinoma cell types 
Chemokine receptors are frequently overexpressed on different carcinoma cell 
types, whilst in normal epithelial cells their expression is either low or absent 
[287, 418]. This has made the chemokine receptor a promising therapeutic 
target. 
There are currently 23 known chemokine receptors, with 4 considered atypical 
and do not signal via Gαi/βγ, and as such are not considered important for cell 
migration [35, 431]. Amongst the “typical” chemokine receptors, their 
expression on cancer cells can be dependent on the cell type [130]. 
To identify chemokine signalling pathways which could be important 
carcinoma metastasis, two chemokine receptors CCR5 and CCR1 were 
stained for on four separate carcinoma cell types: MCF-7 and MDA-MB-231 
(both breast), PC-3 (prostate) and MIA PaCa-2 (pancreatic). CCR5 and CCR1 
are normally expressed on leukocytes and are involved in inflammation [48, 
432]. Both receptors have overlapping cognate ligands CCL3, CCL5 and CCL8 
which allows us to identify any chemokine specific bias in cancer cell migration. 
CCR5 expression has been identified on several cancer cell lines including 
MCF-7, MDA-MB-231, MIA PaCa-2 and PC-3 [338, 420, 433, 434]. 
Nonetheless there have been conflicting reports on chemokine receptor 
expression on the same cell lines [435, 436]. The immunofluorescence stain 
was therefore performed to gain insight into possible receptor expression prior 
to the chemokine screen. Furthermore CCR5 was also stained for on the CHO-
CCR5 cells as a control for the CCR5 antibody 83a15j. 
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Figure 3.1. Immunofluorescence staining of CCR5. Anti-CCR5 stain 
(83a15j) counterstained using anti-rat FITC. Control (-) was anti-Rat FITC 
alone. All images are representative of the cell population and were taken at 
63x objective with a Leica DMI6000 inverted microscope and using Leica 
application suite. 
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Figure 3.2. Immunofluorescence staining of CCR5. CHO-CCR5 cells 
express CCR5. Anti-CCR5 stain (83a15j) counterstained using anti-rat FITC. 
Control (-) was anti-rat FITC alone. Images are representative of the cell 
populations and were imaged at 63x objective with a Leica DMI6000 inverted 
microscope and using Leica application suite. 
 
 
Figure 3.3. Immunofluorescence staining of CCR1. Images are 
representative of the cell populations. Anti-CCR1 stain (MAB145) 
counterstained with anti-mouse TRITC in MCF-7 cells and anti-mouse FITC in 
MDA-MB-231 cells. Control (-) was anti-mouse TRITC and anti-mouse FITC 
for MCF-7 and MDA-MB-231 cells respectively. MCF-7 cells were imaged at 
10x objective and MDA-MB-231 cells were imaged at 63x objective with a 
Leica DMI6000 inverted microscope and using Leica application suite. 
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Figure 3.4. Immunofluorescence staining of CCR1. MIA PaCa-2 and PC-3 
cells do not express CCR1. Anti-CCR1 stain (MAB145) counterstained with 
anti-mouse TRITC. Control (-) was TRITC alone. Images are representative of 
the cell population and were taken at 10x objective with a Leica DMI6000 
inverted microscope and using Leica application suite. 
 
Staining for CCR5 with 83a15j identified possible CCR5 expression on MCF-
7, MIA PaCa-2, MDA-MB-231 and PC-3 and unsurprisingly in stably 
transfected CHO-CCR5 cells (figures 3.1 and 3.2). Immunofluorescence 
staining for CCR1 using MAB145 showed some CCR1 expression in MCF-7 
cells but only within a small area of collected cells which may indicate that 
CCR1 is only expressed in a small subset of MCF-7 cells (figure 3.3). None of 
the other cell lines showed any clear evidence of CCR1 expression (figures 
3.3 and 3.4).   
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3.4 CCL2 and CCL3 promote scratch closure in PC-3 and 
MCF-7 cells respectively after 24 hrs  
To identify chemokine signalling pathways involved in carcinoma metastasis a 
screen of seven different chemokines: CCL2, CCL3, CCL4, CCL8, CCL23, 
CXCL9 and CXCL12, was devised for testing in four separate secondary 
carcinoma cell lines: MCF-7 and MDA-MB-231, MIA PaCa-2 and PC-3. 
Amongst the selected chemokines, many of the CC chemokines are ligands 
for the same receptors (see table 3.1) allowing us to identify potential ligand or 
receptor redundancy in chemokine signalling. The four different carcinoma cell 
types, cover three types of carcinoma and two breast cancer subtypes: 
hormone positive (MCF-7) and triple negative (MDA-MB-231), as well as 
exhibiting varying degrees of invasiveness. These phenotypic differences 
allow us to observe any carcinoma specific effects and potentially prognostic 
significance in chemokine signalling.
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Table 3.1. Chemokines (screened), cognate receptors and published studies on MCF-7, MDA-MB-231, MIA 
PaCa-2 and PC-3 cell migration in vitro 
Chemokines Chemokine  
receptors 
MCF-7 MDA-MB-231 MIA PaCa-2 PC-3 
CCL23 CCR1     
CCL3 CCR1, 5 CTX [437] 
WH [346] 
   
CCL4 CCR1, 5 CTX [437]   WH [438] 
CTX [438] 
CCL8 CCR1, 2, 3, 5     
CCL2 CCR2, 3 CTX [437, 439] 
WH [439] 
CTX [440]  CTX [441] CTX [278, 441] 
CXCL9 CXCR3     
CXCL12 CXCR4, 7 WH [340, 346] AS [442] 
WH [443] 
CTX [444-446] 
CTX [447] 
AS [448]  
CTX [278, 448] 
WH [448] 
 
References in green highlight studies which showed a promotion of cell migration, whilst red studies showed no effect on cell migration 
and orange mixed depending on endogenous or exogenous chemokine source. Abbreviations: AS = Agarose spot, CTX = 
Chemotaxis, WH = wound healing assay. Chemokines and their listed cognate receptors were based on the published studies listed 
in table 2.3. 
   
 
97 
 
One of the methods commonly used by researchers to understand carcinoma 
metastasis is using the wound healing assay, an assay which partly mimics 
the in vivo wound healing process in vitro. Wound healing in vivo, is a process 
comprised of four main stages, beginning with haemostasis, whereby following 
injury, platelets and fibrin, aggregate to clot the blood [135, 449]. Thereafter, 
leukocytes flood the injured area, removing cellular debris, foreign particles or 
any microorganisms as part of the inflammatory stage. During the proliferative 
stage, the wound is contracted by myofibroblasts, and the extracellular matrix 
is assembled, with angiogenesis and re-epithelialisation occurring within the 
injury site [135, 449]. The final stage involves remodelling of the collagen from 
type III to type I giving rise to denser collagen fibres to strengthen the 
epithelium. As a chemoattractant, chemokines play a vital role in regulating 
wound healing by recruiting leukocytes, endothelial cells, and keratinocytes for 
inflammation, angiogenesis and re-epithelialisation respectively [450]. 
The wound healing assay is particularly useful for understanding collective 
migration of adherent cells, but it can also measure cell proliferation, spreading 
and survival. The assay involves adherent cells forming a 100% confluent 
cellular monolayer on the bottom of the well. Scratches are then introduced 
across the monolayer, normally with a pipette tip, and thereafter are imaged 
either continuously or at specific timepoints, to track cellular migration. The 
advantage of the assay lies not only in its simplicity, but as the cells grow to 
form a sheet, it simulates how cells normally exist within the epithelium [451] 
and how carcinoma cells invade the surrounding tissue [141, 452]. For these 
reasons the wound healing assay was used as a model to screen the seven 
separate chemokines for their involvement in carcinoma cell migration.  
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Figure 3.5. Chemokine screening in the wound healing assay of MCF-7 
cells. (a)  CCL3 (10 nM) promotes MCF-7 scratch closure after 24 hrs. A value 
of 1 denotes no migration, whilst 0 denotes complete migration. (b) 
Representative image of CCL3 (10 nM) scratch closure in MCF-7 cells after 24 
hrs. MCF-7 cells treated with CCL3 (24 hrs) had a scatch width ratio of 0.58 
compared to 0.89 for the basal. All images were taken at 10x objective with a 
Leica DMI6000 inverted microscope and using Leica application software. 
Results represent the mean ± S.E.M. of four independent experiments (One-
way ANOVA, Uncorrected Fisher's LSD, with * = p≤0.05). 
   
 
99 
 
C h e m o k in e s  (C o n c  1 0  n M )
S
c
r
a
tc
h
 w
id
th
r
a
ti
o
: 
6
 h
r
s
/ 
0
h
r
s
)
B
a
s
a
l
C
C
L
2
3
C
C
L
3
C
C
L
4
C
C
L
5
C
C
L
8
C
C
L
2
C
X
C
L
9
C
X
C
L
1
2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0 ns
 
Figure 3.6. Chemokine screening in the wound healing assay of MDA-
MB-231 cells for 6 hrs. A value of 1 denotes no migration, whilst 0 denotes 
complete migration. Results represent the mean ± S.E.M. of at least five 
independent experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = 
p value≥0.05 of no significance).  
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Figure 3.7. Chemokine screening in the wound healing assay of MDA-
MB-231 cells for 24 hrs. A value of 1 denotes no migration, whilst 0 denotes 
complete migration. Results represent the mean ± S.E.M. of at least three 
independent experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = 
p value≥0.05 of no significance).  
   
 
100 
 
C h e m o k in e s  (C o n c  1 0  n M )
S
c
r
a
t
c
h
 w
id
t
h
r
a
ti
o
:
 2
4
 h
r
s
/0
 h
r
s
B
a
s
a
l
C
C
L
3
C
X
C
L
1
2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
ns
a
C h e m o k in e s  (C o n c  1 0  n M )
C
e
ll
 c
o
v
e
r
a
g
e
r
a
t
e
:
 0
 h
r
s
/2
4
 h
r
s
)
B
a
s
a
l 
C
C
L
3
 
C
X
C
L
1
2
 
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
ns
b
 
Figure 3.8. CCL3 (10 nM) and CXCL12 (10 nM) do not affect MDA-MB-231 
scratch closure after 24 hrs. (a) Cell migration was assessed by measuring 
changes in scratch width. (b) Cell migration was assessed by measuring 
changes in cell coverage. A value of 1 denotes no migration, whilst 0 denotes 
complete migration. Results represent the mean ± S.E.M. of at least four 
independent experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = 
p value≥0.05 of no significance).  
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Figure 3.9.  Chemokine screening in the wound healing assay of MIA 
PaCa-2 cells for 24 hrs. A value of 1 denotes no migration, whilst 0 denotes 
complete migration. Results represent the mean ± S.E.M. of at least three 
independent experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = 
p value≥0.05 of no significance).  
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Figure 3.10.  Chemokine screening in the wound healing assay of MIA 
PaCa-2 cells. MIA PaCa-2 cells were treated with chemokines (10 nM) for 6 
hrs (a) and 48 hrs (b). A value of 1 denotes no migration, whilst 0 denotes 
complete migration.  Results represent the mean ± S.E.M. of at least two 
independent experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = 
p value≥0.05 of no significance).  
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Figure 3.11. Chemokine screening in the wound healing assay of PC-3 
cells for 6 hrs. A value of 1 denotes no migration, whilst 0 denotes complete 
migration. Results represent the mean ± S.E.M. of at least two independent 
experiments. (One-way ANOVA, Uncorrected Fisher's LSD, ns = p value≥0.05 
of no significance).  
 
 
 
 
 
 
 
   
 
103 
 
C h e m o k in e s  (C o n c  1 0  n M )
S
c
r
a
tc
h
 w
id
th
r
a
ti
o
: 
2
4
 h
r
s
/0
 h
r
s
B
a
s
a
l
C
C
L
2
3
 
C
C
L
3
 
C
C
L
4
 
C
C
L
8
 
C
C
L
2
 
C
X
C
L
9
 
C
X
C
L
1
2
 
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
*
a
 
 
Figure 3.12. Chemokine screening in the wound healing assay of PC-3 
cells for 24 hrs. (a) CCL2 (10 nM) promotes PC-3 scratch closure after 24 
hrs. A value of 1 denotes no migration, whilst 0 denotes complete migration. 
(b) Representative image of CCL2 scratch closure in PC-3 cells after 24 hrs. 
PC-3 cells treated with CCL2 (24 hrs) had a scratch width ratio of 0.3704 
compared to 0.723 for the basal. All images were taken at 10x objective with 
a Leica DMI6000 inverted microscope and using Leica application software. 
Results represent the mean ± S.E.M. of at least four independent experiments. 
(One-way ANOVA, Uncorrected Fisher's LSD, * = p≤0.05). 
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From the chemokine screen, CCL2 (10 nM) and CCL3 (10 nM) showed 
significant increases in PC-3 and MCF-7 scratch closure against the basal 
after 24 hrs respectively (p≤0.05), suggesting that both are able to promote 
cell migration in their respective cell type (figures 3.5a-b and 3.12a-b). With 
regards to the kinetics of CCL2 signalling in PC-3 cells, after 6 hrs there was 
a mean difference of 0.135 in scratch width ratio between CCL2 and the basal 
(figure 3.11) which then increased to 0.305 following 24 hrs. This implies that 
CCL2 is inducing some migration in PC-3 cells after 6 hrs and that the kinetics 
of this signalling pathway continues over a 24 hrs period.  
Amongst the remaining chemokines screened, none had a significant effect on 
scratch closure in the different carcinoma cell types at any time point (figures 
3.5-3.12). Although CXCL12 (10 nM) tended to display greater scratch closure 
in both PC-3 and MCF-7 cells after 24 hrs (figures 3.5a and 3.12a), with a 
similar trend also shown in PC-3 cells for CCL4 and possibly CCL23 after 24 
hrs (figure 3.12a). CCL5 (10 nM) was also tested on MDA-MB-231 cells as 
previous studies have identified it as a promoter of MDA-MB-231 migration 
[338, 453], though no effect on scratch closure after either 6 hrs or 24 hrs was 
detected (figure 3.6 and 3.7).  
Unlike MCF-7 cells, MDA-MB-231 cells did not form clear and distinct scratch 
edges. So an additional approach was used by measuring the change in cell 
coverage of CCL3 and CXCL12 scratch closure after 24 hrs. Similar to scratch 
width measurements (figure 3.8a) there was no significant difference in the cell 
coverage between either CCL3 or CXCL12 and the basal after 24 hrs (figure 
3.8b). This demonstrates that measuring changes in scratch width is still a valid 
method for assessing scratch closure. 
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3.5 CCL3 promotes MCF-7 scratch closure through the 
activation of both CCR1 and CCR5  
CCL3 has at least two known cognate receptors: CCR1 and CCR5 [47] (tables 
2.3 and 3.1). To further explore the molecular mechanism underpinning CCL3 
driven migration in MCF-7 cells, two small molecule inhibitors were used to 
block CCR1 and CCR5, either separately or at the same time, to establish 
whether one receptor is primarily involved or if there is functional redundancy 
between the two.  
For targeting CCR5, the allosteric inhibitor for CCR5, maraviroc was used. 
Since 2007, maraviroc has been used as a licensed drug for treating HIV-1: by 
blocking viral entry into lymphocytes via CCR5 [454].  Crystallography data 
has revealed that maraviroc binds deep inside CCR5s transmembrane 
domain, and inside this pocket maraviroc, interacts with the Tyr248 residue in 
helix 6 through its benzene ring. This hydrophobic interaction is thought to 
stabilise CCR5s inactive conformation upon ligand binding [33]. Maraviroc is 
therefore considered to be an inverse agonist rather than an antagonist [455].  
To block CCR1 another potent allosteric inhibitor J113863 was used. J113863 
has been shown to block CCL3 binding to CCR1 in CHO cells with an IC50 of 
0.9 nM, as well as, intracellular calcium signalling in U937 cells expressing 
CCR1 with an IC50 of 0.73 nM [397]. CCR1 shares structural homology with 
CCR2, CCR3 and CCR5, therefore J113863 may have off-target effects. This 
was highlighted in a very recent study by showing that J113863 was able to 
bind to and activate both CCR5 and CCR2 by displacing CCL4 (pIC50 = 5,9 ± 
0.1) and CCL2 (pIC50 = 5.5 ± 0.1), as well as, having a pEC50 of 8.2 ± 0.1 and 
6.4 ± 0.1 in increasing intracellular calcium respectively. In cell migration, 
J113863 was an agonist for CCR2, whilst for CCR5, J113863 acted as an 
antagonist for CCL4 [456]. Although Corbisier et al. (2017) identified J113863 
as an agonist for CCR2 and CCR5, this was only achieved at concentrations 
over a 1000 fold greater than the IC50 ≈ 1 nM. Indicating that J113863 is a weak 
agonist. However J113863 does appear to be a potent antagonist for CCR5 
induced chemotaxis by fully blocking CCL4 chemotaxis in CCR5-L1.2 cells 
above 1 nM concentration [456]. 
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Figure 3.13. Scratch closure of MCF-7 cells after 24 hrs. (a) J113863 (10 
nM) and Maraviroc (10 nM) together inhibit CCL3 (10 nM) induced scratch 
closure in MCF-7 cells after 24 hrs. (b) Representative image of CCL3 scratch 
closure in MCF-7 cells after 24 hrs. MCF-7 cells treated with CCL3 as well as 
Maraviroc and J113863 had a scratch width ratio of 0.84 compared to 0.53 
when treated with CCL3 alone. Cells were imaged at 10x objective with a Leica 
DMI6000 inverted microscope and using Leica application suite. CCR1 
inhibitor: J113863. CCR5 inhibitor: Maraviroc. Results represent the mean ± 
S.E.M. of at least three independent experiments. (One-way ANOVA, Tukey’s 
test, *** = p ≤0.001). 
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When using J113863 (10 nM) and Maraviroc (10 nM) to target CCR1 and 
CCR5 respectively in MCF-7 cells treated with CCL3 (10 nM). The data 
showed that only when both J113863 and Maraviroc were added at the same 
time was CCL3 scratch closure significantly inhibited (p≤0.001 n=5) (figure 
3.13). Neither Maraviroc nor J113863 were able to significantly inhibit CCL3 
scratch closure independently. Although the addition of J113863 alone did 
show some inhibition on CCL3 scratch closure, which could suggest that CCL3 
relies more on CCR1 activation than CCR5 to drive MCF-7 cell migration. 
Overall, the data suggests that CCL3 utilises both CCR1 and CCR5 to promote 
MCF-7 cell migration, indicating significant receptor redundancy underlying 
this process. 
 
3.6 Maraviroc and J113863 show no cytotoxicity in MCF-7 
cells after 25 hrs 
To ensure that the inhibitory effects of J113863 and Maraviroc on MCF-7 
scratch closure was not a result of compound cytotoxicity, the MTS cell 
proliferation assay was used to measure cytotoxicity. This cell proliferation 
assay works by measuring the absorbance of formazan (a product of MTS 
tetrazolium metabolisation by NAD(P)H dehydrogenase) for quantifying the 
number of viable cells. To determine cellular proliferation, the background 
(growth media) was measured against the control (cells only). Whilst for 
identifying compound cytotoxicity, all the conditions tested were assessed 
against the control. 
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Figure 3.14. Cell proliferation assay in MCF-7 cells. J113863 (10 nM) and 
Maraviroc (10 nM) does not cause cytotoxicity in MCF-7 cells after 24 hrs 
incubation and 1 hrs MTS metabolisation. CCR1 inhibitor: J113863. CCR5 
inhibitor: Maraviroc. Results represent the mean ± S.E.M of four independent 
experiments (One-way ANOVA, Dunnett’s test, ** = p≤0.01, ns indicating a p 
value≥0.05 of no significance). 
 
The data from the MTS assay on J113863 and Maraviroc showed no 
significant evidence of cytotoxicity in MCF-7 cells either independently or 
together following 25 hrs incubation (figure 3.14). This confirms that the 
inhibition observed for J113863 (10 nM) and Maraviroc (10 nM) on the scratch 
closure of MCF-7 cells in response to CCL3 was not due to any significant 
cellular cytotoxicity. 
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3.7 PC-3 cells do not migrate towards CCL2 or CXCL12 in the 
transwell migration assay. Agarose spot cannot be used to 
measure migration in MDA-MB-231 cells 
The wound healing assay is one of the most commonly used method to assess 
for cellular migration. However one of its biggest limitations is it can only 
measure non-directed migration (chemokinesis) and not chemotaxis as no 
concentration gradient can be formed within the assay.  
Chemokines function as a chemoattractant to promote cancer metastasis 
[115]. Therefore to assess for chemotaxis, two chemotaxis migration assays 
were used: the transwell migration and agarose spot.  
Several published studies have used these assays to observe chemokine 
induced chemotaxis in the same cancer cell lines used in the wound healing 
assays presented in this thesis (see table 3.1). The transwell migration assay 
relies on a semi-permeable membrane to generate a concentration gradient. 
Cells are seeded on top of the membrane with the chemoattractant 
underneath. The number of cells counted on the underside of the membrane 
is used to quantify chemotaxis. The agarose spot assay on the other hand 
uses the diffusion of chemokines into the surrounding media from a chemokine 
concentrated agarose spot. The number of cells which enter the agarose spot 
is used as a measurement of chemotaxis [442, 448].  
For the transwell migration assay the PC-3 cells were used as the cellular 
system to identify CCL2 and CXCL12 induced chemotaxis. Both CCL2 and 
CXCL12 were selected as they displayed the greatest effect on scratch closure 
(figure 3.12).  For the agarose spot CXCL12 was used as the chemoattractant 
for MDA-MB-231 cells to try and reproduce the data from Vinadar. V et al. 
(2011) [442].   
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Figure 3.15. Transwell migration assay in PC-3 cells. CCL2 (10 nM) and 
CXCL12 (10 nM) do not induce chemotaxis in PC-3 cells after 24 hrs. Data 
was normalised to the basal. Results represent the mean ± S.E.M. of four 
independent experiments. (Kruskal Wallis test, Dunn's multiple comparisons 
test, ns indicating a p value≥0.05 of no significance). 
 
 
Figure 3.16. Agarose spot assay in MDA-MB-231 cells. Representative 
image of the control agarose spot (0.1% BSA/PBS) after 24 hrs. White line 
shows the edge of the agarose spot and the MDA-MB-231 cells. No image was 
able to be obtained for the CXCL12 agarose spot (125 nM). 
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Using the transwell migration assay, neither CCL2 (10 nM) nor CXCL12 (10 
nM) demonstrated any significant evidence of chemotaxis in PC-3 cells after 
24 hrs (figure 3.15). For the agarose spot, no meaningful data on MDA-MB-
231 cell migration in response to CXCL12 (125 nM) was obtained (figure 3.16). 
The lack of useable data was due to the agarose spots not remaining properly 
fixed to either the plastic or glass bottom during the experiment. This caused 
the agarose spots to be easily dislodged and move, which prevented any cell 
migration between the control and CXCL12 agarose spots from being 
measured. As such no images of the CXCL12 agarose spot are presented in 
this thesis. 
Overall, neither approach appears to be effective in detecting chemokine 
induced chemotaxis in either of these two cell lines. 
 
3.8 Characterising chemokine signalling in MCF-7 and PC-3 
cells  
Chemokine receptors are primarily coupled to Gαi [36-39]. In the canonical 
Gαi/βγ pathway, the Gβγ subunit binds and activates PLC, which in turn 
cleaves PIP2 into DAG and IP3. IP3 opens the IP3 channels on the ER releasing 
calcium ions into the cytosol to act as a secondary messenger for signal 
transduction [88]. For many years now researchers have utilized this 
downstream release of calcium from the intracellular stores as a marker for 
chemokine receptor activation by using the fluorescent dye Fura-2 AM [457, 
458]. Fura-2 AM has a high affinity for calcium ions and is ratiometric as it can 
be excited at both 340 and 380 nm depending on whether it is bound or 
unbound to Ca2+ respectively. Despite having two excitation states, Fura-2 AM 
still emits light at 510 nm [459]. Therefore the levels of intracellular calcium 
before and after receptor activation can be detected by measuring the 
difference in fluorescence levels between the two excitations states (340 and 
380 nm) at 510 nm.  
To confirm whether MCF-7 cells express CCR1 and/or CCR5, increases in 
intracellular calcium was measured in response to varying doses of CCL3. To 
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identify whether PC-3 cells express CCR2, changes in intracellular calcium 
levels were measured in response to CCL2 stimulation.  
In addition the remaining chemokines were screened to firstly identify whether 
the PC-3 and MCF-7 cells expressed any other chemokine receptors such as 
CXCR3. Secondly to compare the efficacy levels of the different chemokines 
with respect to receptor activation as this may explain functional differences 
between the different chemokines. 
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Figure 3.17. Increases in intracellular calcium in MCF-7 cells. (a) CCL3 
dose dependent increase in intracellular calcium in MCF-7 cells (n=3). (b) 
J113863 inhibition of CCR1 does not block CCL3 (200 nM) intracellular 
calcium signalling in MCF-7 cells (n=5). (c) Representation of an intracellular 
calcium measurement trace following CCL3 stimulation in MCF-7 cells 
pretreated (30 mins) with different concentrations of J113863 (CCR1 inhibitor) 
after 70 secs. Results represent mean ± SEM of at least three independent 
experiments. (One-way ANOVA, Dunnett’s test, ns indicating a p value≥0.05 
of no significance). 
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Figure 3.18. Increases in intracellular calcium towards varying 
concentrations of CCL2 in PC-3 cells. (a) CCL2 induces a weak increase in 
intracellular calcium in PC-3 cells. (b) Representation of an intracellular 
calcium measurement trace following CCL2 injection in PC-3 cells at 
concentrations of 50, 100 and 200 nM after 70 secs. Results represent the 
mean ± SEM of three independent experiments. 
 
The results showed that CCL3 was able to induce a dose dependent increase 
in intracellular calcium in MCF-7 cells, with an EC50 of 184.8 nM (figure 3.17a). 
This firstly indicates that MCF-7 cells express either CCR1 and/or CCR5 and 
secondly that the receptors are functional. To gain further detail on whether 
CCL3 was signalling through either CCR1 or CCR5, the CCR1 antagonist 
J118363 was used at a range of concentrations to ensure maximal effect on 
CCL3 intracellular calcium increase in MCF-7 cells. The data from this 
experiment showed no inhibition of CCL3 signalling by J113863 at any 
concentration (figure 3.17b and c).  
There are two possible explanations for this result. The first explanation is that 
CCL3 signals through CCR5 only, or secondly that there is functional 
redundancy between CCR1 and CCR5, similar to what was observed in the 
wound healing assay (figure 3.13). In order to confirm which one of these 
hypothesis is correct the activation of CCR5 would need to be blocked. 
Unfortunately, as the CCR5 inhibitor maraviroc has been shown to increase 
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intracellular calcium in THP-1 cells [460], the use of maraviroc to block CCR5 
activation was not possible for the intracellular calcium flux assay. 
Additionally the PC-3 cells were stimulated with three separate concentrations 
of CCL2: 50, 100 and 200 nM. However, only a small increase in intracellular 
calcium was measured in response to CCL2 (200 nM), with a mean of 0.069 
(figure 3.18). This suggests that PC-3 cells could express some functional 
CCR2 and/or CCR3. 
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Figure 3.19. Chemokine screening in MCF-7 cells with the intracellular 
calcium flux assay. (a) Chemokine increases in intracellular calcium in MCF-
7 cells when measuring the difference between the peak and base readings 
(n=3). (b) Chemokine increases in intracellular calcium in MCF-7 cells 
measured using the area under the curve (AUC). (c) Representation of an 
intracellular calcium measurement trace following chemokine injection in MCF-
7 cells after 70 secs. Results represent the mean ± S.E.M. of at least three 
independent experiments (One-way ANOVA, Uncorrected Fisher's LSD, 
*=p≤0.05, ns = p≥0.05 of no significance). 
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When quantifying changes in intracellular calcium using the peak and base 
readings, MCF-7 cells were shown to significantly respond to CCL3 and CCL4 
(200 nM) stimulation (p≤0.05, n=3). Furthermore a possible response to 
CXCL9 (200 nM) was also detected with a mean of 0.0907 ± 0.025 (figure 
3.19a). This suggests that MCF-7 cells could be expressing functional CCR5 
with the evidence from the immunofluorescence stain also suggesting possible 
CCR5 expression (figure 3.1).  
One limitation with measuring the difference between the peak and base 
readings to quantify increases in intracellular calcium, is that it cannot measure 
differing responses, such as whether the increase in intracellular calcium is 
high and short-lived or lower and more prolonged. As such the same data was 
remeasured using the area under a curve (AUC) to see if the chemokines 
induced different responses.  
When measuring the AUC the trend was similar to measurements made using 
the peak and base readings, however, this time there was no significant 
difference between the increases in intracellular calcium amongst the 
chemokines screened (figure 3.19b). This suggests that the overall increase 
in intracellular calcium is similar between the chemokines with perhaps the 
exception of CCL8. This indicates that the chemokines are inducing differing 
responses in MCF-7 cells. Which was also observed from the intracellular 
calcium measurement traces (figure 3.19c). From these traces CCL3 
stimulation appears to induce a higher and shorter-lived increase in 
intracellular calcium, whilst CCL5, CCL23, and CXCL9 displayed a lower but 
prolonged increase in intracellular calcium. CCL4 stimulation also showed a 
prolonged response although it was much higher than any of the other 
chemokines screened. Amongst the chemokines screened only CCL8 showed 
no detectable increase in intracellular calcium in MCF-7 cells. These results 
suggest that different chemokines have differing levels of efficacy and produce 
distinct responses within the same cell type. 
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Figure 3.20. Chemokine screening in PC-3 cells with the intracellular 
calcium flux assay. (a) Chemokine increases in intracellular calcium in PC-3 
cells when measuring the difference between the peak and base readings 
(n≥4). (One-way ANOVA, Uncorrected Fisher's LSD, * = p≤0.05). (b) 
Representation of an intracellular calcium measurement trace following 
chemokine injection (200 nM) in PC-3 cells after 70 secs. (c) CCL4 (200 nM) 
induces significant increase in intracellular calcium when measuring the 
difference between the peak and base readings (n≥2). One-way ANOVA, 
Dunnett’s test, * = p≤0.05). (d) Representation of an intracellular calcium 
measurement trace following chemokine or H2O injection in PC-3 cells after 70 
secs.  Results represent the mean ± S.E.M. of at least two independent 
experiments. 
 
In PC-3 cells only CCL4 (200 nM) displayed a significant increase in 
intracellular calcium compared to the other chemokines screened (p≤0.05) 
(figure 3.20a). As a control increases in intracellular calcium from CCL3, CCL4 
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and CCL8 were measured against the background stimulation (injection of 
H2O), which confirmed that PC-3 cells respond to CCL4 and that they likely 
express CCR5. (p≤0.05, n=3) (figures 3.20c and d). None of the other 
chemokines demonstrated any obvious increase in intracellular calcium. This 
indicates that CCL3, CCL5 and CCL8 have a lower level of efficacy than CCL4 
in PC-3 cells. For CCL23 and CXCL9 the results from the intracellular calcium 
flux assay may suggest that PC-3 cells do not express their cognate receptors 
CCR1 and CXCR3 respectively and hence why no clear increases in 
intracellular calcium was detected. 
 
3.9 Screening for chemokines involved in carcinoma cell actin 
polymerisation 
Actin polymerisation is a key component and driving force for cell physiological 
changes such as adhesion, spreading and migration [143, 179, 461]. The 
process of actin polymerisation begins with G-actin nucleation which is 
elongated further to form F-actin. Elongated F-actin extends towards the cell 
membrane and forces protrusions to arise, allowing cells to migrate [143]. This 
cellular migration is maintained when actin polymerisation is at a steady state 
[179]. At the surface of a cells leading edge, F-actin can form two types of 
protusions: filopodia and lamellipodia. The filopodia function as sensors, 
allowing changes in the external environment to be detected by the cell [153, 
154]. Whilst the lamellipodia is considered to be the mechanical force behind 
cell migration [155]. Besides the lamellipodia and filopodia, another F-actin 
structure also formed within the cell are the stress fibers which function to 
generate traction for cell migration [143, 179]. Due to the importance of actin 
polymerisation in cell migration, these chemokines were further investigated to 
determine if they were able to form identifiable F-actin structures in the different 
carcinoma cell lines. For imaging intracellular F-actin structures, researchers 
commonly use the bicyclic peptide phalloidin, which is a toxin originally derived 
from the death cap mushroom.  Phalloidin has a high affinity for F-actin but not 
G-actin and is commonly conjugated to a fluorophore to give high quality and 
detailed images of the F-actin cytoskeleton [462].  
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Figure 3.21. Phalloidin actin staining of MCF-7 cells in the absence and 
presence of different chemokines (10 nM) over 24 hrs. MCF-7 cells were 
fixed and stained with Phalloidin CruzFluor TM594 conjugate (red) for imaging 
the F-actin cytoskeleton. Images are a representation of the cell population 
and were taken at 63x objective with a Leica DMI6000 inverted microscope 
and using Leica imaging suite. 
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Figure 3.22. Phalloidin actin staining of MCF-7 cells in the absence and 
presence of CCL3 (10 nM) over 24 hrs. MCF-7 cells were fixed and stained 
with Phalloidin CruzFluor TM594 conjugate (red) for imaging the F-actin 
cytoskeleton. Images are a representation of the cell population and were 
taken at 63x objective with a Leica DMI6000 inverted microscope and using 
Leica imaging suite. 
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Figure 3.23. Phalloidin actin staining of MDA-MB-231 cells in the absence 
and presence of different chemokines (10 nM) over 24 hrs. MDA-MB-231 
cells were fixed and stained with Phalloidin CruzFluor TM594 conjugate (red) 
for imaging the F-actin cytoskeleton. Images are a representation of the cell 
population and were taken at 63x objective with a Leica DMI6000 inverted 
microscope and using Leica imaging suite. 
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FFigure 3.24. Phalloidin actin staining of PC-3 cells in the absence and 
presence of different chemokines (10 nM) over 24 hrs. PC-3 cells were 
fixed and stained with Phalloidin CruzFluor TM594 conjugate (red) for imaging 
the F-actin cytoskeleton. Images are a representation of the cell population 
and were taken at 63x objective with a Leica DMI6000 inverted microscope 
and using Leica imaging suite. 
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Figure 3.25. Phalloidin actin staining of PC-3 cells in the absence and 
presence of CXCL12 (10 nM) over 24 hrs. PC-3 cells were fixed and stained 
with Phalloidin CruzFluor TM594 conjugate (red) for imaging the F-actin 
cytoskeleton. Images are a representation of the cell population and were 
taken at 63x objective with a Leica DMI6000 inverted microscope and using 
Leica imaging suite. 
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Figure 3.26.  Quantification of actin polymerisation on PC-3 cells after 24 
hrs. ImageJ 1.48v was used to calculate the corrected to cellular fluorescence 
(CTCF) for all images from the phalloidin stain before being normalised to the 
control.  Results represent the mean ± S.E.M of at least three independent 
experiments. (Kruskal Wallis test, Dunn's multiple comparisons test, ns = 
p≥0.05 of no significance). 
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Amongst the cell lines imaged, the PC-3 cells provided the most detailed 
images, allowing for stress fibers, lamellipodia and filopodia to be occasionally 
identified, due to their larger size (figure 3.24). In MCF-7 and MDA-MB-231 
cells, F-actin structures were difficult to identify and subsequently these cell 
lines appear to be unsuitable models for imaging the actin cytoskeleton 
(figures 3.21-3.23). Preliminary data with MDA-MB-231 cells, showed cells 
treated with CCL8 appeared to have a more elongated morphology than the 
control (figure 3.23) Overall, chemokine stimulation (10 nM) induced no 
obvious changes to cellular morphology in any of the cell lines over 24 hrs. 
Nonetheless when looking at the cellular fluorescence levels some notable 
differences following chemokine stimulation were identified. For MCF-7 cells 
treatment with CXCL12 frequently displayed a greater level of fluorescence, 
though this was often in cells which were heavily clustered together (figure 
3.21). Hence, it is unclear whether this was a genuine effect or merely a result 
of cell clustering as a similar effect was also observed amongst the other 
chemokines. In MDA-MB-231 cells, greater fluorescence levels were observed 
for cells incubated with CCL4, CCL8 and CXCL12 (figure 3.23). Whilst in PC-
3 cells, treatment with CCL2 consistently displayed higher levels of 
fluorescence (figure 3.24). Consequently, the fluorescence levels of CCL2 and 
the other chemokines in the PC-3 cells were quantified using ImageJ 1.48v 
software by measuring the corrected total cellular fluorescence. From the data 
analysis none of the chemokines showed a significant difference in 
fluorescence levels against the control. However both CCL2 and CXCL12 did 
have a trend towards greater levels of fluorescence (figure 3.26). 
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3.10 CCL3 induces cellular elongation in CHO-CCR5 cells 
Previous results showed that CCL3 promoted MCF-7 cell migration in the 
wound healing assay, but showed no observable changes to the F-actin 
cytoskeleton when stained with phalloidin. One explanation is that MCF-7 cells 
are a poor model for actin staining, therefore the CHO-CCR5 cells were used 
as an alternative model to characterise the effects of CCL3 on the actin 
cytoskeleton. CHO cells are commonly used for actin staining due to their 
larger size, allowing F-actin structures to be easily identified [184, 463]. Also, 
CHO-CCR5 express high levels of CCR5 so any effects should be enhanced 
here. 
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Figure 3.27. Quantification of actin staining on CHO-CCR5 cells after 24 
hrs. (a) CTCF was measured in the absence and presence of CCL3 (10 nM) 
using ImageJ 1.48v. Results were normalised to the control. (Wilcoxon signed-
rank test). (b) Aspect ratio was measured in the absence and presence of 
CCL3 (10 nM) using ImageJ 1.48v. (c) Cell circularity was measured in the 
absence and presence of CCL3 (10 nM) using ImageJ 1.48v. (d) Cell 
roundness was measured in the absence and presence of CCL3 (10 nM) using 
ImageJ 1.48v. Results represents the mean ± S.E.M. of at least 10 
independent experiments (Student’s t-test, ** = p≤0.01, * = p≤0.05 and ns = 
p≥0.05 of no significance).   
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Figure 3.28. CCL3 promotes cellular elongation in CHO-CCR5 cells. CHO-
CCR5 cells were stimulated with 10 nM of CCL3 for 24 hrs. Following 24 hrs, 
CHO-CCR5 cells were fixed and stained with Phalloidin CruzFluor TM594 
conjugate (red) for imaging the F-actin cytoskeleton. Cells outlined in white are 
a representation of the cell populations. Images were taken at 63x objective 
with a Leica DMI6000 inverted microscope and using Leica imaging suite. 
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Figure 3.29. Quantification of actin staining on CHO-CCR5 cells after 24 
hrs. (a) Maraviroc (10 nM) does not significantly inhibit CCL3 (10 nM) induced 
cellular elongation (aspect ratio) in CHO-CCR5 cells after 24 hrs. (b) Maraviroc 
(10 nM) shows no inhibitory effect on CTCF in CHO-CCR5 cells after 24 hrs. 
CCR5 inhibitor: Maraviroc. Results were normalised to control (absence of 
CCL3 and Maraviroc) and represent the mean ± S.E.M. of at least 4 
independent experiments. (Kruskal-Wallis test, Dunn's multiple comparisons 
test, * = p≤0.05). 
   
 
127 
 
 
Figure 3.30. CHO-CCR5 cells stimulated with CCL3 (10 nM) in the 
presence and absence of Maraviroc (10 nM) after 24 hrs. CCR5 inhibitor: 
Maraviroc. Cells were fixed and stained with Phalloidin CruzFluor TM594 
conjugate (red) for imaging F-actin. Cells outlined in white are a representation 
of the cell populations. Images were taken at 63x objective with a Leica 
DMI6000 inverted microscope and using Leica imaging suite. 
 
From the ImageJ shape descriptors, the aspect ratio was shown to be 
significantly higher (p≤0.01, n=10) and the cell roundness significantly lower 
(p≤0.05, n=10) in CHO-CCR5 cells in the presence of CCL3 (10 nM) after 24 
hrs (figure 3.27b and d). Whilst no significant change was measured in cell 
circularity (figure 3.27c). The aspect ratio is the ratio of the cells maximal 
length/minimal length, thus the higher value the more elongated the cell is, 
which was observed from the images (figure 3.28). The cellular roundness 
measures both cellular elongation and size. From the data it would appear that 
although CCL3 is able to induce some elongation of CHO-CCR5 cells 
generally these cells still retain their shape.  
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CHO-CCR5 cells only express one chemokine receptor CCR5 and so to 
confirm whether CCL3s effects on cellular elongation was genuine, maraviroc 
(10 nM) was used in an attempt to block this effect. Although maraviroc did not 
significantly block CCL3s effect on the aspect ratio there was a trend in 
inhibition which could also be observed from the images (figure 3.29a and 
3.30). Furthermore there was a significant difference in cellular elongation 
between maraviroc alone and CCL3 alone suggesting that CCL3 is most likely 
inducing some changes to the cellular shape. 
Besides analysing cell shape descriptors, changes to CTCF upon CCL3 
stimulation was also measured. When looking at changes to CTCF no 
significant difference was detected although CHO-CCR5 cells incubated with 
CCL3 had a mean difference of 31.88% ± 20.65 above the control (figure 
3.27a).  Nonetheless when using maraviroc there was no reversal of this trend 
(figure 3.29b). Suggesting that CCL3 has either no genuine effect on actin 
polymerisation or that the approach was not sensitive enough to detect or 
measure these changes. 
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3.11 Maraviroc shows no cytoxicity in CHO-CCR5 cells after 
25 hrs 
To confirm the absence of a cytotoxic effect by maraviroc on CHO-CCR5 cells. 
The CHO-CCR5 were treated with maraviroc (10 nM) for 24 hrs using the MTS 
reagent to identify any effects on cellular viability. The results from this MTS 
assay showed no evidence of cytotoxicity (figure 3.31). 
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Figure 3.31. Cell proliferation assay in CHO-CCR5 cells.  Maraviroc (10 
nM) does not cause cytotoxicity in CHO-CCR5 after 24 hrs and 1 hrs MTS 
metabolisation (data from Wing Yee Lai). CCR1 inhibitor: J113863. CCR5 
inhibitor: Maraviroc. Results represent the mean ± S.E.M in four independent 
experiments (Kruskal-Wallis test, Dunn's multiple comparisons test, ** = 
p≤0.01 and ns = p≥0.05 of no significance). 
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3.12 Discussion 
The chemokine signalling network is frequently dysregulated in many 
carcinoma types which as a result leads to the ectopic migration of cancer cells 
to other sites within the body [115, 130]. Cancer dissemination is often fatal for 
the patient and therefore blocking chemokine signalling could be 
therapeutically beneficial for improving the survival rates of cancer patients. 
Unfortunately however this strategy has been particularly unsuccessful for 
carcinomas, with chemokine promiscuity and/or inappropriate target selection 
being two of the main issues [317].  
The main objective of this chapter was to identify chemokine signalling 
pathways involved in the invasion of carcinoma cells for potential therapeutic 
targeting. The second aim was to establish the extent of functional redundancy 
underlying chemokine signalling in cancer cells. 
To identify chemokine signalling pathways involved in carcinoma cell 
migration, seven different chemokine ligands were screened using the wound 
healing assay. From the screen CCL2 and CCL3 were identified as being 
involved in PC-3 and MCF-7 cell migration respectively (figures 3.5a and 
3.12a) which corresponds with results from previous studies [278, 346, 437, 
441].  
The results from the intracellular calcium flux assay suggest that both PC-3 
and MCF-7 cells express CCR5 (figures 3.19a-c and 3.20a-d). Therefore the 
different responses to CCL3 in the wound healing assay by MCF-7 and PC-3 
cells could imply that CCL3 has a cell specific bias for promoting migration in 
MCF-7 cells. Although it may also be possible that the differences between the 
PC-3 and MCF-7 cells could be caused by different expression levels of CCR5 
and/or CCL3 efficacy, as CCR5 expression was not quantified nor was 
different concentrations of CCL3 used.  
In MCF-7 cells neither CCL4 nor CCL8 had any effect on scratch closure 
indicating that CCL3 could also be a biased agonist for CCR5 in promoting 
MCF-7 cell migration. When measuring increases in intracellular calcium both 
CCL4 and CCL3 demonstrated similar levels of efficacy in MCF-7 cells (figure 
3.19a and b). However, due to differences in the kinetics and chemokine 
   
 
131 
 
concentration used to measure intracellular calcium levels (70 secs and 200 
nM) and scratch closure (24 hrs and 10 nM), the efficacy levels of CCL3 and 
CCL4 between these two assays may not be comparable. Therefore efficacy 
cannot be rule out as a contributing factor for the differing responses to CCL3 
and CCL4 in the wound healing assay. CCL8 on the other hand showed no 
receptor activation in MCF-7 cells which could be why no effect on scratch 
closure was observed. 
Similarly in PC-3 cells, CCL8 also showed no effect on scratch closure unlike 
CCL2. Both CCL2 and CCL8 can activate CCR2 and CCR3 which may 
suggest that CCL2 is a biased agonist for CCR2 in PC-3 cell migration. 
Nonetheless data from the intracellular calcium flux assay was unable to 
properly establish the activation of CCR2 by either CCL2 or CCL8 in PC-3 cells 
(figures 3.18 and 3.20). Therefore CCR2 and CCR3 expression on PC-3 cells 
would need to be established using antibodies. 
When probing the molecular mechanisms behind CCL3s activity in MCF-7 cell 
migration, the role of both CCR5 and CCR1 appeared to be redundant (figure 
3.13). Evidence from the intracellular calcium flux assay also suggested that 
CCR1 could be functionally redundant for CCL3 signalling (figure 3.17b). 
Although to confirm this CCR5 activation would also need to be blocked as 
well. However as experimental data from Dr. Richard Jacques has shown that 
maraviroc acts as an agonist by increasing intracellular calcium in THP-1 cells  
[460], the use of maraviroc would not have been appropriate. Alternatively, 
siRNA could be used to knock down CCR5 expression instead.  
Aside from CCL3 and CCL2 no other chemokines were identified as being 
involved in scratch closure, which contradicts the results from several 
previously published studies especially regarding CXCL12 (see table 3.1). 
Therefore there is a worrying lack of reproducibility with the wound healing 
assay. One explanation for this could be the narrow window available to 
measure differences in scratch closure between the basal and chemokine 
treatment. This was particularly evident in the less invasive cell lines such as 
the MCF-7 cells, with the mean difference in scratch width ratio between the 
basal and CCL3 just 0.127. As such, variability between batches of the same 
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cell line e.g. migration speed, chemokine efficacy and chemokine receptor 
expression, could have easily eroded this difference. Another issue 
surrounding the wound healing assay is the lack of sensitivity for more invasive 
cell types such as the PC-3 and MDA-MB-231 cells. As the higher basal 
migration could have concealed chemokine induced migration, especially if the 
cognate receptor was only expressed on a subset of cells such as CCR5 on 
MDA-MB-231 cells [338]. Therefore one alternative and perhaps a more 
sensitive approach would be to measure chemotaxis rather than scratch 
closure for detecting chemokine induced migration. As a consequence the 
effects of both CXCL12 and CCL2 on PC-3 chemotaxis were assessed using 
the transwell migration assay. Furthermore the agarose spot assay was used 
to measure the actions of CXCL12 on MDA-MB-231 cell migration.  
Using the transwell migration assay no clear evidence of chemotaxis was 
measured for either CXCL12 or CCL2 in PC-3 cells (figure 3.15). Whilst for the 
agarose spot no meaningful data was collected (figure 3.16). Both of these 
approaches have been successfully used in previous studies to detect 
chemokine induced migration [278, 442, 448, 464].  
The possible sources for the differing outcomes could have been the 
chemokine concentration, incubation time and cell density used. For the 
transwell migration assay two separate cell concentrations 25x104 and 10x104 
per mL-1 were used (the data presented in this thesis was 10x104 per mL-1). 
Although PC-3 cells suspended at a cell density of 25x10^4 per mL-1 did 
display greater migration this did vary. CCL2 and CXCL12 were also tested at 
a concentration of 1 nM but this had no effect on migration whatsoever. Lastly 
PC-3 cells were incubated for 24 hrs, which was similar to another published 
study [278]. As such there is currently no definitive answer as to why this 
approach did not reproduce similar results as published in the wider literature. 
For the agarose spot assay all conditions were kept the same as in Vinadar. V 
et al. (2011). However the main issue with the agarose spot assay was the 
inability to fix the agarose spot to either glass or plastic which prevented any 
cell migration from being measured. From trialling these two techniques it 
would appear that neither are easily reproducible.  
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Other approaches which can be used to study chemotaxis instead include the 
Boyden chamber and the under the agarose cell migration assay. The Boyden 
chamber has been tried and tested for measuring chemokine induced 
chemotaxis [465]. Whilst no studies to our knowledge have used the under 
agarose assay to measure cellular migration in response to chemokine 
stimulation. Another approach is the OrisTM migration assay which similar to 
the wound healing assay measures the movement of cells into a cell free zone 
and has already shown promising results in the lab with the PC-3 cells in 
response to CXCL8 and CXCL12. However one important limitation with these 
assays is that all migration is assessed in 2D rather than 3D which can lead to 
different cellular behaviour and gene expression [466, 467]. Therefore 3D 
migration models such as the spheroid invasion assay could be used to more 
accurately emulate in vivo metastasis and are already being used to study 
chemokine induced chemotaxis [468]. 
As an additional complementary experiment to the wound healing assay the 
effects of chemokine stimulation on the actin cytoskeleton of MCF-7, PC-3 and 
MDA-MB-231 cells for 24 hrs was explored using phalloidin staining. Overall 
neither PC-3 nor MCF-7 cells showed any obvious morphological differences 
following chemokine treatment (figures 3.21, 3.22, 3.24 and 3.25), although 
preliminary data with MDA-MB-231 cells showed cells treated with CCL8 had 
a more elongated morphology (figure 3.23). In PC-3 cells, treatment with CCL2 
and CXCL12 tended to have higher levels of fluorescence when measuring 
the CTCF (figure 3.26). Interesting this trend also correlates with the wound 
healing assay data as both CCL2 and CXCL12 displayed greater levels of 
scratch closure after 24 hrs as well (figure 3.12a). Quantifying phalloidin 
fluorescence to measure F-actin formation was not a sensitive approach and 
as such western blotting or flow cytometry would be a more reliable and 
accurate way to detect changes in F-actin polymerisation. Also to truly 
determine an association between F-actin remodelling and scratch closure an 
F-actin inhibitor such as Cytochalasin D would need to be used to see if both 
of the observed effects for CCL2 and CXCL12 could be reversed. 
To investigate the role of the CCL3-CCR5 signalling axis in the remodelling of 
the actin cytoskeleton the CHO-CCR5 cells were used, as they are a proven 
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cellular model for observing stress fiber formation [184]. From both the images 
and data analysis CCL3 stimulation was able to induce cellular elongation in 
the CHO-CCR5 cells (figures 3.27b and 3.28), which although not significantly 
blocked using maraviroc some inhibition was observed (figures 3.29a and 
3.30). CCL3 treatment did show higher levels of fluorescence however 
maraviroc was unable to inhibit this effect and therefore as previously 
discussed the CTCF is not a reliable method for quantifying F-actin levels. 
Cellular elongation and polarity is a common feature of migrating cells and 
requires alterations to the actin cytoskeleton [469]. The CHO-CCR5 cells can 
serve as an independent and additional model to elucidate the molecular 
mechanisms of the CCL3-CCR5 signalling pathway involved in cytoskeletal 
changes. 
In summary the evidence from the chemokine screen did not identify 
substantial functional redundancy amongst the chemokine ligands within and 
between specific cell types in the wound healing assay. Though evidence of 
chemokine receptor redundancy was identified. Due to the lack of sensitivity 
and reproducibility of the cell migration assays used in this chapter, whether 
inappropriate target selection could be a contributing factor for the low clinical 
success rate in the targeting of chemokine signalling for cancer treatment was 
not established.  
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3.13 Conclusion 
The main findings from this chapter were also follows: 
 CCL3 and CCL2 promote scratch closure in MCF-7 and PC-3 cells 
respectively, with the CCL3 acting on both CCR1 and CCR5. 
 
 CCL4 induces intracellular calcium signalling in both PC-3 and MCF-7 
cells. CCL3 also induces receptor activation in MCF-7 cells. 
 
 CHO-CCR5 cells can be used as a model to investigate CCL3 induced 
cellular elongation. 
 
 The wound healing assay is not a reliable approach for assessing 
chemokine induced migration. Whilst using the transwell migration and 
agarose spot assays to identify carcinoma chemotaxis towards 
chemokines is not highly reproducible. 
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Chapter 4.0 Investigating the downstream molecular 
mechanisms of G-protein signalling via different 
chemokines and in different cancer cell types 
 
4.1 Introduction  
Chemokine receptors are members of the G-protein coupled receptor 
superfamily and signal downstream through the dissociation of the 
heterotrimeric G-protein (Gα/βγ subunits). There are four main classes of the 
Gα subunit based on their genomic sequence and downstream effectors: Gαs, 
Gαq, Gα12 and Gαi. [36]. Chemokine receptors are primarily coupled to the Gαi 
class. Upon receptor activation the G-protein is recruited to the second and 
third intracellular loops resulting in the exchange of GDP for GTP on the Gαi 
subunit [25]. This activates the G-protein leading to its dissociation into the Gαi 
and Gβγ subunits. Gαi is a negative regulator of adenylate cyclase and blocks 
cAMP generation [470]. Alternatively Gαi can activate Src, a regulator of FAK, 
PI3K and MAPK signalling. Gβγ meanwhile can bind to Phospholipase C 
(PLC) which in turn cleaves PIP2 into IP3 and DAG. IP3 travels to and opens 
the IP3 channels on the endoplasmic reticulum which results in release of 
calcium from the intracellular stores. Intracellular calcium together with DAG 
activate PKC [88]. The downstream signalling pathways of FAK, PI3K, MAPK 
and PKC control many cellular physiological changes including cell migration 
and their dysregulation is associated with cancer metastasis [471-474]. 
Consequently many of these proteins are considered valid targets for cancer 
therapy and could serve as alternative therapeutic targets to the chemokine 
ligand or receptor.  
Within the Mueller lab differences in the downstream pathway have been 
observed for distinct chemokine families [346, 347] and cell types [340]. 
However in the wider scientific literature understanding of the downstream 
signalling pathway for individual chemokines in different cancer types remains 
somewhat limited. This therefore restricts the selection of viable therapeutic 
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targets for blocking chemokine downstream signalling within metastatic cancer 
cells.  
4.2 Aim 
To investigate and probe the molecular machinery downstream of chemokine 
G-protein signalling within different types of cancer. This will potentially allow 
the identification of any novel chemokine and cell type specific intracellular 
signalling transducers which could be used for selective therapeutic targeting 
of the chemokine signalling network. 
 
4.3 PLC is a cell specific mediator of intracellular calcium 
signalling for CCL3 in MCF-7 cells and chemokine signalling 
in THP-1 cells 
PLC is a key mediator of chemokine increases in intracellular calcium and is 
often overexpressed in breast [475] and colorectal cancers [476]. Therefore 
establishing whether PLCs role is ubiquitous for the downstream signalling of 
different chemokines within separate cancer cell types could identify its 
importance as a therapeutic target.  
To elucidate the molecular mechanisms in chemokine downstream signalling, 
intracellular calcium levels were measured to determine whether a protein 
could be important for this particular signalling event. The initial aim was to 
characterise the role of PLC in the downstream signalling of different 
chemokines by using PC-3, MCF-7 and THP-1 cells as cellular models for 
intracellular calcium signalling, as they all express both CCR5 and CXCR4 
[436, 477-479].  
The most commonly used small molecule for probing PLCs role in cellular 
based assays is the U73122, which disrupts PIP2 hydrolysis [406]. U73122 has 
been widely shown to effectively attenuate the release of calcium from the 
intracellular stores [480-483]. Although there have also been some concerns 
regarding the potential for off-target effects, such as on calcium channels 
[484], SERCA [485] and even PLC activation [486], although the latter 
occurring within a cell free assay. Currently there are not many commercially 
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available PLC inhibitors, and amongst them, U73122 is the most well validated 
inhibitor for the pharmacological blockade of PLC in cell based assays. 
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Figure 4.1. U73122 (1 µM) inhibition of PLC in the intracellular calcium 
flux assays of MCF-7 and PC-3 cells. (a) PC-3 cells were pretreated with 
U73122 (30 mins) prior to chemokine stimulation (n=3). (b) U73122 inhibits 
CCL3 intracellular calcium signalling in MCF-7 cells (n≥3). The double lines 
between CCL3 and CCL4 indicate separate experiments. (c)  Representation 
of an intracellular calcium measurement trace following CCL3 stimulation in 
MCF-7 cells pretreated with U73122 (30 mins) after 70 secs.  Data was 
normalised to the vehicle control (DMSO 1%) and represent the mean ± SEM 
of at least three independent experiments. (Wilcoxon Signed Rank Test, * = 
p≤0.05, and ns = p≥0.05 of no significance). 
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Figure 4.2. U73122 (1 µM) inhibition of PLC in the intracellular calcium 
flux assay of THP-1 cells. (a) U73122 inhibits chemokine intracellular calcium 
signalling in THP-1 cells. Representation of an intracellular calcium 
measurement trace following CCL3 (b) and CXCL12 (c) stimulation in THP-1 
cells pretreated with U73122 (30 mins) after 70 secs. Data represents the 
mean ± SEM of at least four independent experiments (multiple t-tests, Holm-
Šídák method, * = p≤0.05). 
 
In THP-1 cells U73122 (1 μM) was able to significantly block increases in 
intracellular calcium amongst all the chemokines screened with the Student’s 
t-test. Although multiple comparisons with the Holm-Šídák method showed no 
statistical significance this was likely obscured by the high standard deviation 
within the experiment (figure 4.2). This data implies that PLC is crucial for 
chemokine downstream signalling within THP-1 cells. In MCF-7 cells U73122 
only significantly blocked increases in intracellular calcium from CCL3 (200 
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nM) indicating that PLC is important for CCL3 intracellular calcium signalling 
but not for CCL23, CCL5 or CXCL12 (figure 4.1b, c and d). For CCL4 signalling 
the U73122 did show a tendency to block increases in intracellular calcium. 
CCL3, CCL4 and CCL5 are all cognate ligands for CCR5 therefore the 
difference between PLCs importance in intracellular calcium signalling of 
CCL5 and that of CCL3 suggests that in MCF-7 cells, PLCs role is dependent 
on the chemokine ligand rather than the receptor. This was also observed for 
CCL3 and CCL23 intracellular calcium signalling as both chemokines activate 
CCR1 however U73122 only blocked CCL3 intracellular calcium signalling.  
Blocking PLC activity in PC-3 cells displayed no significant effect on the 
increase in intracellular calcium of CCL3 (200 nM) or CXCL12 (15 nM). Though 
some reduction following CCL3 stimulation was observed with U73122 (figure 
4.1a). Hence it appears that PLC is not crucial for CCL3 and CXCL12 
intracellular calcium signalling in PC-3 cells. 
 
4.4 U73122 blocks CCL3 increases in intracellular calcium in 
a concentration dependent manner in THP-1 cells  
To ensure that the inhibition of chemokine intracellular calcium signalling by 
U73122 in THP-1 cells was due to a specific effect on PLC rather than a non-
specific or off-target effect. A concentration response of U73122 at four 
separate concentrations: 50, 100, 500 nM and 1 µM was performed on CCL3 
intracellular calcium signalling in THP-1 cells.  
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Figure 4.3. U73122 inhibits CCL3 (200 nM) intracellular calcium signalling 
in a concentration dependent manner in THP-1 cells. PLC inhibitor: 
U73122. Result represent the mean ± S.E.M. of at least three independent 
experiments. (One-way ANOVA, Dunnett's multiple comparisons test, * = 
p≤0.05, and ns = p≥0.05 of no significance). 
 
The data from the concentration response of U73122 showed that U73122 was 
able to significantly inhibit CCL3 (200 nM) intracellular calcium signalling at 
both 500 nM and 1 µM, as well as having a moderate but non-significant 
inhibition on increases in intracellular calcium at 50 and 100 nM (figure 4.3). 
This demonstrates that U73122 inhibits increases in intracellular calcium in a 
concentration dependent manner and confirms a role for PLC in the 
downstream signalling pathway of chemokines in THP-1 cells. 
 
 
 
 
   
 
142 
 
4.5 U73122 is not cytotoxic in THP-1 after 2 hrs and in MCF-
7 cells after 30 mins incubation  
As an additional control the effects of U73122 was assessed on the cellular 
viability of THP-1 and MCF-7 cells using an MTS cell proliferation assay. 
Thereby excluding the possibility of compound cytotoxicity during the 30 mins 
pretreatment time prior to intracellular calcium measurements.  
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Figure 4.4. Cell proliferation assay of THP-1 cells. U73122 is not cytotoxic 
at concentrations of 50, 100, 500 nM and 1 μM in THP-1 cells after 2 hrs 
incubation with MTS reagent. PLC inhibitor: U73122. Result represent ± SEM 
of four independent experiments (One-way ANOVA, Dunnett's multiple 
comparisons test, * = p≤0.05 and ns = p≥0.05 of no significance). 
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Figure 4.5. Concentration response of U73122 on MCF-7 cell 
proliferation. (a) U73122 is not significantly cytotoxic after 2 hrs incubation 
with MTS reagent. (b) U73122 is not cytotoxic after 30 mins incubation with 
MTS reagent. PLC inhibitor: U73122. Results were normalised to the control 
and represent ± SEM of four independent experiments (Kruskal-Wallis test, 
Dunn's multiple comparisons test, * = p≤0.05 and ns = p≥0.05 of no 
significance). 
 
The results from the MTS assay showed that U73122 was not cytotoxic at any 
of the four concentrations (50, 100, 500 nM and 1 μM) in THP-1 cells and MCF-
7 cells after 2 hrs incubation (figure 4.4). However in MCF-7 cells U73122 
showed some decrease in cell viability at concentrations of 100, 500 nM, and 
1 μM following 2 hrs incubation (figure 4.5a).  
For the intracellular calcium flux assay U73122 was incubated for 30 mins prior 
to chemokine stimulation and the MTS assay was therefore repeated with 
U73122 incubated for 30 mins instead to see if there was still evidence of some 
possible cytotoxicity. After 30 mins incubation U73122 displayed no significant 
effect on MCF-7 cellular viability at any of the four concentrations tested. 
Although lower levels of absorbance were still observed with 1 µM of U73122 
(figure 4.5b). 
Overall the MTS assay data indicates that using U73122 at a concentration of 
1 µM is still appropriate to functionally assess the role of PLC on intracellular 
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calcium signalling in THP-1 cells. For MCF-7 cells it is unlikely that U73122s 
effect on CCL3 intracellular calcium signalling was due to cytotoxicity as 
U73122 had no effect on CCL5, CCL23 and CXCL12 increases in intracellular 
calcium (figure 4.1b). However it appears that MCF-7 cells display some 
sensitivity towards to the effects of U73122 (1 μM). 
 
4.6 CCL3 and CXCL12 do not signal through Gβγ in MCF-7 
cells 
In MCF-7 cells PLCs importance was shown to be specific to only CCL3. To 
establish whether the differing roles of PLC in CCL3 and CXCL12 intracellular 
calcium signalling in MCF-7 cells was a result of diverging signalling 
mechanisms upstream of PLC. The Gβγ subunit was targeted using the small 
molecule inhibitor gallein in MCF-7 cells prior to CCL3 or CXCL12 stimulation.  
Gallein binds to the WD40 repeat structural motif of Gβγ which is the main 
protein binding site and thereby inhibits Gβγ intracellular activity [487]. Gallein 
has been shown to effectively block neutrophil [488] and T-lymphocyte 
chemotaxis [347]. For intracellular calcium signalling gallein was able to inhibit 
H1R agonism [489] however gallein had no such effect on glucose [490], 
CXCL11 or CCL3 [347]. Treatment with gallein alone has been shown not to 
induce increases in intracellular calcium [491]. 
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Figure 4.6. Gallein inhibition of Gβγ in the intracellular calcium flux assay 
of MCF-7 cells. Results represent the mean ± S.E.M. in at least four 
independent experiments (multiple t-tests, Holm-Sidak test, ns = p≥0.05 of no 
significance). 
 
Incubating MCF-7 cells with gallein (10 µM) for 30 mins prior to chemokine 
stimulation did not inhibit CCL3 (200 nM) or CXCL12 (15 nM) intracellular 
calcium signalling compared to the vehicle control (etoh 1%) (figure 4.6). In 
contrast, upon CXCL12 simulation pre-incubation with gallein had a tendency 
to display a higher level of increase in intracellular calcium than the vehicle. 
The data shows that Gβγ is not important for the increases in intracellular 
calcium by CCL3 or CXCL12 in MCF-7 cells.  
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4.7 CCL4, CCL5 and CXCL12 signal through Gαi/βγ in MCF-
7 cells 
The results from the intracellular calcium flux assays with gallein conflicts with 
the current understanding of the canonical Gαi signalling pathway, whereby 
Gβγ is needed for PLC activation [74, 75]. Therefore it is possible to speculate 
that CCR1/5 and CXCR4 could be coupled to an alternative class of G-protein 
within MCF-7 cells, in particular Gαq which can also activate PLC to mobilise 
calcium from the intracellular stores [28]. To test this hypothesis pertussis toxin 
(PTX) was used to completely block Gαi/βγ coupling to the chemokine 
receptor. 
In
tr
a
c
e
ll
u
la
r
 c
a
lc
iu
m
 l
e
v
e
ls
(R
a
ti
o
: 
3
4
0
 n
m
/3
8
0
 n
m
)
C
C
L
5
 
(2
0
0
 n
M
)
C
C
L
4
(2
0
0
 n
M
)
C
X
C
L
1
2
(1
5
 n
M
)
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
C o n tro l
P T X
1 0 0  n g /m l
*
**
a
In
tr
a
c
e
ll
u
la
r
 c
a
lc
iu
m
 l
e
v
e
ls
(p
e
r
c
e
n
ta
g
e
 o
v
e
r
 b
a
s
a
l)
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
1 3 0 C o n tro l
P T X
(1 0 0  n g /m l)
B a s e lin e
C C L 4  (2 0 0  n M )
in je c tio n
b
T im e  (s e c s )
In
tr
a
c
e
ll
u
la
r
 c
a
lc
iu
m
 l
e
v
e
ls
(p
e
r
c
e
n
ta
g
e
 o
v
e
r
 b
a
s
a
l)
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
1 3 0 C o n tro l
P T X
(1 0 0  n g /m l)
T im e  (s e c s )
B a s e lin e
C C L 5  (2 0 0  n M )
in je c tio n
c
In
tr
a
c
e
ll
u
la
r
 c
a
lc
iu
m
 l
e
v
e
ls
(p
e
r
c
e
n
ta
g
e
 o
v
e
r
 b
a
s
a
l)
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
1 3 0
C o n tro l
P T X
(1 0 0  n g /m l)
T im e  (s e c s )
B a s e lin e
C X C L 1 2  (1 5  n M )
in je c tio n
d
 
Figure 4.7. PTX inhibition of Gαi/βγ coupling in MCF-7 cells. (a) PTX (100 
ng/ml) abolishes CCL4, CCL5 and CXCL12 intracellular calcium signalling in 
MCF-7 cells. (b)  Representation of an intracellular calcium measurement trace 
following CCL4 stimulation in MCF-7 cells pretreated with PTX (16 hrs) after 
70 secs. (c) Representation of an intracellular calcium measurement trace 
following CCL5 stimulation in MCF-7 cells pretreated with PTX (16 hrs) after 
70 secs. Representation of an intracellular calcium measurement trace 
following CXCL12 stimulation in MCF-7 cells pretreated with PTX (16 hrs) after 
70 secs. Results represent the mean ± S.E.M. in at least three independent 
experiments. (multiple t-tests, Holm-Sidak test, * = p≤0.05, ns = p≥0.05 of no 
significance). 
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The intracellular calcium measurement experiments with PTX showed that 
PTX (100 ng/ml) significantly abolishes the intracellular calcium signalling of 
CXCL12 (15 nM), CCL4 and CCL5 (200 nM) in MCF-7 cells (figure 4.7 a-d). 
The data confirms that in MCF-7 cells both CXCR4 and CCR5 are coupled to 
and signal via Gαi. 
 
4.8  FAK14 inhibits CXCL12 increases in intracellular calcium 
in THP-1 cells.  
Aside from the PLC mediated signalling pathway, chemokine downstream 
signalling can also occur via the Gαi-Src signalling axis [60]. Src is a tyrosine 
kinase which regulates the activity of a variety of downstream proteins 
including FAK and PI3K [61, 62, 65, 67]. In cancer, FAK is often overexpressed 
[471] whilst PI3K is frequently mutated [472]. Consequently FAK and PI3K are 
considered important for cancer progression and therefore could contribute to 
chemokine associated metastasis.  
PI3K has been implicated in CXCL12 downstream signalling for T-cell 
leukaemia [340], breast [340, 342, 343], bile duct [492] and colon cancers 
[493], as well as, melanoma [494], glioblastoma [495] and multiple myeloma 
[496]. CXCL12 has also been shown to activate FAK within multiple myeloma 
[496], glioblastoma [497], leukaemia [498], breast [342, 343, 499], pancreatic 
[500], cervical [501], liver [501], prostate [502] and gastric cancers [503]. 
Despite the substantial evidence of FAK and PI3K activation downstream of 
CXCL12 signalling within cancer, much of this data especially for FAK is 
derived entirely from western blotting and therefore provides little insight into 
functionality, importance or the underlying molecular mechanisms involved.  
To better understand the role of FAK and PI3K in chemokine downstream 
signalling both proteins were blocked within an intracellular calcium flux assay 
to see if they regulate CCL3 and CXCL12 mobilisation of calcium from the 
intracellular stores in PC-3, THP-1 and MCF-7 cells. CHO-CCR5 cells were 
also included as an additional cellular model for CCL3 signalling as much less 
is known about the roles of FAK and PI3K within the CCL3 signalling pathway.  
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To fully determine PI3Ks role two established PI3K inhibitors were used, the 
non-specific PI3K inhibitor LY294002 and the PI3Kγ inhibitor AS605240, 
thereby ensuring all PI3K isoforms were targeted. For blocking FAK kinase 
activity PF562271 was used, as it binds inside the ATP binding pocket of FAK 
[400]. FAK activation was also blocked using FAK14, which interacts with the 
Tyr397 residue to disrupt FAK autophosphorylation [399]. In addition to 
PF562271, another tyrosine kinase inhibitor masitinib was also used. Masitinib 
primarily targets Lyn B however it may also inhibit some FAK activity due to its 
ability to displace ATP within the tyrosine kinase domain [401, 504]. This range 
of FAK inhibitors allows the identification of potential functional differences in 
FAK activity as well as adding greater reliability to the results.   
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Figure 4.8. Inhibition of FAK and PI3K in CCL3 (200 nM) and CXCL12 (15 
nM) intracellular calcium flux assays. PC-3 cells were pretreated with 
inhibitors (30) mins prior to CCL3 (a) or CXCL12 (b) stimulation. MCF-7 cells 
were pretreated with inhibitors (30 mins) prior to CCL3 (c) or CXCL12 (d) 
stimulation. (e) THP-1 cells were pretreated with inhibitors (30 mins) prior to 
CCL3 stimulation. (f) CHO-CCR5 cells were pretreated with inhibitors (30 
mins) prior to CCL3 stimulation. FAK inhibitors: FAK14, Masitinib and 
PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Results 
represents the mean ± S.E.M. in at least 3 independent experiments. (One-
way ANOVA, Dunnett's multiple comparisons test, Fischer’s LSD Test, ns = 
p≥0.05 of no significance). 
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Figure 4.9. CXCL12 (15 nM) increases in intracellular calcium levels in 
THP-1 cells. (a) FAK14 (1 µM) abolishes CXCL12 intracellular calcium 
signalling in THP-1 cells. (b) Representation of an intracellular calcium 
measurement trace following CXCL12 stimulation in THP-1 cells pretreated 
with FAK14 (30 mins) after 70 secs. FAK inhibitors: FAK14, Masitinib and 
PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Results 
represents the mean ± S.E.M data in three independent experiments. (One-
way ANOVA, Dunnett’s multiple comparison test, Fischer’s LSD Test, * = 
p≤0.05). 
 
From the intracellular calcium measurement experiments only FAK14 (1 μM) 
was able to significantly attenuate CXCL12 (15 nM) signalling in THP-1 cells 
(p≤0.05, n=3, Fischer’s LSD Test) (figure 4.9). None of the other compounds 
displayed any significant inhibitory effect on CCL3 (200 nM) or CXCL12 (15 
nM) signalling in any of the cell lines used. In THP-1 cells incubation with 
PF562271 (10 nM) displayed a 30% lower increase in intracellular calcium 
than the vehicle control (DMSO 1%) in response to CCL3 stimulation (figure 
4.8e). In CHO-CCR5 and MCF-7 cells incubation with LY294002 (10 μM) 
tended to show higher levels of intracellular calcium upon CCL3 stimulation 
compared to the vehicle alone (figure 4.8c and f).  
These results indicate that FAK could be important for CXCL12 intracellular 
calcium signalling in THP-1, but not CCL3 or in MCF-7 or PC-3 cells. 
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4.9 FAK14 and U73122 show no additive effect on CXCL12 
intracellular calcium signalling in THP-1 cells 
The previous data indicated that CXCL12 intracellular calcium signalling in 
THP-1 cells is dependent on both PLC and FAK. To establish if PLC and FAK 
were acting on the same or two independent pathways both FAK14 and 
U73122 were used at lower concentrations to identify whether both inhibitors 
when added together would have a greater inhibitory effect on intracellular 
calcium signalling. An additive effect would indicate that both proteins are part 
of two independent pathways, hence the increase in inhibition. 
 
Figure 4.10. U73122 and FAK14 do not have an additive inhibition on 
CXCL12 (25 nM) intracellular calcium signalling in THP-1 cells. PLC 
inhibitor: U73122. FAK inhibitor: FAK14. Results represent the mean ± S.E.M. 
in five independent experiments. (One-way ANOVA, Dunnett's multiple 
comparisons test, ns = p≥0.05 of no significance). 
 
Using concentrations of 100 nM for U73122, and 100 and 500 nM for FAK14 
showed no significant inhibition on CXCL12 (25 nM) increases in intracellular 
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calcium in THP-1 cells when adding the compounds together (figure 4.10). 
However, incubating THP-1 cells with both FAK14 and U73122 did display 
lower increases in intracellular calcium compared to the other conditions. 
Neither FAK14 nor U73122 showed any inhibition against the vehicle control 
when added separately.  
Overall, when added together neither U73122 nor FAK14 showed a significant 
additive effect. However as neither inhibitor showed any inhibition alone, 
whether FAK or PLC belong to the same or separate downstream signalling 
pathways could not be concluded from this experiment. 
 
4.10 Src/Syk and c-Raf are important for CXCL12 intracellular 
calcium signalling in MCF-7 cells 
Src is known to activate FAK and PI3K signalling but Src can also regulate the 
MAPK signalling pathway through the phosphorylation of Raf [64, 505]. Raf is 
a serine/threonine kinase and initiates a phosphorylation cascade by targeting 
MEK, which in turn phosphorylates ERK. Phosphorylated ERK translocates to 
the nucleus to regulate transcription factors such as FOXO, Elk and c-Fos, to 
increase cellular proliferation and cell survival [506]. 
The previous blockade of FAK and PI3K in CCL3 and CXCL12 intracellular 
calcium flux assays only identified the involvement of FAK in CXCL12 
signalling in THP-1 cells (figure 4.9). Neither FAK nor PI3K were shown to be 
important for CCL3 intracellular calcium signalling or in MCF-7 cells.  
To investigate whether CCL3 or CXCL12 could be increasing intracellular 
calcium through the activation of Src and/or MAPK signalling instead of PI3K 
or FAK, Src/Syk and c-Raf were targeted using MNS and ZM336372 
respectively. 
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Figure 4.11. MNS (10 μM) and ZM336372 (1 μM) inhibition of Src/Syk and 
c-Raf respectively in the intracellular calcium flux assay. (a) MCF-7 cells 
were pretreated with MNS and ZM336372 (30 mins) prior to CCL3 (200 nM) 
stimulation. (b) CHO-CCR5 cells were pretreated with MNS and ZM336372 
(30 mins) prior to CCL3 (200 nM) stimulation. Results represent the mean ± 
S.E.M. in at least 3 independent experiments. (One-way ANOVA, Dunnett's 
multiple comparisons test, ns = p≥0.05 of no significance). 
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Figure 4.12. MNS (10 μM) and ZM336372 (1 μM) inhibition of Src/Syk and 
c-Raf respectively in the intracellular calcium flux assay of THP-1 cells. 
THP-1 cells were pretreated with MNS and ZM336372 (30 mins) prior to CCL3 
(200 nM) (a) or CXCL12 (15 nM) (b) stimulation. Results for CXCL12 were 
normalised to the control (DMSO 1%) and analysed using the Kruskal-Wallis 
test, Dunn's multiple comparisons test. Results represent the mean ± S.E.M. 
in at least 3 independent experiments. (One-way ANOVA, Dunnett's multiple 
comparisons test, ns = p≥0.05 of no significance). 
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Figure 4.13. CXCL12 (15 nM) increases in intracellular calcium levels in 
MCF-7 cells. (a) MNS and ZM336372 inhibit CXCL12 intracellular calcium 
signalling in MCF-7 cells. (b) Representation of an intracellular calcium 
measurement trace following CXCL12 stimulation in MCF-7 cells pretreated 
with MNS or ZM336372 (30 mins) after 70 secs. Src/Syk inhibitor: MNS. c-Raf 
inhibitor: ZM336372. Results represent the mean ± S.E.M. of three 
independent experiments. (One-way ANOVA, Dunnett's multiple comparisons 
test, ** = p≤0.01). 
 
From the intracellular calcium measurement experiments only MCF-7 cells 
showed a significant reduction of CXCL12 (15 nM) intracellular calcium 
signalling when treated with either MNS (10 μM) or ZM336372 (1 μM) (figure 
4.13). Neither MNS nor ZM336372 had any effect on CXCL12 (15 nM) or CCL3 
(200 nM) increase in intracellular calcium in THP-1 cells (figure 4.12c and d), 
or on CCL3 intracellular calcium signalling in MCF-7 and CHO-CCR5 cells 
(figures 4.12a and b). This suggests that Src/Syk and c-Raf are important for 
CXCL12 intracellular calcium signalling in MCF-7 cells but not in THP-1 cells 
or for CCL3. 
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4.11 U73122 inhibits CXCL12 chemotaxis of Jurkat cells 
Chemokines primarily function as a chemoattractant and as such cell migration 
is a key cellular response to their signalling. In migrating cells, macromolecular 
structures known as focal adhesions (FA) are formed for adherence to the 
extracellular matrix and to generate traction [181, 182]. Within these FA, FAK 
can act as a scaffold for integrin binding, as well as binding to intracellular 
proteins such as Src, p130cas and paxillin for FA assembly [507]. Aside from 
FA formation, FAK and also PI3K can promote cell migration by regulating Rho 
GTPase activity [68, 508]. PI3K has been implicated in the migration of 
numerous different cancer cell types in response to chemokines [340, 342, 
509-512]. But for FAK its role within chemokine cancer cell migration remains 
largely confined to a few studies [343, 498, 513] 
To improve the understanding of FAKs role in chemokine stimulated migration, 
THP-1 cancer cells were used to model CCL3 and CXCL12 induced 
chemotaxis. The leukemic T-cell line, the Jurkat cells, was used as an 
additional cellular model to characterise the downstream signalling of CXCL12 
chemotaxis. Jurkat cells express high levels of CXCR4 and as such display a 
high level of cellular mobility in response to CXCL12. This makes them an ideal 
model for studying CXCL12 chemotaxis.  
To assess for cellular chemotaxis one of the most established methods used 
is the transwell migration assay. Transwell migration assays are comprised of 
two main components: the 96 well plate which contains the chemoattractant 
and a semipermeable membrane where cells are loaded onto. The 
semipermeable membrane is placed on top of the 96 well plate and the cells 
along with the chemoattractant are incubated together for a defined period of 
time. After incubation, the membrane and remaining cells are removed from 
the plate and the number of cells in each well are counted. The difference 
between the number of cells in the well with the chemoattractant and that of 
the buffer alone (the control) is used to measure chemotaxis. 
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Figure 4.14. Inhibition of FAK in CCL3 (1 nM) and CXCL12 (5 nM) 
chemotaxis in THP-1 cells. (a) Treatment with FAK inhibitors does not inhibit 
CCL3 chemotaxis of THP-1 cells. (b) Treatment with FAK inhibitors does not 
inhibit CXCL12 chemotaxis of THP-1 cells after 4 hrs. FAK inhibitors: FAK14, 
Masitinib and PF562271. All results were normalised to DMSO (1 %) with 
CCL3 (1 nM) or CXCL12 (5 nM) and represent the mean ± SEM of three 
independent experiments. (Kruskal-Wallis test, Dunn's multiple comparisons, 
ns = p≥0.05 of no significance). 
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Figure 4.15.  U73122 (1 µM) inhibition of PLC blocks CXCL12 (1 nM) 
chemotaxis in Jurkat cells after 4 hrs. PLC inhibitor: U73122. FAK inhibitors: 
FAK14, Masitinib and PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: 
AS605240. Results represent the mean ± SEM of at least three independent 
experiments. (One-way ANOVA, Dunnett's multiple comparisons test, **** = 
p≤0.0001). 
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Figure 4.16. MNS (10 µM) and ZM336372 (1 µM) inhibition of Src/Syk and 
c-Raf respectively does not block CXCL12 (1 nM) chemotaxis in Jurkat 
cells after 4 hrs. All results were normalised to DMSO (1 %) with CXCL12 (1 
nM) and represent the mean ± SEM in four independent experiments. (Kruskal-
Wallis test, Dunn's multiple comparisons, ** = p≤0.01, ns = p≥0.05 of no 
significance). 
 
FAK blockade showed no inhibition on THP-1 chemotaxis to either CCL3 (1 
nM) or CXCL12 (5 nM) after 4 hrs (figure 4.14). In THP-1 cells incubation with 
FAK14 did display higher levels of cell migration towards CCL3 than the 
vehicle control. In Jurkat cells only U73122 (1 µM) was able to block CXCL12 
(1 nM) induced chemotaxis (figure 4.14). FAK, PI3K, c-Raf or Src/Syk 
blockade in Jurkat cells showed no significant inhibition on CXCL12 (1 nM) 
chemotaxis after 4 hrs (figures 4.15 and 4.16). Though treatment with 
PF562271 (10 nM) did show higher levels of CXCL12 chemotaxis when 
compared to the vehicle control (figure 4.15).  
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Overall it appears that FAK is not important for promoting THP-1 chemotaxis 
towards CCL3 and CXCL12 or in Jurkat cells towards CXCL12. Whilst only 
PLC is crucial for CXCL12 chemotaxis of Jurkat cells. 
 
4.12 U73122 is cytotoxic in Jurkat and THP-1 cells after 6 hrs 
and 29 hrs respectively 
From the chemotaxis data U73122 (1 μM) was shown to significantly inhibit 
CXCL12 chemotaxis in Jurkat cells after 4 hrs (figure 4.15). To account for 
compound cytotoxicity as a possible cause for chemotaxis inhibition. All 
compounds used in the transwell migration assay were assessed for cellular 
cytotoxicity in both the THP-1 and Jurkat cell lines using the MTS cellular 
proliferation assay. 
The data from the MTS identified that U73122 (1 µM) was cytotoxic in both 
THP-1 and Jurkat cells following 29 hrs and 6 hrs incubation respectively 
(figure 4.17). This indicates that U73122 inhibition on CXCL12 chemotaxis in 
Jurkat cells was due to cellular cytotoxicity rather than any functionality. None 
of the other compounds demonstrated any significant cytotoxicity in either cell 
line and as such were suitable to avoid cytotoxicity in the transwell migration 
assay. 
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Figure 4.17. Cellular proliferation assay of THP-1 and Jurkat cells. (a) 
U73122 (1 μM) was significantly cytotoxic in THP-1 cells following 24 hrs 
incubation and 5 hrs MTS reagent metabolisation (n=3). (b) U73122 (1 μM) 
was significantly cytotoxic in Jurkat cells after 2 hrs incubation and 4 hrs MTS 
metabolisation (n=3). PLC inhibitor: U73122. FAK inhibitors: FAK14, Masitinib 
and PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Src/Syk 
inhibitor: MNS. c-Raf inhibitor: ZM336372. All results represent ± SEM of three 
independent experiments. (One-way ANOVA, Dunnett's multiple comparisons 
test, *** = p≤0.001 and * = p≤0.05). 
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4.13 PI3K is not important for CCL3 induced scratch closure 
of MCF-7 cells 
The transwell migration assay is a reliable approach for measuring 
chemotaxis, but for the assay to be effective cells are required to be in 
suspension. For leukemic cells such as THP-1 and Jurkats, this mimics the in 
vivo environment. But for MCF-7 cells which are adherent this approach does 
not model their migratory mode as accurately.  
MCF-7 cells are of epithelial origin and as such form cellular sheets. During 
cancer development some of these epithelial cells can adopt a mesenchymal 
phenotype by displaying a greater migratory behaviour and less adherence 
[514]. In the wound healing assay cells are grown as sheets and as such is a 
more applicable method for studying the migration of MCF-7 cells in response 
to chemokine stimulation.  
A recent published study from the Mueller lab has shown that PI3K is important 
for CXCL12 induced migration in MCF-7 cells. However in this study PI3Ks 
role was determined by siRNA and not with the LY294002 [340]. To better 
understand the importance of PI3K in CCL3 induced migration in MCF-7 cells, 
both LY294002 and AS604520 were used in the wound healing assay of MCF-
7 cells. 
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Figure 4.18.  LY294002 (10 μM) and AS604520 (2.5 μM) inhibition of PI3K 
and PI3Kγ respectively does not block CCL3 (10 nM) scratch closure in 
MCF-7 cells after 24 hrs. A value of 1 denotes no migration, whilst 0 denotes 
complete migration. Results represent the mean ± SEM in four independent 
experiments. (One-way ANOVA, Tukey’s test, ns = p≥0.05 of no significance).
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Figure 4.19. MCF-7 scratch closure in the presence and absence of CCL3 (10 nM) and respective PI3K and PI3Kγ inhibitors 
LY294002 (10 μM) and AS604520 (2.5 μM) after 24 hrs. Images are a representation of the cell population and were taken at 10x 
objective with a Leica DMI6000 inverted microscope and using Leica imaging suite. 
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When using LY294002 (10 μM) and AS604520 (2.5 μM) to block PI3K and 
PI3Kγ activity respectively, no significant inhibition on CCL3 (10 nM) scratch 
closure was detected (figure 4.18). However treatment with LY294002 did 
appear to reduce CCL3 induced scratch closure after 24 hrs. Although this 
could be due to cytotoxicity as two of the datasets showed observable cellular 
loss following LY294002 incubation (figure 4.19).  
CCL3 treatment did show a tendency to enhance MCF-7 scratch closure after 
24 hrs however it was not statistically significant. Also there was a similar level 
of scratch closure for AS604520 treatment alone when compared against 
CCL3 only. This raises substantial doubt as to whether CCL3 had any true 
effect on MCF-7 cell migration within this experiment.  
 
4.14 None of the PI3K or FAK inhibitors were cytotoxic in 
MCF-7 cells following 25 hrs incubation 
Due to the evidence of potential cellular cytotoxicity in MCF-7 cells following 
24 hrs incubation with LY294002 (10 µM) in the wound healing assay (figure 
4.19). An MTS assay was performed on the FAK and PI3K inhibitors to 
establish their effects on MCF-7 cell viability after 24 hrs. 
Amongst the compounds tested none showed any significant effect on MCF-7 
cell viability after 25 hrs incubation (figure 4.20). This confirms that the FAK 
and PI3K compounds used in this chapter are suitable to avoid cellular 
cytotoxicity for a 24 hrs wound healing assay experiment (at the concentration 
tested). 
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Figure 4.20. None of the compounds were significantly cytotoxic in MCF-
7 cells following 24 hrs incubation and 1 hrs MTS metabolisation. FAK 
inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: LY294002. PI3Kγ 
inhibitor: AS605240. All results represent ± SEM of at least three independent 
experiments. (One-way ANOVA, Dunnett's multiple comparisons test, **** = 
p≤0.0001 and ns = p≥0.05 of no significance). 
 
4.15 FAK, PI3K and PLC do not affect the actin cytoskeleton 
in CHO-CCR5 and PC-3 cells. 
The phalloidin staining of CHO-CCR5 cells identified that CCL3 induced 
greater cellular elongation (aspect ratio) following 24 hrs incubation (figure 
3.27b). Furthermore CCL3 and CXCL12 both tended to exhibit higher levels of 
fluorescence (CTCF) in CHO-CCR5 and PC-3 cells respectively after 24 hrs 
(figures 3.26 and 3.27a).  
As previously discussed, FAK and PI3K are known to effect the actin 
cytoskeleton by regulating the Rho GTPases family [68, 508]. Consequently 
both PC-3 and CHO-CCR5 cells were used to investigate whether the FAK 
and PI3K inhibitors would have any chemokine specific or non-specific effect 
on the actin cytoskeleton when stained with phalloidin. FAK is also known to 
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play a role in cell spreading [515] and so measurements of cell size (number 
of pixels) were also included to assess for any cellular spreading. 
 
 
 
Figure 4.21. Inhibition of FAK, PI3K and PLC in the presence and absence 
of CCL3 (10 nM) does not affect the CTCF in CHO-CCR5 cells after 24 hrs. 
ImageJ 1.48v was used to calculate the CTCF for all images from the phalloidin 
stain, before being normalised to the control (absence of CCL3 and 
compounds). PLC inhibitor: U73122. FAK inhibitors: FAK14, Masitinib and 
PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Results 
represent the mean ± SEM of at least two independent experiments. (Kruskal-
Wallis test, Dunn's multiple comparisons, ns = p≥0.05 of no significance). 
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Figure 4.22. Inhibition of FAK, PI3K and PLC in the presence and absence 
of CCL3 (10 nM) does not affect the aspect ratio of CHO-CCR5 cells after 
24 hrs. PLC inhibitor: U73122. FAK inhibitors: FAK14, Masitinib and 
PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Results 
represent the mean ± SEM of at least two independent experiments. (One-way 
ANOVA, Tukey’s test, ns = p≥0.05 of no significance). 
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Figure 4.23. Inhibition of FAK, PI3K and PLC in the presence and absence 
of CCL3 (10 nM) does not affect the total area of CHO-CCR5 cells after 24 
hrs. PLC inhibitor: U73122. FAK inhibitors: FAK14, Masitinib and PF562271. 
PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240. Results represent the 
mean ± SEM of at least two independent experiments. (One-way ANOVA, 
Tukey’s test, ns = p≥0.05 of no significance). 
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Figure 4.24. Phalloidin actin staining of CHO-CCR5 cells in the presence and absence of CCL3 (10 nM) with FAK and PI3K 
inhibitors after 24 hrs. FAK inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: LY294002. PI3Kγ inhibitor: AS605240.CHO-
CCR5 cells were fixed and stained with Phalloidin CruzFluor TM594 conjugate (red) for imaging the F-actin cytoskeleton. Images are 
a representation of the cell population and were taken at 63x objective with a Leica DMI6000 inverted microscope and using Leica 
imaging suite. 
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Figure 4.25. Phalloidin actin staining of CHO-CCR5 cells in the presence 
and absence of CCL3 (10 nM) and the PLC inhibitor U73122 (1 µM) after 
24 hrs. CHO-CCR5 cells were fixed and stained with Phalloidin CruzFluor 
TM594 conjugate (red) for imaging the F-actin cytoskeleton. Images are a 
representation of the cell population and were taken at 63x objective with a 
Leica DMI6000 inverted microscope and using Leica imaging suite. 
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Figure 4.26. Inhibition of FAK, PI3K, PLC and CXCR4 in the presence of 
CXCL12 (10 nM) does not affect the CTCF of PC-3 cells following 24 hrs 
incubation. CXCR4 inhibitor: AMD3100. PLC inhibitor: U73122. FAK 
inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: LY294002. PI3Kγ 
inhibitor: AS605240. All data represented was normalised to cells treated with 
the CXCL12 (10 nM) alone. Results represent ± SEM of at least two 
independent experiments. (Kruskal-Wallis test, Dunn's multiple comparisons, 
ns = p≥0.05 of no significance, ns = p≥0.05 of no significance). 
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Figure 4.27. Inhibition of FAK, PI3K, PLC and CXCR4 in the presence of 
CXCL12 (10 nM) does not significantly affect the aspect ratio of PC-3 cells 
following 24 hrs incubation. CXCR4 inhibitor: AMD3100. PLC inhibitor: 
U73122. FAK inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: 
LY294002. PI3Kγ inhibitor: AS605240. All data represented was normalised to 
cells treated with the CXCL12 (10 nM) alone. Results represent ± SEM of at 
least two independent experiments. (Kruskal-Wallis test, Dunn's multiple 
comparisons, ns = p≥0.05 of no significance). 
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Figure 4.28. Inhibition of FAK, PI3K, PLC and CXCR4 in the presence of 
CXCL12 (10 nM) does not significantly affect the total area of PC-3 cells 
following 24 hrs incubation. CXCR4 inhibitor: AMD3100. PLC inhibitor: 
U73122. FAK inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: 
LY294002. PI3Kγ inhibitor: AS605240. All data represented was normalised to 
cells treated with CXCL12 (10 nM) alone. Results represent ± SEM of at least 
two independent experiments. (Kruskal-Wallis test, Dunn's multiple 
comparisons, ns = p≥0.05 of no significance). 
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Figure 4.29. Phalloidin actin staining of PC-3 cells in the presence of CXCL12 (10 nM) with FAK, PI3K, PLC and CXCR4 
inhibitors after 24 hrs. CXCR4 inhibitor: AMD3100. PLC inhibitor: U73122. FAK inhibitors: FAK14, Masitinib and PF562271. PI3K 
inhibitor: LY294002. PI3Kγ inhibitor: AS605240. PC-3 cells were fixed and stained with Phalloidin CruzFluor TM594 conjugate (red) 
for imaging the F-actin cytoskeleton. Images are a representation of the cell population and were taken at 63x objective with a Leica 
DMI6000 inverted microscope and using Leica imaging suite. 
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Amongst the compounds tested none showed a significant inhibitory effect on 
the actin cytoskeleton in either the presence of CXCL12 (10 nM) or in the 
presence and absence of CCL3 (10 nM) in PC-3 or CHO-CCR5 cells 
respectively when measuring for fluorescence (CTCF) and cellular elongation 
(aspect ratio) (figures 4.21, 4.22, 4.26 and 4.27). None of the compounds had 
any effect on PC-3 or CHO-CCR5 cell size when measuring the total area (no. 
pixels) (figures: 4.23 and 4.28).   
Despite the absence of statistical significance some trends across the datasets 
were observed. In CHO-CCR5 cells incubating the compounds with CCL3 
showed lower levels of CTCF compared to CCL3 alone except for PF562271, 
this was particularly evident for U73122 (1 μM) (figure 4.21). The effect of the 
compounds on the fluorescence levels of CCL3 could be clearly observed from 
the images (figures 4.24) although not with U73122 (figure 4.25). U73122 also 
showed a similar reduction in the aspect ratio compared to CCL3 alone (figure 
4.22) which was evident from the images (figure 4.25). 
In PC-3 cells treatment with both LY294002 (10 μM) and CXCL12 (10 nM) 
tended to have a larger area size when compared to treatment with either 
CXCL12 (10 nM) alone or the control (figure 4.28). However no clear evidence 
of this could be observed from the images (figure 4.29).  A modest increase in 
cell size was also measured in PC-3 cells following treatment with either 
PF562271 (10 nM) and FAK14 (1 μM) together with CXCL12 (10 nM) (figure 
4.28).  
In summary from both the images and the data analysis of CHO-CCR5 
phalloidin staining there was no evidence of FAK, PI3K or PLC playing a 
decisive role in CCL3 induced cellular elongation. Also none of the compounds 
showed any significant non-specific effects on F-actin formation, cellular 
elongation or cell size in either PC-3 or CHO-CCR5 cells following 24 hrs 
incubation.  
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4.16 U73122 is cytotoxic in CHO-CCR5 cells after 25 hrs 
incubation 
Although none of the inhibitors demonstrated any significant effect on either F-
actin formation, cellular elongation or cell size in the CHO-CCR5 cells after 24 
hrs incubation. Their effects on the viability of CHO-CCR5 cells after 24 hrs 
was still performed in order to provide additional information on these 
compounds which could be a useful reference for other researchers looking to 
use these same compounds in other cell based assays. 
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Figure 4.30. U73122 (1 μM) is cytotoxic in CHO-CCR5 cells after 24 hrs 
incubation and 1 hrs MTS metabolisation. PLC inhibitor: U73122. FAK 
inhibitors: FAK14, Masitinib and PF562271. PI3K inhibitor: LY294002. PI3Kγ 
inhibitor: AS605240. Results were normalised to the control and represent ± 
SEM of at least three independent experiments (data from Wing Yee Lai). 
(One-way ANOVA, Dunnett's multiple comparisons test, ** = p≤0.01 and * = 
p≤0.05). 
 
When assessing for cell viability in the CHO-CCR5 cells following 25 hrs 
incubation, only U73122 (1 µM) was identified as being significantly cytotoxic 
(figure 4.30). All the other compounds tested displayed no effect on cell viability 
at their respective concentration. Therefore the results indicate that U73122 
above 1 µM is unsuitable to be used on CHO-CCR5 cells for 24 hrs. 
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4.17 Discussion 
Chemokine receptors are overexpressed in many different cancer types with 
their downstream signalling pathway inducing a variety of cellular responses 
which can contribute to metastasis [115, 130]. Targeted treatments against 
either the chemokine ligand or receptor have been unsuccessful at the clinical 
stage thus far possibly owing in a large part to chemokine ligand promiscuity 
and receptor redundancy. Hence there is still an urgent need to develop 
alternative approaches to therapeutically target the chemokine signalling 
network with the downstream signalling pathway being one alternative. 
Chemokines receptors are GPCRs and typically signal via the Gαi class [88]. 
Both the Gαi and Gβγ subunits activate various downstream effectors such as 
FAK, PI3K and PLC, all of which have been implicated in cancer dissemination 
[88, 225, 350, 352]. Consequently the aim of this chapter was to validate the 
downstream effectors of the Gαi/βγ as potential therapeutic targets to block 
cancer metastasis. 
To build a detailed picture of the chemokine downstream signalling pathway in 
cancer PLC was blocked with U73122 in three separate cancer lines: MCF-7 
(breast), PC-3 (prostate) and THP-1 (acute myeloid leukaemia), all of which 
had been stimulated with different chemokines. From these experiments PLC 
was identified as being crucial for chemokine intracellular calcium signalling in 
THP-1 cells (figure 4.2) whilst in MCF-7 cells this was only the case for CCL3 
and perhaps CCL4 (figure 4.1b, c and d). In PC-3 cells PLC did not appear to 
be important (figure 4.1a). PLCs role in downstream signalling appears to be 
cell type and chemokine specific and therefore suggests that chemokines can 
display both a tissue and ligand specific bias for intracellular calcium signalling.  
The PLC-PIP2 signalling axis is considered the main downstream pathway for 
intracellular calcium mobilisation following chemokine receptor activation with 
limited evidence of any alternative pathways in the wider literature. However 
one possibility for intracellular calcium signalling to be independent of PLC 
activity is through the activation of the ryanodine receptors present on the ER. 
Studies in THP-1 and rat neonatal cardiomyocytes cells have shown that CCL3 
and CXCL12 increases in intracellular calcium is reliant on the IP3 channels 
and not the ryanodine receptors respectively [516, 517]. However in rat 
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microglia cells treated with lipopolysaccharides, CCL3 intracellular calcium 
signalling was shown to occur via the ryanodine receptors although for CCL5 
it was still through the IP3 channels [518]. To the contrary, in natural killer cells 
it was CCL5 but not CXCL12 which was shown to be partly dependent on the 
ryanodine receptors for intracellular calcium signalling [519]. Furthermore, 
blocking ryanodine receptors with ryanodine (10 µM) in both CHO-CCR5 and 
THP-1 cells actually enhanced CCL3 intracellular calcium signalling 
suggesting that the ryanodine receptors may regulate some release of calcium 
from the ER intracellular stores [517]. This therefore presents further evidence 
of chemokine and tissue specific biases which can influence the downstream 
signalling pathway. 
To establish whether chemokine specific biases in PLC mediated intracellular 
calcium signalling in MCF-7 cells was due to differing molecular mechanisms 
upstream. The role of both Gβγ and Gαi/βγ in the downstream signalling 
pathway of CCR1/5 and CXCR4 receptor activation was probed with gallein 
and PTX respectively. Treatment with gallein had no effect on CCL3 or 
CXCL12 intracellular calcium signalling (figure 4.6) whilst PTX abolished 
CCL4, CCL5 and CXCL12 intracellular calcium signalling (figure 4.7). 
Therefore in MCF-7 cells CXCR4 and CCR5 signalling occurs via Gαi though 
neither receptor appears to be dependent on Gβγ for the mobilisation of 
calcium from the intracellular stores.  
It is widely understood that chemokines signal via the Gαi [36] with Gβγ 
activating PLC to mediate increases in intracellular calcium [88]. However the  
results using gallein contradict this, although two other studies have also 
reported similar results with gallein with the intracellular calcium flux assay 
[347, 520]. It is unclear for the reason behind this but one possibility is that 
gallein is ineffective in disrupting Gβγ-PLCβ interactions. Nonetheless a very 
similarly structured compound to gallein, M119, has been proven to disrupt 
Gβγ-PLCβ-3 interactions in both a cell-free [521] and cell based assay [522].  
Alternatively the authors of Kerr. J et al. (2013) proposed that gallein binding 
could perhaps induce a conformational change in Gβγ which disrupts 
canonical binding and causes non-classical interactions as observed with 
other Gβγ inhibitors [347]. However one review reported that neither gallein 
   
 
179 
 
nor M119 binding induced a conformational change in Gβγ when analysed with 
nuclear magnetic resonance [487]. It is therefore possible that there are 
alternative effectors acting independently from Gβγ to induce increases in 
intracellular calcium and which likely involves the Gαi signalling pathway. 
Based on these observations with gallein the importance of Gαi for intracellular 
calcium signalling was investigated by targeting Src/Syk, as well as three 
downstream effectors of Src: FAK, PI3K and c-Raf. From these intracellular 
calcium measurement experiments FAK was identified as being essential for 
CXCL12 intracellular calcium signalling in THP-1 cells (figure 4.9). Whilst c-
Raf and Src/Syk were important for CXCL12 intracellular calcium signalling in 
MCF-7 cells (figure 4.13).  
In THP-1 cells only FAK14 blocked CXCL12 increases in intracellular calcium 
whilst FAK inhibitors PF562271 and Masitinib had no effect (figure 4.9). FAK14 
blocks FAK activation and thereby inhibits both its adaptor and kinase function 
whereas PF562271 and Masitinib inhibit the kinase activity only. This would 
therefore imply that in THP-1 cells CXCL12 intracellular calcium signalling 
relies on FAKs role as an adaptor rather than its kinase activity. In the wider 
literature FAK has been shown to mediate increases in intracellular calcium in 
platelets [523] and in ovarian cancer cells [524], with the authors of the latter 
proposing that FAK regulated PLC-γ phosphorylation to mediate intracellular 
calcium signalling [524]. As the data showed that both FAK and PLC were 
crucial for CXCL12 intracellular calcium signalling in THP-1 cells, whether both 
PLC-γ and FAK belonged to the same pathway was explored as both are 
known to interact with one another [525]. To achieve this FAK14 and U73122 
were used at reduced concentrations to see if greater inhibition on CXCL12 
intracellular calcium signalling would be observed. Using this approach no 
significant synergistic inhibition on CXCL12 intracellular calcium signalling with 
FAK14 and U73122 together was measured. However as no inhibition with 
either compound separately was observed this suggests that the 
concentrations were too low for a true additive effect to be detected (figure 
4.10). Therefore to properly map this pathway co-immunoprecipitation could 
be used to identify FAK-PLC binding. Also, confirming the phosphorylation 
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status of FAK Tyr397 in the presence and absence of both CXCL12 and 
U73122 would identify if FAK was acting downstream of PLC. 
CXCL12 intracellular calcium signalling in MCF-7 cells was shown to involve 
both Src/Syk and c-Raf (figure 4.13). As Src/Syk regulate c-Raf [63, 64, 526], 
it is therefore very likely that both Src/Syk and c-Raf are acting on the same 
pathway. Based on the findings in this chapter, the data would indicate that in 
MCF-7 cells CXCL12 intracellular calcium signalling is reliant on the Gαi-
Src/Syk-c-Raf signalling axis but not on Gβγ-PLC. The molecular mechanisms 
behind the Gαi-Src/Syk-c-Raf mediated increases in intracellular calcium is not 
obvious, but if the mobilisation of calcium from the ER is independent of IP3 
production then alternative sources for this mobilisation of calcium could be 
the ryanodine receptors or calcium channels on the cell membrane. Ryanodine 
receptors are regulated by several effectors: Homer, AKAP, PKA, PP2A and 
calmodulin [527], however none are known to be activated by MAPK signalling. 
There are however a few examples of MAPK regulating transmembrane 
calcium channel activity [528, 529]. Therefore as the cells were incubated in a 
CaCl2 containing buffer prior to chemokine stimulation, these calcium channels 
could be an additional mechanism for increases in intracellular calcium 
following CXCL12 stimulation. 
None of the cell lines in this chapter showed any dependence on PI3K activity 
for intracellular calcium signalling in response to either CCL3 or CXCL12 
(figure 4.8). Which is similar to the results from two other published studies 
which also used LY294002 [89, 347]. Nonetheless another study has shown 
that PI3K blockade using either wortmannin or LY294002 did abolish CX3CL1 
intracellular calcium signalling in CHO cells [530] which suggests that PI3Ks 
role could be chemokine specific.  
To investigate whether any of the observations made from the intracellular 
calcium measurement experiments had any functional relevance in the 
migration of cancer cells. THP-1 cells were treated with the three FAK 
inhibitors whilst Jurkat cells were treated with FAK, PIK3, PLC, Src/Syk and c-
Raf inhibitors. Overall only PLC appeared to be important for CXCL12 
chemotaxis in Jurkat cells, however, a follow up experiment using the MTS 
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reagent confirmed that this was due to cytotoxicity (figure 4.17b). U73122 (1 
μM) also displayed cytotoxicity in THP-1 cells (figure 4.17a) and potential 
cytotoxicity in MCF-7 cells (figure 4.5a) and as such is not a reliable research 
tool for probing PLCs role within cell based assays. In Jurkat cells previous 
studies have shown that CXCL12 chemotaxis is dependent on PLC, Src, Raf 
and PI3K [340, 531], which besides PLC is a vast contrast to the results 
presented in this chapter (figure 4.15).  
To block Src/Syk activity MNS (10 µM) was used, which is lower than the 
reported IC50 for Src inhibition at around 29.3 µM [403]. It is therefore unlikely 
that Src was fully blocked during Jurkat chemotaxis and hence why these 
results may have differed from the literature [340]. In Mills. SC et al. (2016) Raf 
inhibition was achieved using the pan-Raf inhibitor L779450, whilst for this 
thesis a c-Raf specific inhibitor (ZM336372) was used instead. Therefore the 
differences between these results would imply that for CXCL12 chemotaxis, 
Jurkat cells rely on the B-Raf and/or A-Raf isoforms rather than c-Raf for 
cellular migration.  
In Mills. SC et al. (2016) the LY294002 was able to successfully block CXCL12 
chemotaxis in Jurkat cells, however despite this, these results were unable to 
be reproduced in this chapter using a similar experimental approach. The only 
possible explanation for this could be the difference in the chemotactic 
response between the two batches of Jurkat cells. As for Mills. SC et al. (2016) 
the Jurkat chemotactic response towards CXCL12 was far superior with a 
mean ≈ 400x104 per mL-1 compared to ≈ 40x104 per mL-1 for the data presented 
in this chapter. Hence this migratory response was perhaps too low to detect 
the moderate inhibition on CXCL12 chemotaxis by LY294002 which was 
observed in Mills. SC et al. (2016) [340].  
Aside from chemotaxis the effect of PI3K inhibition on MCF-7 scratch closure 
in response to CCL3 was also assessed. In this experiment PI3K was shown 
not to be important for CCL3 scratch closure using either LY294002 or 
AS605240 (figure 4.18). These results with the LY294002 agree with the 
findings from Mill. SC et al. (2016) on CXCL12 scratch closure in MCF-7 cells 
[340]. In addition there was no significant difference in scratch closure 
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measured between CCL3 treatment and the basal. This reemphasises the 
issue surrounding reproducibility using the wound healing assay, as previously 
discussed in chapter 3.  
In the previous chapter the CHO-CCR5 cells were identified as a model for 
assessing CCL3 induced cellular elongation. As such, this model was used to 
assess the importance of FAK, PLC and PI3K on the remodelling of the actin 
cytoskeleton though neither FAK, PLC nor PI3K demonstrated a clear role in 
cellular elongation (figure 4.22 and 4.24). However the U73122 did show some 
inhibition on CTCF and the aspect ratio but this was once again likely due to 
cytotoxicity (figure 4.30). Aside from U73122 all the other compounds besides 
PF562271 showed a tendency to reduce the fluorescence levels of CCL3 
stimulated CHO-CCR5 cells (figure 4.21). However as discussed in the 
previous results chapter, using the CTCF to quantify phalloidin fluorescence is 
not a sensitive enough approach to identify any specific changes to F-actin 
formation. 
In addition to the CHO-CCR5 cells, a similar investigation was performed with 
the same compounds on the PC-3 cells to assess their effect on actin 
cytoskeleton in the presence of CXCL12. However contrary to the results from 
chapter 3 (figure 3.26), treatment with CXCL12 displayed lower levels of 
fluorescence compared to the basal and as a result the PC-3 cells were not a 
suitable model for assessing any CXCL12 specific effects on the actin 
cytoskeleton. 
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4.18 Conclusion 
The main findings from this chapter were as follows: 
 U73122 is a highly cytotoxic compound and not suitable for assessing 
PLCs role in cell based assays long term. 
 
 FAK mediates CXCL12 intracellular calcium signalling but not 
chemotaxis in THP-1 cells. 
 
 Src/Syk and c-Raf are involved in CXCL12 intracellular calcium 
signalling in MCF-7 cells. 
 
 
 
 PLCs importance for intracellular calcium signalling is dependent on 
both the chemokine and cell type. 
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Chapter 5.0 The role of the cellular cytoskeleton in 
chemokine downstream signalling within different 
cancer types 
 
5.1 Introduction 
Chemokines are mediators of the immune system response by promoting 
leukocyte migration towards either sites of infection and inflammation or to the 
lymph nodes and peripheral sites in the body for immunosurveillance. 
Consequently chemokine signalling can induce the remodelling of the cellular 
cytoskeleton in leukocytes to promote chemotaxis [532]. 
The cellular cytoskeleton is composed of three distinct protein filaments: 
microtubules, intermediate filaments and F-actin. Microtubules provide 
structure, organelle arrangement and are important for chromatid segregation 
in cell division [533, 534]. F-actin is the most dynamic of the three cytoskeletal 
proteins and plays a crucial role in cellular migration, though the microtubules 
can also be involved [535]. The intermediate filaments provide additional 
support to both the microtubules and F-actin [534]. 
When cells migrate, F-actin polymerisation occurs at the leading edge of the 
cell giving rise to F-actin rich structures: lamellipodia and filipodia. F-actin 
polymerisation is promoted by Arp2/3 which initiates actin nucleation at Arp2/3 
bound sites on the F-actin. Arp2/3 is activated by members of the 
WASP/WAVE family which in turn are regulated by members of the Rho 
GTPase family Rac and Cdc42, which initiate lamellipodia and filopodia 
formation respectively [153, 155]. 
A key hallmark of cancer cells is their enhanced ability to migrate allowing them 
to invade the surrounding tissue. As such many of the molecular mechanisms 
driving “normal” cellular migration are also associated with the invasiveness of 
cancer cells. Many cancers display elevated levels of Rho GTPases [536], 
WAVE [537] and Arp2/3 [538], with WAVE2 and Arp2 co-expressed in 
colorectal [539], breast [540] and lung cancer [541]. Whilst the knocking down 
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of WAVE [537] and the pharmacological blockade of Rac [542] has been 
shown to reduce cancer cell invasion. Hence the Rac-WAVE-Arp2/3 signalling 
axis is an attractive target for cancer therapy. 
In chemokine signalling Rac has been shown to be important for the 
chemotaxis of CXCL12 but not CCL3 in cancer cells [346]. However aside from 
Rac and RhoA-ROCK signalling [322, 346, 543-545] the involvement and 
importance of other cytoskeletal regulators in chemokine induced chemotaxis 
of cancer cells is not properly understood.  
 
5.2 Chapter Aim 
To improve understanding of the molecular mechanisms regulating the cellular 
cytoskeleton in chemokine downstream signalling in both carcinoma and 
leukemic cell types. 
 
5.3 DOCK1/2/5 is important for the intracellular calcium 
signalling of CCL3 and CXCL12 in MCF-7 and THP-1 cells, 
whilst Arp2/3 and Taxol are cell type or chemokine specific 
Calcium is an important secondary messenger for both chemokine 
downstream signalling and cellular migration. Calcium ions can directly 
activate a variety of proteins such as PKC, calcineurin and calmodulin-
dependent protein kinase II to regulate PI3K, FAK and MLCK activity for focal 
adhesion turnover and cytoskeletal remodelling [172]. As calcium ions can 
influence changes to the actin cytoskeleton, whether any of the regulators of 
the actin cytoskeleton could also influence intracellular calcium signalling as 
part of a possible feedback loop to regulate cell migration is not known. 
Therefore to explore this possibility of a feedback loop both Arp2/3 and 
members of the DOCK A subfamily DOCK1/2/5, a GEF for Rac, were blocked 
using two small molecule inhibitors CK666 and CPYPP respectively. CK666 
blocks Arp2/3 nucleation activity by stabilising its inactive splayed structure 
[546]. CPYPP binds to the DHR-2 domain of DOCK1/2/5, to block guanine 
nucleotide exchange activity and subsequently Rac activation [408]. To see if 
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the cytoskeleton also influences chemokine signalling the role of the 
microtubules was investigated using the chemotherapeutic agent Taxol which 
stabilises the microtubules against depolymerisation [547]. 
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Figure 5.1. CPYPP and CK666 inhibition of DOCK1/2/5 and Arp2/3 
respectively and Taxol microtubule stabilisation on CCL3 (200 nM) and 
CXCL12 (15 nM) intracellular calcium signalling in MCF-7 cells. (a) 
CPYPP (100 μM) and CK666 (10 μM) inhibits CCL3 intracellular calcium 
signalling in MCF-7 cells (n=4). (b) Representation of an intracellular calcium 
measurement trace following CCL3 stimulation in MCF-7 cells pretreated with 
CPYPP and Taxol (30 mins) after 70 secs. (c) CPYPP, CK666 and Taxol (1 
nM) inhibit CXCL12 intracellular calcium signalling in MCF-7 cells (n≥2). (d) 
Representation of an intracellular calcium measurement trace following 
CXCL12 stimulation in MCF-7 cells pretreated with CPYPP, CK666 and Taxol 
(30 mins) after 70 secs. Results represents the mean ± S.E.M. in at least two 
independent experiments. (One-way ANOVA, Dunnett's multiple comparisons 
test, **** = p≤0.0001, *** = p≤0.001, ** = p≤0.01, * = p≤0.05, and ns = p≥0.05 
of no significance). 
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Figure 5.2. CPYPP and CK666 inhibition of DOCK1/2/5 and Arp2/3 
respectively and Taxol microtubule stabilisation on CCL3 (200 nM) and 
CXCL12 (15 nM) intracellular calcium signalling in THP-1 cells. (a) CPYPP 
abolishes CCL3 intracellular calcium signalling in THP-1 cells (n=4). (One-way 
ANOVA, Dunnett's multiple comparisons test). (b) Representation of an 
intracellular calcium measurement trace following CCL3 stimulation in THP-1 
cells pretreated with CPYPP (30 mins) after 70 secs. (c) CPYPP abolishes 
CXCL12 intracellular calcium signalling in THP-1 cells (n=7). (Kruskal-Wallis 
test, Dunn's multiple comparisons). Results for CXCL12 were normalised to 
the control (DMSO 1%). (d) Representation of an intracellular calcium 
measurement trace following CXCL12 stimulation in THP-1 cells pretreated 
with CPYPP (30 mins) after 70 secs. Results represent the mean ± S.E.M. in 
at least four independent experiments. (** = p≤0.01, * = p≤0.05, and ns = 
p≥0.05 of no significance). 
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Figure 5.3. CPYPP and CK666 inhibition of DOCK1/2/5 and Arp2/3 
respectively and Taxol microtubule stabilisation on CCL3 (200 nM) 
intracellular calcium signalling in CHO-CCR5 cells. Results represents the 
mean ± S.E.M. in three independent experiments. (One-way ANOVA, 
Dunnett's multiple comparisons test, ns = p≥0.05 of no significance). 
 
When investigating the role of DOCK1/2/5, Arp2/3 and microtubules in CCL3 
(200 nM) and CXCL12 (15 nM) intracellular calcium signalling, CPYPP (100 
μM) was shown to abolish increases in intracellular calcium in response to both 
CCL3 and CXCL12 in MCF-7 and THP-1 cells (figure 5.1 and 5.2). In CHO-
CCR5 cells CPYPP also showed a similar trend following CCL3 stimulation 
(figure 5.3).  
CK666 (10 μM) showed inhibition on both CCL3 and CXCL12 intracellular 
calcium signalling in MCF-7 cells (figure 5.1). Whereas in CHO-CCR5 cells, 
CK666 tended to show higher increases in intracellular calcium following CCL3 
stimulation (figure 5.3). Taxol displayed significant inhibition on CXCL12 
intracellular calcium signalling in MCF-7 cells (figure 5.1c and d). In THP-1 
cells Taxol displayed a trend of higher levels of CCL3 intracellular calcium 
signalling (figure 5.2c). 
The data suggests that DOCK1/2/5 is essential in the downstream signalling 
of both CCL3 and CXCL12 in MCF-7 and THP-1 cells. For Arp2/3 its role in 
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chemokine intracellular calcium signalling was shown to be specific for MCF-
7 cells only. The role of the microtubules appears specific to CXCL12 
intracellular calcium signalling for MCF-7 cells suggesting that its role is both 
chemokine and cell specific. 
 
5.4 Nocodazole does not inhibit CCL3 or CXCL12 intracellular 
calcium signalling in MCF-7, THP-1 or CHO-CCR5 cells. 
Incubating MCF-7 cells with Taxol inhibited CXCL12 intracellular calcium 
signalling (figure 5.1a). To further probe the role of the microtubules in 
chemokine downstream signalling the microtubule disrupter nocodazole was 
used to see if similar effects to Taxol (microtubule stabiliser) would be 
observed or whether differences would arise. 
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Figure 5.4. Nocodazoles (3 μM) disruption of microtubule polymerisation 
on CCL3 (200 nM) and CXCL12 (15 nM) intracellular calcium signalling. 
MCF-7 cells were pretreated with nocodazole (30 mins) prior to CCL3 (a) or 
CXCL12 (b) stimulation. THP-1 cells were pretreated with nocodazole (30 
mins) prior to CCL3 (c) or CXCL12 (d) stimulation. (e) CHO-CCR5 cells were 
pretreated with nocodazole (30 mins) prior to CCL3 stimulation. Results 
represents the mean ± S.E.M. in at least three independent experiments. 
(Student’s t-test, ns = p≥0.05 of no significance). 
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Using nocodazole (3 µM) to perturb microtubule polymerisation prior to CCL3 
(200 nM) and CXCL12 (15 nM) stimulation, showed no significant effect on 
increases in intracellular calcium in MCF-7, THP-1 and CHO-CCR5 cells 
(figure 5.4). These results demonstrate that microtubule polymerisation is not 
important for CCL3 or CXCL12 intracellular calcium signalling in MCF-7, THP-
1 and CHO-CCR5 cells.  
 
5.5  CPYPP, Taxol and CK666 do not show any compound 
cytotoxicity in Jurkat cells after 6 hrs. CPYPP (5 mM) appears 
to be cytotoxic in THP-1 cells  
To investigate whether CPYPPs inhibitory effect on chemokine increases in 
intracellular calcium in MCF-7 and THP-1 cells could be a result of cellular 
cytotoxicity, the effects of CPYPP on the cell proliferation of both THP-1 and 
MCF-7 cells was investigated. The Jurkat cell line was also included to 
establish whether the concentrations used for CPYPP, CK666 and Taxol in the 
intracellular calcium flux assay would also be suitable for assessing their effect 
on Jurkat chemotaxis after 4 hrs of treatment. 
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Figure 5.5. Compound cytotoxicity in THP-1 and Jurkat cells using the 
MTS cellular proliferation assay. (a) None of the compounds are cytotoxic 
in Jurkat cells after 2 hrs incubation and 4 hrs MTS metabolisation (n=3). (b) 
CPYPP is not cytotoxic in MCF-7 cells after 1 h incubation and MTS 
metabolisation (n=3). (c) CPYPP (5 mM) appears to be cytotoxic in THP-1 cells 
after 72 hrs incubation and 4 hrs MTS metabolisation. (Data from Wing Yee 
Lai, Georgia Eagleton and Veronica Youssef) (n=2). (d) CPYPP (5 mM) 
appears to be cytotoxic in Jurkat cells after 72 hrs incubation and 4 hrs 
metabolisation. (Data from Wing Yee Lai, Georgia Eagleton and Veronica 
Youssef) (n=2). DOCK1/2/5 inhibitor: CPYPP. Arp2/3 inhibitor: CK666. 
Microtubule stabiliser: Taxol. All results represent ± SEM of at least two 
independent experiments. (One-way ANOVA, Dunnett's multiple comparisons 
test, * = p≤0.05 and ns = p value≥0.05 of no significance). 
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In Jurkat cells neither CPYPP (100 μM), CK666 (10 μM) and Taxol (1 nM) were 
found to be cytotoxic following 6 hrs incubation (figure 5.5a). CPYPP also 
demonstrated no cytotoxicity in MCF-7 cells after 1 h incubation (figure 5.5b). 
Preliminary data from CPYPP concentration response experiments on THP-1 
and Jurkat cell proliferation suggest that CPYPP is only cytotoxic at 5 mM and 
after 72 hrs (figures 5.5c and d).  
This MTS data confirms that working concentrations of 100 µM for CPYPP, 1 
nM for Taxol and 10 µM for CK666 are suitable for measuring chemotaxis in 
Jurkat cells. The data also confirms that the inhibitory effects of CPYPP on the 
intracellular calcium flux assays of MCF-7 and THP-1 cells was not due to any 
cytotoxicity. 
 
5.6 CPYPP (100 μM) inhibits Thapsigargin increases in 
intracellular calcium in THP-1 cells 
CPYPP (100 μM) was able to block CCL3 and CXCL12 intracellular calcium 
signalling in both MCF-7 and THP-1 cells. As well as displaying a similar effect 
in CHO-CCR5 cells.  
To quantify changes in intracellular calcium levels Fura-2 AM fluorescence is 
measured both before and after chemokine receptor activation. CPYPP is a 
dark red coloured compound and frequently displayed lower levels of 
background fluorescence when added to the cells. As CPYPP is a relatively 
newly marketed compound no previous studies to our knowledge have 
reported using CPYPP in intracellular calcium flux assays before. To ensure 
that the inhibitory effects of CPYPP was not due to any quenching of the 
fluorescence, Triton x-100 was used to permeabilize the cell to release 
cytosolic Fura-2 AM into the CaCl2 containing buffer to increase fluorescence 
levels independent of any cellular signalling. Furthermore to confirm that 
CPYPP was not depleting the intracellular calcium stores prior to receptor 
activation the ER Ca2+ ATPase inhibitor Thapsigargin was used to induce 
calcium release from the intracellular stores independent of any chemokine 
signalling. 
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Figure 5.6. CPYPP (100 µM) does not quench Fura-2 AM fluorescence in 
THP-1 cells. (a) Representation of a calcium measurement trace following 
Triton x-100 (10%) and EDTA (10%) injection in THP-1 cells pretreated with 
CPYPP (30 mins) after 160 secs. Calcium levels were determined by 
measuring the difference between the peak and base readings (b) or the AUC 
(c). Results represents the mean ± S.E.M data in three independent 
experiments. (Student’s t-test, ns = p≥0.05 of no significance).
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Figure 5.7. CPYPP (100 µM) depletes the intracellular calcium stores in 
THP-1 cells. (a)  Representation of an intracellular calcium measurement 
trace following Thapsigargin (1%) injection in THP-1 cells pretreated with 
CPYPP (30 mins) after 90 secs. Increases in intracellular calcium was 
determined by either measuring the difference between the peak and base 
readings (b) or the AUC (c). ER Ca²⁺ ATPase inhibitor: Thapsigargin. Results 
represent the mean ± S.E.M data in three independent experiments. (Student’s 
t-test, ** = p≤0.01, * = p≤0.05). 
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Figure 5.8. CPYPP (10 µM) does not deplete the intracellular calcium 
stores of THP-1 cells. (a) THP-1 cells were pretreated with CPYPP (30 mins) 
prior to Thapsigargin injection with the increases in intracellular calcium 
determined by measuring the difference between the peak and base readings 
(n=4). (b) THP-1 cells were pretreated with CPYPP (30 mins) prior to CCL3 
(200 nM) stimulation, with the increases in intracellular calcium determined by 
measuring the difference between the peak and base readings (n=3). ER Ca²⁺ 
ATPase inhibitor: Thapsigargin. DOCK1/2/5 inhibitor: CPYPP. All results were 
normalised to the control (DMSO 1%) and represent the mean ± S.E.M data in 
at least three independent experiments. (Wilcoxon Signed Rank Test, ns = 
p≥0.05 of no significance). 
 
When using Triton x-100 (10%) to increase the levels of calcium bound Fura-
2 AM, pretreatment with CPYPP (100 μM) showed no effect on the 
fluorescence levels in THP-1 cells (figure 5.6). The calcium chelating agent 
EDTA (10%) confirmed the increase in calcium bound Fura-2 AM by 
decreasing the levels of fluorescence (figure 5.6a). This experiment 
demonstrates that CPYPP does not quench Fura-2 AM fluorescence.  
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When assessing for the depletion of calcium from the intracellular stores. 
CPYPP (100 μM) showed significant inhibition of Thapsigargin (1%) increases 
in intracellular calcium (mean difference between peak and base readings = 
0.3033 ± 0.07965 (p≤0.05)) (figure 5.7). This indicates that pretreatment with 
CPYPP (100 μM) for 30 mins is able to deplete some calcium from the 
intracellular stores of THP-1 cells.  
In response to these findings the concentration of CPYPP was reduced to 10 
μM and its effects on increases in intracellular calcium was reassessed within 
THP-1 cells treated with either Thapsigargin or CCL3 (200 nM). In these two 
experiments CPYPP (10 μM) showed no significant inhibition on either 
Thapsigargin or CCL3 increases in intracellular calcium (figure 5.8a). However 
some blocking of CCL3 intracellular calcium signalling was still observed with 
CPYPP (10 μM) (figure 5.8b).  
Overall these experiments would suggests that CPYPPs (100 μM) inhibition 
on chemokine intracellular calcium signalling can be partly attributed to some 
depletion of the intracellular calcium stores with the remaining inhibitory effect 
likely to be associated with DOCK1/2/5 blockade.  
 
5.7 CPYPP inhibits CXCL12 chemotaxis of Jurkat cells in a 
concentration dependent manner   
As discussed in the introduction cytoskeletal arrangement is crucial for cellular 
migration. Previous chemotaxis studies with CPYPP have shown that it can 
significantly block the migration of both neutrophils [548] and lymphocytes 
[408].  Whilst studies using CK666 and Arp2/3 knockouts did not show any 
effect on the chemotaxis of dendritic cells [549] or macrophages [550] in 
response to CCL21 or CXC3CL1 respectively. For Taxol its effect on 
chemokine induced migration is unknown. Therefore to see how the results 
from the intracellular calcium measurement experiments would compare in a 
more functional context such as cellular migration the roles of Arp2/3, 
DOCK1/2/5 and microtubule stabilisation were explored within a disease state 
using Jurkat and THP-1 cells to model CXCL12 cancer cell migration. 
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Figure 5.9. CPYPP (100 μM) inhibition of DOCK1/2/5 blocks CXCL12 (1 
nM) chemotaxis of Jurkat cells after 4 hrs. DOCK1/2/5 inhibitor: CPYPP. 
Arp2/3 inhibitor: CK666. Microtubule stabiliser: Taxol. Results were normalised 
to DMSO (1 %) with CXCL12 (1 nM) and represent the mean ± S.E.M data in 
four independent experiments. (Kruskal-Wallis test, Dunn's multiple 
comparisons test, ** = p≤0.01). 
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Figure 5.10. Concentration response of CPYPP against CXCL12 (1 nM) 
chemotaxis of Jurkat cells after 4 hrs. (a) CPYPP blocks CXCL12 
chemotaxis in a concentration dependent manner. (b) Concentration curve of 
CPYPP against CXCL12 (1 nM) chemotaxis of Jurkat cells. DOCK1/2/5 
inhibitor: CPYPP. Results represent the mean ± S.E.M data in four 
independent experiments. (Kruskal-Wallis test, Dunn's multiple comparisons 
test, * = p≤0.05). 
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Figure 5.11. CPYPP (10 μM) inhibition of DOCK1/2/5 has no effect on 
CXCL12 (10 nM) chemotaxis in THP-1 cells after 4 hrs. (Data from Wing 
Yee Lai, Georgia Eagleton and Veronica Youssef). DOCK1/2/5 inhibitor: 
CPYPP. Results represent the mean ± S.E.M data in two independent 
experiments. (One-way ANOVA, Tukey’s test, ns = p value≥0.05 of no 
significance). 
 
The results from the chemotaxis assay in Jurkat cells identified that CPYPP 
(100 μM) was able to significantly block CXCL12 (1 nM) chemotaxis 
(p≤0.0001) (figure 5.9). Neither Taxol (1 nM) nor CK666 (10 μM) showed any 
inhibition on the chemotaxis of Jurkat cells towards CXCL12.  
As the chemotaxis experiment with the Jurkat cells used CPYPP at a high 
concentration (100 μM), the specificity of CPYPPs inhibition on CXCL12 
chemotaxis in Jurkat cells was established by titrating various concentrations 
of CPYPP against CXCL12 (1 nM) stimulated Jurkat cells. Data from the 
concentration response experiment showed a concentration dependent 
blocking of Jurkat cell migration by CPYPP (figure 5.10a). From this 
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concentration response curve the IC50 of CPYPP was calculated as 11.72 μM 
(figure 5.10b).  
Furthermore the effects of CPYPP (10 μM) on CXCL12 (10 nM) chemotaxis in 
THP-1 cells was also assessed with the preliminary data showing treatment 
with CPYPP had no effect on CXCL12 chemotaxis (figure 5.11).  
Overall these experiments suggest that DOCK1/2/5 is important for CXCL12 
induced chemotaxis in Jurkat but not THP-1 cells. 
 
5.8 CPYPP, U73122, EHT 1864 and Bosutinib do not block 
CXCL12 chemotaxis in Jurkat cells. 
Published studies from the Mueller group using the small molecule inhibitors 
EHT 1864 and Bosutinib have shown that CXCL12 relies on Rac and Src 
activation respectively to promote Jurkat chemotaxis [340, 346]. In the 
canonical downstream signalling pathway, DOCK2 acts downstream of 
members of the Src family to promote Rac activity and cell migration [551]. 
Based on these findings the positioning of DOCK1/2/5 in the downstream 
signalling pathway of CXCL12 chemotaxis in Jurkat cells was explored.  
To map this signalling pathway both EHT 1864 (100 nM) and Bosutinib (25 
and 250 nM) were used together with CPYPP (10 μM) to establish the 
presence or absence of an additive effect on the inhibition of Jurkat chemotaxis 
in response to CXCL12. Src and PLC are considered to be involved in two 
independent G-protein signalling pathways: Gαi and Gβγ respectively. As such 
the Jurkat cells were also incubated with U73122 (100 nM) together with 
CPYPP to identify whether DOCK1/2/5 could be acting downstream of Gβγ-
PLC signalling. 
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Figure 5.12. CPYPP (10 μM) showed no additive effect on CXCL12 (1 nM) 
chemotaxis of Jurkat cells after 4 hrs. PLC inhibitor: U73122. DOCK1/2/5 
inhibitor: CPYPP. Src inhibitor: Bosutinib. Rac inhibitor: EHT 1864. Results 
were normalised to DMSO (0.4%) and CXCL12 (1 nM) and represent the mean 
± S.E.M data in at least two independent experiments.  (Kruskal-Wallis test, 
Dunn's multiple comparisons test, ns = p≥0.05 of no significance). 
 
Incubating Jurkat cells with CPYPP (10 μM) alone, or together with either EHT 
1864 (100 nM), U73122 (100 nM) or Bosutinib (25 nM and 250 nM) showed 
no significant inhibition on CXCL12 chemotaxis after 4 hrs. Nonetheless, 
Jurkat cells treated with CPYPP did have a tendency to display lower levels of 
migration towards CXCL12 (figure 5.12). Overall there was no additive effect 
when using EHT 1864, U73122 or Bosutinib together with CPYPP. 
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5.9 CPYPP and CK666 do not inhibit PC-3 cell velocity  
Chemokine receptor activation can increase the migratory speed of cells [552, 
553] which may contribute to their chemotactic effect. Preliminary experiments 
from the Mueller lab have shown that PC-3 cells stimulated with CXCL12 (10 
nM) display a faster cellular velocity after 10 hrs when compared against the 
basal migration. 
To explore whether CPYPP could also affect cellular velocity a separate 
cancer model, the PC-3 cells were used to measure the speed of cellular 
migration over 10 hrs in response to CXCL12. The PC-3 cells were chosen 
instead of the MCF-7 cells as PC-3 cells have a much higher migratory speed. 
For this experiment the PC-3 cells were stimulated with CXCL12 (10 nM) in 
both the presence and absence of CPYPP (100 μM) and CK666 (10 μM) to 
establish if DOCK1/2/5 and Arp2/3 respectively promoted PC-3 cell migration 
in response to CXCL12. 
 
Figure 5.13. CPYPP (100 μM) and CK666 (10 μM) inhibition of DOCK1/2/5 
and CK666 respectively does not block CXCL12 (10 nM) induced velocity 
of PC-3 cells after 10 hrs. Results were normalised to CXCL12 (10 nM) and 
represent the mean ± S.E.M data in three independent experiments. (Data 
produced by Isabel Hamshaw). (Kruskal-Wallis test, Dunn's multiple 
comparisons test, ns = p≥0.05 of no significance). 
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Figure 5.14. Endpoint images from time-lapse tracking of PC-3 cell after 
10 hrs. (a) Control. (b) CXCL12 (10 nM). (c) CXCL12 (10 nM) & CK666 (10 
µM). (d) CXCL12 (10 nM) & CPYPP (100 µM). Images are a representation of 
the cell population and were taken at 10x objective with a Zeiss Axiovert 200M 
microscope and using AxioVision Rel 4.8 software. 
 
Treating PC-3 cells with and without CXCL12 (10 nM) and in the presence of 
either CPYPP (100 μM) or CK666 (10 μM), had no significant effect on PC-3 
cell velocity after 10 hrs (figure 5.13). Though PC-3 cells treated with CPYPP 
did display lower levels of cellular velocity compared to both the basal and 
CXCL12 alone. This was also observed in two of the time lapse videos. 
Whereby PC-3 cells incubated with CPYPP showed limited cellular movement 
and protrusions and retained a circular morphology throughout the 10 hrs. Also 
in the presence of CPYPP there were less cells present and higher levels of 
detachment compared to the other conditions: indicating cytotoxicity (figure 
5.14d). Overall CXCL12 treatment only displayed a modest upward trend in 
cell velocity compared to the basal. Whilst there was no clear evidence of 
DOCK1/2/5 and Arp2/3 being important for the migration speed of PC-3 cells.
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5.10 EHT 1864 and Y27632 have no significant effect on the 
actin cytoskeleton of CHO-CCR5 and PC-3 cells 
Actin staining of CHO-CCR5 cells with phalloidin showed that CCL3 increases 
cellular elongation after 24 hrs (figure 3.27). Previous investigation of this 
downstream signalling pathway suggested that neither PI3K nor FAK were 
important for inducing cellular elongation caused by CCL3 stimulation (figure 
4.22).  
Changes to the cellular shape is known to be driven by cytoskeleton 
remodelling. Therefore the roles of Rac and ROCK, a serine/threonine kinase 
regulated by RhoA [554] were investigated to determine whether they were 
acting downstream of CCL3 signalling to facilitate CHO-CCR5 cellular 
elongation.  
To inhibit Rac and ROCK, CHO-CCR5 cells were treated with EHT 1864 and 
Y27632 respectively for 24 hrs, before being fixed and stained with Phalloidin 
CruzFluor TM594. Y27632 is an orthosteric ROCK inhibitor which disrupts ATP 
binding and therefore inhibits ROCK’s kinase activity. Y27632 has been 
proven to interfere with actin stress fiber formation [184]. 
PC-3 cells were also used as a secondary model for actin staining. As although 
CXCL12 had no definite effect on the F-actin or cell shape, the PC-3 cells could 
serve as an additional control for any non-specific effects caused by EHT 1864 
or Y27632.  
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Figure 5.15. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the corrected total cellular fluorescence 
(CTCF) of CHO-CCR5 cells in the absence or presence of CCL3 (10 nM) 
after 24 hrs. ImageJ 1.48v was used to calculate the CTCF for all images of 
phalloidin staining before being normalised to the control (CCL3 absent). 
Results represent the mean ± SEM of at least two independent experiments. 
(Kruskal-Wallis test, Dunn's multiple comparisons test, ns = p value≥0.05 of no 
significance). 
 
Figure 5.16. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the aspect ratio of CHO-CCR5 cells in 
the absence or presence of CCL3 (10 nM) after 24 hrs. Results represent 
the mean ± SEM of at least two independent experiments. (One-way ANOVA, 
Tukey’s test, ns = p value≥0.05 of no significance). 
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Figure 5.17. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the total area of CHO-CCR5 cells in the 
absence or presence of CCL3 (10 nM) after 24 hrs. Results represent the 
mean ± SEM of at least two independent experiments. (One-way ANOVA, 
Tukey’s test, ns = p value≥0.05 of no significance). 
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Figure 5.18. Phalloidin actin staining of CHO-CCR5 cells in the presence and absence of CCL3 (10 nM) with EHT 1864 (100 
nM) and Y27632 (20 µM) inhibitors after 24 hrs. Rac inhibitor: EHT 1864. ROCK inhibitor: Y27632. CHO-CCR5 cells were fixed 
and stained with Phalloidin CruzFluor TM594 conjugate (red) for imaging the F-actin cytoskeleton. Images are a representation of the 
cell population and were taken at 63x objective with a Leica DMI6000 inverted microscope and using Leica imaging suite. 
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Figure 5.19. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the CTCF of PC-3 cells stimulated with 
CXCL12 (10 nM) after 24 hrs. ImageJ 1.48v was used to calculate the CTCF 
for all images from the phalloidin stain before being normalised to CXCL12 
(alone). Results represent the mean ± SEM of three independent experiments. 
(Kruskal-Wallis test, Dunn's multiple comparisons test, ns = p value≥0.05 of no 
significance). 
 
Figure 5.20. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the aspect ratio of PC-3 cells stimulated 
with CXCL12 (10 nM) after 24 hrs. Results were normalised to CXCL12 
(alone) and represent the mean ± SEM of three independent experiments. 
(Kruskal-Wallis test, Dunn's multiple comparisons test, ns = p value≥0.05 of no 
significance). 
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Figure 5.21. EHT 1864 (100 nM) and Y27632 (20 μM) inhibition of Rac and 
ROCK respectively did not affect the total area of PC-3 cells stimulated 
with CXCL12 (10 nM) after 24 hrs. Results were normalised to CXCL12 
(alone) and represent the mean ± SEM of three independent experiments. 
(Kruskal-Wallis test, Dunn's multiple comparisons test, ns = p value≥0.05 of no 
significance). 
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Figure 5.22. Fluorescent and brightfield images of PC-3 cell staining with phalloidin in the presence of CXCL12 (10 nM), EHT 
1864 (100 nM) and Y27632 (20 µM) inhibitors after 24 hrs. Rac inhibitor: EHT 1864. ROCK inhibitor: Y27632. PC-3 cells were fixed 
and stained with Phalloidin CruzFluor TM594 conjugate (red) for imaging the F-actin cytoskeleton. Images represent a population of 
cells and were taken at 10x objective with a Leica DMI6000 inverted microscope and using Leica imaging suite. 
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Blockade of Rac and ROCK using EHT 1864 (100 nM) and Y27632 (20 μM) 
respectively, showed no significant effect on the fluorescence levels (CTCF), 
cellular elongation (aspect ratio) and cell size (total area in no. pixels) in either 
PC-3 and CHO-CCR5 cells after 24 hrs (figures 5.15-5.22)  
There were however some identifiable trends from both the data analysis and 
images. Treatment with Y27632 displayed lower levels of fluorescence (CTCF) 
compared to the control in PC-3 cells (figure 5.19) as well as for CCL3 in CHO-
CCR5 cells (figure 5.15). This was clearly shown from the images of both PC-
3 (figure 5.20) and CHO-CCR5 (figure 5.15) actin staining.  
In one of the PC-3 experiments treatment with Y27632 showed a larger cell 
size and exhibited a spindly morphology as clearly evidenced from the images 
(figure 5.22). However the data analysis of PC-3 cell size only showed a 
modest increase in total area when treated with Y27632 (figure 5.21). 
In summary Rac and ROCK have no significant measureable effect on cell 
shape or F-actin formation in both PC-3 and CHO-CCR5 cells. However there 
did appear to be a visible and mostly likely non chemokine specific effect of 
ROCK blockade on PC-3 cell morphology. 
 
5.11 EHT 1864 and Y27632 are not cytotoxic in CHO-CCR5 cells 
From the phalloidin staining a tendency of the Y27632 (20 μM) to display lower 
levels of fluorescence in both the absence and presence of CCL3 in CHO-
CCR5 cells was observed. To establish any possibility of cytotoxicity with EHT 
1864 (100 µM) and Y27632 (20 µM) in CHO-CCR5 cells, the effect of both 
these compounds on cellular proliferation after 24 hrs was assessed using an 
MTS assay. 
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Figure 5.23. Cell proliferation assay of CHO-CCR5 cells after 24 hrs 
incubation and 1 hrs MTS metabolisation. Rac inhibitor: EHT 1864. ROCK 
inhibitor: Y27632. Results were normalised to the control and represent the 
mean ± SEM of at least three independent experiments (Data from Wing Yee 
Lai). (Kruskal-Wallis test, Dunn's multiple comparisons test, * = p≤0.05, ns = p 
value≥0.05 of no significance). 
 
The data from the MTS assay showed that neither EHT1864 nor Y27326 were 
cytotoxic at 100 nM and 20 µM in CHO-CCR5 cells after 25 hrs incubation 
respectively (figure 5.23). Therefore both inhibitors were at suitable 
concentrations to avoid cytotoxicity in CHO-CCR5 cells for phalloidin staining. 
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5.12 Discussion 
Remodelling of the cellular cytoskeleton is crucial for the migration of both 
adherent and suspension cells and as such chemokine signalling activates 
various modulators for F-actin assembly at the cells leading edge to facilitate 
chemotaxis [555]. Aberrations within this signalling pathway is associated with 
cancer metastasis and therefore many of its downstream effectors like Rac, 
RhoA and WAVE2 are considered potential therapeutic targets for cancer 
treatment [536, 537]. However these downstream signalling pathways are not 
always uniform and can vary substantially according to the cell type and 
chemokine involved which limits the development of targeted treatments.  
The aim of this chapter was to delineate the molecular mechanisms which 
influence cytoskeletal remodelling in CCL3 and CXCL12 signalling in two 
leukemic and carcinoma cell lines: THP-1 and MCF-7 cells respectively. The 
CHO-CCR5 cell line was used to additionally characterise the CCL3-CCR5 
signalling axis. 
This chapter began by exploring the role of two known regulators of F-actin 
remodelling Arp2/3 and DOCK1/2/5 (using CK666 and CPYPP respectively) 
as well as microtubule stabilisation (Taxol) in the increase of intracellular 
calcium downstream of CXCR4 and CCR1/5 activation. From the findings 
relating to F-actin remodelling, DOCK1/2/5 was identified as being involved in 
the intracellular calcium signalling of CCL3 and CXCL12 in both THP-1 and 
MCF-7 cells, whilst Arp2/3 was more important for chemokine intracellular 
calcium signalling in MCF-7 rather than THP-1 cells (figures 5.1 and 5.2). 
DOCK1/2/5 and Arp2/3 belong to the same signalling axis: DOCK1/2/5-Rac-
WAVE2-Arp2/3 and neither have been directly implicated in intracellular 
calcium signalling before. Research from the Mueller lab has shown that Rac 
is not essential for CCL3 and CXCL12 increases in intracellular calcium in 
THP-1 cells [346]. For MCF-7 cells the role of Rac in chemokine intracellular 
calcium signalling has not yet been defined. As such it is possible that MCF-7 
cells utilize the DOCK1/2/5-Rac-WAVE2-Arp2/3 signalling axis for CCL3 and 
CXCL12 increases in intracellular calcium. Whereas for THP-1 cells the data 
would suggest that DOCK1/2/5 activates an alternative pathway independent 
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of Rac and Arp2/3 for intracellular calcium signalling (figure 5.24). Rac is 
currently the only known effector downstream of DOCK1/2/5 activity and as 
such an alternative pathway is completely unknown.  
 
Figure 5.24. Current model of the DOCK1/2/5-Rac-WAVE-Arp2/3 pathway 
in the intracellular calcium signalling of CCL3 and CXCL12 in MCF-7 and 
THP-1 cells. DOCK1/2/5 is important for chemokine intracellular calcium 
signalling in both THP-1 and MCF-7 cells. Whereas Arp2/3s role in chemokine 
intracellular calcium signalling was important for MCF-7 cells only. Neither Rac 
nor Arp2/3 are important for chemokine induced increases in intracellular 
calcium in THP-1 cells. In THP-1 cells neither CCL3 nor CXCL12 appear to 
rely on intracellular calcium signalling for cell migration. WAVEs role in the 
intracellular calcium signalling of chemokines in MCF-7 and THP-1 cells is 
unknown. Whilst the importance of Rac in chemokine intracellular calcium 
signalling and the role of this calcium signalling for MCF-7 cell migration has 
not been determined. Faded arrows and objects indicate that they are not 
important for the signalling pathway.  
 
DOCK1/2/5 and Arp2/3 both regulate F-actin formation, therefore it is possible 
that changes in the F-actin cytoskeleton could contribute to intracellular 
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calcium signalling. Several studies have identified the involvement of F-actin 
in the increase of intracellular calcium in neurons [556], T-cells [557] and 
platelets [558]. Furthermore, upstream modulators of F-actin assembly such 
as WAVE2 and DOCK7 (a member of the related DOCK subfamily C and 
regulator of both Cdc42 and Rac) have also been implicated in increases in 
intracellular calcium [559, 560]. However the exact mechanisms behind F-actin 
mediated increase in intracellular calcium remains unclear.  
One proposed model is that the actin cytoskeleton is involved in the direct 
coupling of the ER membrane to the calcium channels present on the plasma 
membrane to induce an influx of calcium into the cell [558]. As the intracellular 
calcium measurement experiments were performed in the presence of CaCl2, 
the possibility of extracellular calcium as a source of, or some of the 
intracellular calcium flux observed cannot be excluded. Alternatively, F-actin is 
also associated with the recycling of chemokine receptors following activation 
[561]. Therefore F-actin perturbation could lead to less receptor recycling and 
thus a lower cell surface expression thereby reducing the levels of intracellular 
calcium signalling. Due to the fast kinetics of intracellular calcium signalling (70 
secs) it is more likely that the down regulation of the chemokine receptor would 
have occurred during the 30 mins pretreatment time with either CK666 or 
CPYPP. Although this would need to be confirmed using flow cytometry. 
In CHO-CCR5 cells, CK666 treatment showed a trend towards enhancing 
CCL3 intracellular calcium signalling, which although not significant with 
Dunnett's multiple comparisons test did show a significance with the Fischer’s 
LSD Test (figure 5.3). Previous studies in CHO-CCR5 cells have shown 
showed that F-actin destruction using Cytochalasin D blocked CCR5 
internalisation [184] and enhanced β-arrestin clustering [562] following CCL3 
and CCL5 stimulation respectively. However, treatment with Cytochalasin D 
on CHO-CCR5 cells had no effect on CCL3 intracellular calcium signalling 
[184] nor β-arrestin recruitment [562], suggesting that the actin cytoskeleton is 
not essential for receptor desensitization. Whether this is also the case for 
Arp2/3 remains to be determined but it could be possible that Arp2/3 blockade 
does not completely disturb the actin cytoskeleton in a similar fashion to 
Cytochalasin D. 
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Besides the actin cytoskeleton, the role of the microtubules in chemokine 
signalling was also explored. Using Taxol, microtubule stabilisation was shown 
to attenuate CXCL12 increases in intracellular calcium in MCF-7 cells (figure 
5.1 c and d). Whereas using nocodazole to disrupt microtubule polymerisation 
had no such effect on CXCL12 intracellular calcium signalling in MCF-7 cells 
(figure 5.4). Together these results would imply that microtubule stabilisation 
specifically effects the increase in intracellular calcium of CXCL12 in MCF-7 
cells. However to truly determine the involvement of microtubule turnover for 
chemokine intracellular calcium signalling, a microtubule stain of MCF-7 cells 
would need to be performed to confirm the microtubule depolymerisation and 
stabilisation activities of nocodazole and Taxol respectively.  
To further explore the functionality of DOCK1/2/5, Arp2/3 and microtubule 
stabilisation on cell migration the effects of CPYPP, CK666 and Taxol were 
assessed on the chemotaxis of Jurkat cells towards CXCL12, as well as in 
THP-1 cells with CPYPP. From these experiments DOCK1/2/5 was shown to 
be essential for CXCL12 chemotaxis in Jurkat cells but not in THP-1 cells 
(figures 5.9-5.11). For Jurkat chemotaxis CPYPP had an IC50 of 11.72 μM, 
which was comparable to the IC50 of 22.8 ± 2.4 μM for the inhibition of DOCK2 
guanine nucleotide exchange activity by CPYPP within a cell-free assay [408].   
As DOCK1/2/5 was shown to be important for CXCL12 intracellular calcium 
signalling but most likely not for THP-1 chemotaxis. This suggests that THP-1 
chemotaxis may not be reliant on intracellular calcium signalling, which has 
been similarly reported for the chemotaxis of THP-1 cells towards CCL3 [480]. 
Whether intracellular calcium signalling is important for Jurkat chemotaxis to 
CXCL12 is unclear due to the difficulties in reliably measuring intracellular 
calcium levels. However one way this could be investigated is by using 
Xestospongin C to block IP3 activation during chemokine stimulated 
chemotaxis. Additionally, intracellular calcium imaging of individual Jurkat cells 
could also be performed to accurately model intracellular calcium signalling as 
demonstrated in Tomilin VN et al. (2016) [563].  
To further elucidate the signalling axis involved in CXCL12 chemotaxis of 
Jurkat cells, Rac, Src and PLC and were targeted alongside DOCK1/2/5 to see 
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if any of the compounds had a synergistic inhibition on cell migration. 
Unfortunately, besides CPYPP none of the compounds showed any sign of 
inhibition and thus these results provided no further insight into the 
downstream signalling pathway (figure 5.12). The likely explanation for this 
outcome was that the concentrations used for Bosutinib (Src inhibitor) and 
U73122 (PLC inhibitor) were too low to block any cell migration.  
In Mills S.C et al. (2018), EHT 1864 (100 nM) was able to inhibit around 50% 
of CXCL12 chemotaxis in Jurkat cells [346]. This may suggest that only a 
subpopulation of Jurkat cells use Rac for CXCL12 induced migration. From the 
results presented in this chapter the Jurkats had a chemotactic response of 
33.2 x104 per mL-1 towards CXCL12 compared to 80 x104 per mL-1 for Mills 
S.C et al. (2018). Therefore perhaps a greater window of difference in the cell 
migration between CXCL12 treatment and the basal was required to detect 
EHT1864 (100 nM) inhibition. 
Based on emerging evidence from both Mills S.C et al. (2018) and the results 
from the chemotaxis assays performed in this chapter, a hypothetical model of 
the DOCK1/2/5-Rac-WAVE-Arp2/3 signalling axis in Jurkat and THP-1 
chemotaxis towards CXCL12 has been proposed (see figure 5.25). 
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Figure 5.25. Current model of CXCL12 chemotaxis in Jurkat and THP-1 
cells.  In Jurkat cells CXCL12 activates DOCK1/2/5 and Rac but not Arp2/3 or 
microtubule turnover for chemotaxis. In THP-1 cells CXCL12 activates only 
Rac for chemotaxis. The role of WAVE in CXCL12 chemotaxis is currently 
unknown whilst the importance of Arp2/3 and microtubule turnover for CXCL12 
chemotaxis in THP-1 cells was not established. Faded arrows and objects 
indicate that they are not important for the signalling pathway.  
 
PC-3 cells are known to express DOCK2, however, DOCK2 was shown not to 
be important for CXCL13-CXCR5 cell invasion [564].  Whether this is also true 
for CXCL12-CXCR4 signalling or DOCK1/5 is not known. Therefore the effects 
of CPYPP and CK666 on PC-3 cell velocity in response to CXCL12 was 
assessed. From this time lapse experiment no clear role for DOCK1/2/5 or 
Arp2/3 on PC-3 cellular velocity was identified, with CPYPP displaying 
evidence of cytotoxicity. Furthermore treatment with CXCL12 showed no 
significant increase in PC-3 cellular speed over 10 hrs. This suggests that 
CXCL12-CXCR4 signalling does not influence PC-3 cellular speed. 
Finally, to further probe the molecular mechanisms involved in CCL3 
elongation of CHO-CCR5 cells, known F-actin regulators Rac and ROCK were 
blocked with EHT-1684 and Y27362 respectively. Neither inhibitor showed any 
   
 
220 
 
significant effect on cell morphology indicating that CCL3 elongation of CHO-
CCR5 cells was not dependent on either Rac or ROCK activation (figures 5.16 
and 5.18). As a control both compounds were tested on PC-3 cells stimulated 
with CXCL12 with the results showing no significant effect on cellular 
morphology (figures 5.19-5.21). However, PC-3 cells treated with Y27632 
exhibited a more spindly morphology (figure 5.22) which has also been 
observed by another study on melanoma cells [565]. This observation in PC-3 
cells indicates that the Y27632 is active and identifies an importance of ROCK 
for cellular shape. 
 
5.13 Conclusion 
The main findings from this chapter were also follows: 
 DOCK 1/2/5 is important for the downstream signalling of CCL3 and 
CXCL12 in both THP-1 and MCF-7 cells and furthermore cell specific 
for CXCL12 chemotaxis in Jurkat cells. 
 
 Arp2/3 is involved in the downstream signalling of CCL3 and CXCL12 
in MCF-7 cells. 
 
 Microtubule stabilisation blocks CXCL12 intracellular calcium signalling 
in MCF-7 cells.  
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Chapter 6  Final Discussion 
  
The overall aim of this thesis was to identify alternative and viable therapeutic 
targets to block chemokine associated cancer progression. Consequently in 
this chapter the identification of suitable chemokine signalling axis for blocking 
carcinoma metastasis will be discussed first before proceeding to highlight 
potential therapeutic targets downstream of chemokine G-protein signalling 
and upstream of cytoskeleton remodelling. Furthermore the impact of biased 
signalling on the therapeutic targeting of the chemokine signalling network will 
be discussed, before concluding with future work. 
 
6.1 Chapter 3. Chemokine signalling pathways involved in 
carcinoma metastasis 
To identify the involvement of different chemokines signalling axis in 
carcinoma metastasis a screen comprised of seven different chemokines 
CCL23, CCL2, CCL3, CCL4, CCL8, CXCL9 and CXCL12 was devised. The 
effects of these chemokines were assessed in the wound healing assay of 
breast (MCF-7 and MDA-MB-231), pancreatic (MIA PaCa-2) and prostate 
cancer (PC-3) cell types as a model for cancer metastasis. From the screen, 
two chemokines CCL3 and CCL2 were implicated in the migration of MCF-7 
and PC-3 cells respectively. As both chemokines had been previously 
identified as promoters of cellular migration in their respective cell type [278, 
346, 437, 441] neither can be considered a novel target.   
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6.1.1 CCL2-CCR2 signalling axis 
The CCL2-CCR2 signalling axis is one of the better studied chemokine 
signalling pathways in cancer and is particularly well known for its association 
with prostate cancer [278, 279, 287]. Due to preclinical success in targeting 
the CCL2-CCR2 signalling axis, two antibodies carlumab and MLN1202 were 
developed and underwent clinical trials to target CCL2 and CCR2 respectively 
[307, 308]. Carlumab has been involved in three clinical trials, one in 
combination with docetaxel to treat patients with prostate metastasis and two 
for advanced solid tumours. Unfortunately carlumab demonstrated no 
significant anti-tumour efficacy in both trials perhaps in part due to a lack of 
robust reduction in the CCL2 levels in patients [307, 308, 310]. MLN1202 on 
the other hand showed potentially promising results with 14% of patients 
displaying lower levels of the bone metastasis marker N-telopeptide however 
its efficacy has not been disclosed (Trial registration ID: NCT01015560) [262].  
There is a wealth of preclinical evidence and clear interest in targeting CCL2-
CCR2 signalling especially for prostate cancer. However current approaches 
have not been proven to be beneficial in the clinic [310]. The identification of 
CCL2s role in PC-3 scratch closure could offer the opportunity to interrogate 
the downstream pathway further to discover alternative therapeutic 
candidates. Nonetheless due to the unreliability and variability with the wound 
healing assay this approach could not be used for compound screening with 
the PC-3 cells. Also the lack of detectable chemotaxis and increases in 
intracellular calcium of PC-3 cells in response to CCL2 stimulation prevented 
the use of the transwell migration and intracellular calcium flux assays as 
alternative methods for characterising the downstream signalling pathway. 
Therefore there is still a need for robust and sensitive methods to detect 
chemokine induced migration. Recently implemented cell migration assays 
within the Mueller lab such as the time-lapse, Boyden chamber and OrisTM 
assays have shown some encouraging results with PC-3 cells for detecting 
CXCL8 and CXCL12 induced migration. Therefore these assays could also be 
applied to CCL2 for mapping the downstream signalling pathway. 
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6.1.2 CCL3-CCR1/5 signalling axis 
CCL3 was also identified from the screen as a promoter of MCF-7 scratch 
closure. At least two other cell migration studies have also shown that CCL3 
can induce migration in MCF-7 cells [346, 437]. Besides these studies CCL3s 
role in breast cancer has not been heavily explored although some clinical data 
from breast cancer patients has shown that breast cancers display elevated 
levels of CCL3 mRNA  [566, 567] and that these levels correlated with the 
infiltration of pre-metastatic mononuclear inflammatory cells to the primary 
tumour site [568]. Also in a murine triple negative breast cancer model, CCL3 
was shown to be upregulated in the more invasive cells leading the authors to 
propose a role for CCL3 in breast cancer cell migration [569]. Most of these 
studies have only demonstrated an association between CCL3 and breast 
cancer progression rather than a direct role. Hence CCL3 is a poorly validated 
target for treating breast cancer [566-569].  
To further probe the molecular mechanism of CCL3 in MCF-7 scratch closure 
two of its known cognate receptors CCR1 and CCR5 were targeted using 
J113863 and maraviroc respectively. From this experiment the results showed 
that CCL3 activates both CCR1 and CCR5 to promote MCF-7 scratch closure. 
This provides direct evidence of the involvement of receptor redundancy in 
chemokine induced cancer cell migration and further supports the idea that 
chemokine signalling redundancy is an obstacle for blocking cancer 
metastasis [320].    
Maraviroc has been widely used to establish CCR5s involvement in breast 
cancer metastasis. In these studies mararviroc was shown to successfully 
block MDA-MB-231 bone [570], lung [338, 571], lymph node [571] and thoracic 
[572] metastasis in vivo, with the latter enhanced when combined with an IL-6 
neutralising antibody. Two studies also observed a reduction in MCF-7 and 
MDA-MB-231 cell migration with maraviroc in vitro, although this was in the 
absence of CCL5 [338, 570]. This suggests that maraviroc could have an off-
target or non-specific inhibitory effect on cell migration, although this was not 
observed in the wound healing assay experiments presented in this thesis. 
Interestingly in MDA-MB-231 cells only maraviroc was able to block CCL5 
induced migration whilst the CCR1 and CCR3 antagonists BX513 and 
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SB328437 respectively had no effect [571]. This would imply that there is no 
functional redundancy amongst CCR1, CCR3 and CCR5 in the migration of 
MDA-MB-231 cells in response to CCL5. Which is a contrast to what was 
observed in MCF-7 cells where CCL3 was able to signal via both CCR1 and 
CCR5 to promote scratch closure. This suggests that the importance of a 
chemokine receptor could be dependent on either the chemokine and/or cell 
type and therefore highlights a need for appropriate target selection to 
successfully block chemokine signalling. 
In instances of chemokine receptor redundancy dual inhibitors remain a 
possible option such as Repaxirin, which is a small molecule inhibitor for both 
CXCR1 and CXCR2 and is currently in clinical trial in combination with Taxol 
for treating triple negative breast cancer (Trial registration ID: NCT02370238). 
Nonetheless whether this approach is effective at a clinical level remains to be 
determined. However due to the structural homology of the CCR1 and CCR5 
transmembrane domain (79%) dual inhibition remains a viable option. 
Although it is important to note that CCR1 and CCR5 are also structurally 
similar to CCR3 (85%) and CCR2 (91%) according to their respective pairwise 
sequence alignments [573]. Thus a dual inhibitor for CCR1 and CCR5 would 
also likely target CCR2 and CCR3 which may reduce its in vivo efficacy and/or 
possibly lead to unwanted side effects. 
Consequently the downstream molecular mechanisms of CCL3 signalling in 
MCF-7 cells was investigated by using the wound healing and intracellular 
calcium flux assays as both showed evidence of reproducibility from chapter 
3. 
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6.2 Identifying novel CCL3 and CXCL12 downstream targets 
in cancer 
As previously mentioned, the downstream signalling pathway could serve as 
an alternative strategy to target the chemokine receptor as many proteins 
downstream of receptor activation are frequently dysregulated in a variety of 
different cancers [224-226, 352]. 
To delineate the chemokine and cell specific molecular pathways a 
pharmacological based approach was used to assess the particular 
importance of FAK, PLC, PI3K, c-Raf, Src/Syk, DOCK1/2/5, Arp2/3 and 
microtubule turnover in both cellular signalling and migration. This broad 
spectrum of proteins allows the possibility to build a detailed map of the 
downstream signalling pathway which can then be compared with previous 
research findings. This then enables the development of more accurate 
hypothetical models of the cellular signalling pathway. 
 
6.2.1 Chapter 4. Targeting downstream effectors of G-protein 
signalling 
6.2.1.1 FAK 
Amongst the downstream effectors of G-protein signalling FAK was the most 
comprehensively characterised through the use of three separate inhibitors 
FAK14, PF562271 and Masitinib. Using these inhibitors FAK was only shown 
to be important for CXCL12 intracellular calcium signalling and not chemotaxis 
in THP-1 cells. Similarly neither CCL3 nor CXCL12 induced chemotaxis of 
THP-1 or Jurkat cells relied on FAK for migration respectively. This indicates 
that under these conditions FAK is not an appropriate target for leukemic cell 
invasion.  
FAK is better known for its involvement in carcinoma metastasis than 
leukemogenesis, nevertheless its overexpression has been observed in AML 
(42% of cases) [574] as well as for B-cell but not T-cell leukaemia [575]. In 
THP-1 cells one study showed that FAK was expressed at a low basal level 
but that it was constitutively activated [576]. For chemokine driven 
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leukemogenesis extremely little is known about FAKs role, however an siRNA 
knockdown of FAK was shown to abolish CXCL12 chemotaxis in the B-cell 
leukaemia cell line Reh [498]. Based on this and evidence from this thesis, it 
is perhaps likely that FAKs role in CXCL12 chemotaxis is specific for B-cell but 
not T-cell leukaemia.  
Although FAK was not important for THP-1 chemotaxis, FAK was shown to be 
critical for the mobilisation of calcium from the intracellular stores in response 
to CXCL12. As only cell migration was investigated, FAKs involvement in 
intracellular calcium signalling may indicate that FAK could be important for 
other cell responses e.g. cell survival or adhesion instead. Therefore FAK 
could still present itself as a therapeutic target for CXCL12 signalling in AML 
but just not within the context of cell migration. 
 
6.2.1.2 PI3K 
Besides FAK, a pharmacological blockade of PI3K using both LY294002 and 
AS6052425 was also performed on the intracellular calcium flux assays of 
CCL3 and CXCL12 in PC-3, MCF-7 and THP-1 cells, with no evidence of PI3K 
being important for intracellular calcium signalling. Furthermore, investigations 
into CCL3 and CXCL12 induced migration of MCF-7 and Jurkat cells 
respectively also suggested that PI3Ks role was dispensable. Similar results 
to these have also been reported for CCL3 and CXCL12 induced migration of 
THP-1 and MCF-7 cells respectively [340, 347]. However for the chemotaxis 
of THP-1 cells towards CXCL12, PI3K was shown to play a role [577]. In 
contrast to this thesis, results from Mills S.C et al. (2016) did observe a 
moderate reduction in Jurkat chemotaxis towards CXCL12 using either 
LY294002 or PI3K siRNA [340]. Based on the findings from this thesis and 
those from other studies it appears that PI3K is not an ideal target for blocking 
CCL3 or CXCL12 induced migration of MCF-7 cells, as well as, for CCL3 and 
CXCL12 chemotaxis in THP-1 and Jurkat cells respectively. 
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6.2.1.3 c-Raf and Src/Syk 
Both c-Raf and Src/Syk were discovered to be specific for the downstream 
release of calcium from the intracellular stores of MCF-7 cells in response to 
CXCL12. As no effect on CXCL12 intracellular calcium signalling was 
observed in the presence of PLC and Gβγ inhibitors, this implies that the Gαi-
Syk/Src-c-Raf pathway could be utilised by CXCL12 instead of Gβγ-PLC to 
increase intracellular calcium. Unfortunately due to no reliable model for 
detecting CXCL12 induced migration of MCF-7 cells being available at the time 
the involvement of Src/Syk and c-Raf in MCF-7 cell migration was not 
investigated. Nonetheless previous research has implicated both Src and Raf 
in CXCL12 scratch closure of MCF-7 cells using bosutinib and L779450 
respectively [340]. Due to the concentration used for MNS (10 μM) it is highly 
likely that inhibition observed on CXCL12 intracellular calcium signalling could 
be attributed to Syk (IC50 = 2.5 µM) rather than Src (IC50 = 29.3 µM).  
MCF-7 cells are known to express Syk, with Syk considered as a negative 
regulator of MCF-7 basal migration by phosphorylating PI3K which disrupts 
PI3K-IκBα binding and subsequently the secretion of urokinase-type 
plasminogen activator [578]. In Jurkat cells neither c-Raf nor Src/Syk were 
shown to be essential for CXCL12 chemotaxis. From the wider literature Syk’s 
role in chemokine migration is unknown, although one study confirmed the 
activation of Syk for CCL4 signalling in ‘normal’ T-cells however no 
functionality was established [579]. Whether Syk would also play a tumour 
suppressive role in CXCL12 driven migration in MCF-7 cells remains to be 
established although it is involved in the downstream signalling. Evidence 
already suggests that Raf is involved in CXCL12 induced migration of MCF-7 
cells and thus establishing whether this role would be specific to c-Raf would 
be worthwhile studying. 
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6.2.1.4 PLC 
In THP-1 cells PLC was shown to be pivotal for chemokine intracellular calcium 
signalling, as well as specific to CCL3 increases in intracellular calcium in 
MCF-7 cells. This suggests that PLC could be of critical importance for 
regulating chemokine related cellular responses in THP-1 cells, as well as, for 
CCL3 in MCF-7 cells. However establishing any meaningful functionality of 
PLC in any of these cancer cells using U73122 is impossible due to its high 
level of cellular cytotoxicity. As such other approaches are needed to better 
understand PLCs role, however, there is a current lack of specific PLC 
inhibitors available on the market. One alternative is edelfosine, which has 
been shown to block PLC activity in Swiss 3T3 fibroblasts and BG1 ovarian 
adenocarcinoma cells [580], although it is also an agonist for platelet-activating 
factor receptor and therefore cannot be used in cells expressing this receptor 
[581, 582]. Hence there is a great need to develop suitable inhibitors not only 
for investigating PLCs role in both in vitro and in vivo disease models, but also 
for potential drug development as PLC overexpression has been identified in 
breast and colorectal cancers [350, 351].  
 
6.2.2 Chapter 5. Targeting downstream modulators of the 
cellular cytoskeleton 
6.2.2.1 Arp2/3 
Using the small molecule inhibitor CK666, a significant role for Arp2/3 in CCL3 
and CXCL12 intracellular calcium signalling was identified for MCF-7 but not 
THP-1 cells. This indicates that Arp2/3s role in chemokine intracellular calcium 
signalling is specific to MCF-7 cells. In Jurkat and PC-3 cells, CXCL12 induced 
chemotaxis and cellular velocity was independent of Arp2/3 activity. 
Consequently for Jurkat cells, Arp2/3 is not a suitable target for blocking 
migration. However for PC-3 cells only the cellular speed and not chemotaxis 
was assessed, therefore Arp2/3 could still be important for migration. 
Nonetheless, Arp2/3 overexpression has not yet been established in prostate 
cancer, whilst another Arp2/3 inhibitor CK-0944636 was shown to actually 
   
 
229 
 
enhance PC-3 basal migration [583]. This is therefore an area of cancer 
research that still requires further investigation.  
In breast cancer, coexpression of Arp2/3 and WAVE2 is associated with a 
poorer prognosis in breast cancer patients [540]. Which based on the 
intracellular calcium measurement experiments in MCF-7 cells suggests that 
Arp2/3 merits further validation as a therapeutic target against chemokine 
induced migration of breast cancer cells. 
 
6.2.2.2 DOCK A subfamily 
Using CPYPP to target the downstream signalling of CCL3 and CXCL12, the 
results showed that members of the DOCK A subfamily: DOCK1, DOCK2 and 
DOCK5 were important for the intracellular calcium signalling of both 
chemokines in THP-1 and MCF-7 cells. Furthermore for the CXCL12 
chemotaxis of Jurkat cells the pharmacological blockade of DOCK1/2/5 
completely abolished migration and thus could serve as a therapeutic target 
for T-cell leukaemia. Preliminary experiments with THP-1 cells did not show a 
similar effect suggesting that DOCK1/2/5s role in intracellular calcium 
signalling could involve other cellular responses aside from chemotaxis. In 
Jurkat cells CXCL12 driven chemotaxis is known to utilise Rac [346] and 
therefore to confirm DOCK1/2/5s involvement in CXCL12 chemotaxis the 
inhibition of Rac activation in the presence of CPYPP would need to be 
confirmed. 
DOCK1/2/5 has already been shown to be important for the chemotaxis of 
neutrophils [548] and normal T-cells and B-cells [408]. Indicating that 
DOCK1/2/5 has a general importance for the immune system function. As such 
its pharmacological blockade would most likely impair normal leukocyte 
migration and thus would need to be taken into consideration if used as a form 
of cancer treatment especially for solid tumours. 
In PC-3 cells no significant inhibition on cellular speed in the presence of 
CXCL12 was detected following DOCK1/2/5 blockade. Although evidence of 
cellular cytotoxicity was observed instead which may limit the use of CPYPP 
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as a research tool in PC-3 cells. DOCK2 overexpression has been identified 
in PC-3 cells suggesting it may have a functional importance although this was 
not shown to be the case for CXCL13-CXCR5 migration [512]. Therefore the 
importance of DOCK1/2/5 in prostate cancer progression is still not clear. 
In breast cancer DOCK1 mRNA expression was associated with a poor 
prognosis for both the HER-2 and basal subtypes but not for the luminal 
oestrogen positive subtype [584]. In the triple negative breast cancer model, 
MDA-MB-231 cells, DOCK5 expression was shown to be associated with lung 
metastasis [585] whilst a regulator of DOCK1 activity, ELMO, was implicated 
in CXCL12 induced breast cancer cell migration with the same study 
confirming ELMO-DOCK1 binding [344]. Consequently the DOCK A subfamily 
are an emerging therapeutic candidate for breast cancer. Hence the role of 
DOCK1/2/5 in both CCL3 and CXCL12 intracellular calcium signalling in MCF-
7 cells supports the need for further research in this area. 
 
6.2.2.3 Microtubule turnover 
The effects of microtubule stabilisation on cancer cellular proliferation using 
Taxol is widely known [586, 587]. However with regards to cell migration, in 
particular chemokine facilitated migration the role of the microtubules is less 
clear. To look further into this the effects of Taxol on CXCL12 chemotaxis in 
Jurkat cells was studied though no inhibition was shown. For intracellular 
calcium signalling Taxols effects were shown to be both chemokine and cell 
specific. For MCF-7 cells Taxol blocked CXCL12 intracellular calcium 
signalling. The mechanism behind Taxols effect on intracellular calcium 
signalling are unclear but the use of nocodazole suggested that it was specific 
to microtubule stabilisation. The functional significance of Taxol on CXCL12 
signalling pathway in MCF-7 cells was not established.  
Taxol is widely used for cancer treatment and hence improved understanding 
of its impact on cancer cell behaviour would help better tailor its use in cancer 
patients to either enhance its therapeutic benefit or minimize any deleterious 
effects. 
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6.3 Biased signalling in chemokine mediate cancer 
progression 
As part of the research of this thesis a large range of chemokine ligands and 
cell types were used. This provided the opportunity to identify any signalling 
biases involved within the chemokine signalling network. For cancer cell 
migration there appeared to a potential ligand bias towards CCL3 in MCF-7 
cells and CCL2 in PC-3 cells. Also CCL3 indicated a cell specific bias for MCF-
7 over PC-3 cells in the wound healing assay. When assessing for chemokine 
receptor activation by measuring increases in intracellular calcium, chemokine 
efficacy levels showed no particular correlation to scratch closure. Suggesting 
that differing efficacy levels between the chemokines may not be the only 
contributing factor towards variations in the migratory response. When 
investigating the downstream signalling pathway ligand biases were observed 
within the MCF-7 cells regarding the importance of PLC for CCL3 but not CCL5 
or CCL23 intracellular calcium signalling despite sharing the same receptors.  
This research highlights that although the CCR1/5 receptors exhibit some 
functional redundancy in MCF-7 cell migration there appears to be a potential 
bias towards CCL3 agonism. Interestingly this is somewhat reflected in the 
downstream signalling with CCL3-CCR1/5 signalling relying on PLC activation 
for intracellular calcium signalling and therefore could be important for cell 
migration. In both THP-1 and MCF- cells CCL3-CCR1/5 intracellular calcium 
signalling involved PLC and DOCK1/2/5 whereas Arp2/3 was important in 
MCF-7 cells only. Furthermore in PC-3 cells CCL3 intracellular calcium 
signalling did not rely on PLC. Therefore despite some overlapping molecular 
mechanisms the downstream signalling pathway of CCL3-CCR1/5 is cell type 
dependent (figure 6.1). 
Besides the CCR1/5 receptors the downstream signalling events of CXCL12-
CXCR4 were also investigated in different cell types. As CXCR4 has one 
known cognate ligand (CXCL12) no ligand bias could be explored. Similar to 
CCL3 signalling, CXCL12 also utilised DOCK1/2/5 for mediating increases in 
intracellular calcium in both MCF-7 and THP-1 cells as well as having a specific 
bias towards Arp2/3 in MCF-7 cells and an absence of PLC importance for PC-
3 intracellular calcium signalling. Furthermore there were substantial 
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differences between CXCL12-CXCR4 downstream signalling in MCF-7 and 
THP-1 cells. Whilst MCF-7 cells utilised Src/Syk, c-Raf and the microtubules 
to increase intracellular calcium, the THP-1 cells relied on FAK and PLC 
instead. DOCK1/2/5 also appeared to be cell specific for Jurkat CXCL12 
chemotaxis .This indicates that there is a significant level of diversity within 
CXCL12-CXCR4 downstream signalling in different cell types (figure 6.1). 
 
 
Figure 6.1. Overview and hypothetical model of the main cellular 
signalling pathways investigated in this thesis: CXCL12-CXCR4 and 
CCL3-CCR1/5 in MCF-7 and THP-1 cells. Black arrows corresponds to signal 
transduction whilst red arrow corresponds to hypothetical signalling pathways.  
Dotted lines divide both the THP-1 and MCF-7 cellular models, as well as, the 
CXCL12-CXCR4 and CCL3-CCR1/5 signalling axis. All proteins with faded 
lettering and colour were identified as not important for the respective 
signalling pathways studied in this thesis. 
 
In conclusion although chemokines can be promiscuous in their receptor 
binding, their downstream cellular responses can vary substantially depending 
on the chemokine ligand and cell type. Identifying key cell and chemokine 
specific molecular mechanisms which are important for the progression of 
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cancer would allow the opportunity to develop and tailor more targeted 
treatments for patients diagnosed with higher stage tumours (such as stages 
II and III) to either prevent or slow down metastasis.  
 
6.4 Future work 
One of the biggest drawbacks with the research output from this thesis was 
the lack of characterisation of the downstream signalling pathway for 
carcinoma cell migration. Therefore future work would be to use alternative cell 
migration assays such as OrisTM, Boyden chamber and possibly time lapse to 
establish the functional importance of microtubule stabilisation, Arp2/3, 
DOCK1/2/5 and FAK on the migration of MCF-7, PC-3 and MDA-MB-231 cells 
in response to CCL3, CCL2 and CXCL12. 
Although the effects of CK666 and Taxol were assessed on CCL3 and 
CXCL12 intracellular calcium signalling in THP-1 cells their impact on 
chemotaxis was not established. In THP-1 cells, intracellular calcium signalling 
appears not be essential for chemotaxis and as such the roles of Arp2/3 and 
the microtubules may still be important for CCL3 and CXCL12 migration. 
DOCK1/2/5 is a potential therapeutic target for the chemotaxis of T-cell 
leukaemia towards CXCL12. Therefore further target validation of this pathway 
would be worthwhile. One of the most important controls would be to confirm 
that the blockade of DOCK1/2/5 with CPYPP inhibits Rac activation. Following 
this experiment it would be interesting to further interrogate the importance of 
the different DOCK A subfamily members using siRNA, peptides or more 
specific DOCK1 and DOCK5 small molecule inhibitors such as TBOPP [588] 
and C21 [589, 590] respectively. This would allow the elucidation of more 
subtle differences in the downstream signalling pathway and increase the 
reliability of the findings presented in this thesis, particularly as CPYPP has 
been shown to inhibit another GEF, TRIO [589]. Finally, DOCK1/2/5 are known 
to be regulated by ELMO and Crk [591, 592], thus exploring the upstream 
molecular mechanisms could identify additional therapeutic targets which 
could be beneficial should resistance to DOCK1/2/5 blockade arise. 
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Abbreviations 
 
7TM  Seven transmembrane α-helical domain   
AC   Adenylate cyclase 
ACKR  Atypical chemokine receptor 
AML  Acute myeloid leukaemia 
ANOVA Analysis of variance   
Arp2/3 Actin-related protein 2/3   
AS  Agarose spot assay 
ATP  Adenosine triphosphate 
BSA  Bovine serum albumin  
cAMP  Cyclic adenosine monophosphate 
CCL  CC motif chemokine ligand 
CCR  CC motif chemokine receptor 
CD8 T  CD8 T-cells 
CHO  Chinese hamster ovaries 
CTCF  Corrected total cellular fluorescence 
CTX  Chemotaxis assay 
CXCL  CXC motif chemokine ligand  
CXCR  CXC motif chemokine receptor 
DAG  Diacyl-glycerol 
DMEM Dulbecco's Modified Eagle's Medium  
DMSO Dimethyl sulfoxide     
DOCK  Dedicator of cytokinesis  
EC50 Concentration of agonist which produces 50% of the maximal 
biological response  
ECM Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid  
ELMO  Engulfment and Cell Motility 
ENA/VASP Enabled/Vasodilator-stimulated phosphoprotein   
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ER  Endoplasmic reticulum   
ERK  Extracellular signal-regulated kinase  
ETOH  Ethanol  
FA  Focal adhesion 
FAK  Focal adhesion kinase 
FAT  Focal adhesion targeting 
F-actin Actin filaments  
FCS  Foetal calf serum 
FDA  Food and Drug Administration  
FERM  Four-point-one, Ezrin, Radixin, Moesin  
GAG  Glycosaminoglycans 
GAP  GTPase activating protein   
GDP  Guanosine diphosphate 
GTP  Guanosine triphosphate  
GEF  Guanine nucleotide exchange factors 
GFP  Green fluorescent protein    
GPCR  G-protein coupled receptor  
Grb  Growth factor receptor-bound protein 2 
Grk  G-protein receptor kinase   
GTP  Guanosine triphosphate 
G-actin Globular actin 
G-protein Guanine nucleotide-binding protein 
HEK  Human embryonic kidney  
HTLA HEK293 cell line stably expressing a tTA-dependent luciferase 
reporter and a β-arrestin2-TEV fusion gene 
IC50 Inhibitor concentration which inhibits 50% of the maximal 
biological response   
IP3   Inositol 1,4,5-triphosphate  
IRSp53 Insulin receptor tyrosine kinase substrate p53  
JAK-STAT Janus-family tyrosine kinase-Signal transducer and activator of 
transcription 
JNK  Jun N-terminal kinase 
   
 
236 
 
Kd Concentration of ligand which occupies 50% of the total binding 
sites at equilibrium 
Ki  Inhibitor constant 
Lyn  Lck/Yes novel tyrosine kinase 
MAPK  Mitogen activated protein kinases   
MCF-7 Michigan Cancer Foundation-7 
MDSC Myeloid derived suppressor cells  
MEK  MAPK ERK kinase 
MLCK  Myosin light chain kinase 
MM  Multiple myeloma 
NK  Natural killer cells 
PBS  Phosphate buffered saline 
PC-3  Prostate cancer-3  
PH  Pleckstrin Homology   
PI3K  Phosphoinositide 3-kinases 
PIP2  Phosphatidylinositol 4,5-biphosphate 
PIP3  Phosphatidylinositol (3,4,5)-trisphosphate 
PKC  Protein kinase C 
PLC  Phospholipase C  
PLC2  Phospholipase Cβ2  
PTEN  Phosphatase and tensin homolog  
PTX  Pertussis toxin 
Raf  Rapidly Accelerated Fibrosarcoma     
ROCK  Rho-associated protein kinase 
RPM  revolutions per minute  
RPMI  Roswell Park Memorial Institute 
SH2  Src-homology-2 
SH3  Src-homology-3 
SRC  Sarcoma non-receptor tyrosine kinase 
SYK  Spleen tyrosine kinase 
TAM  Tumour associated macrophages 
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Th1  Type 1 helper T-cells 
Treg  Regulatory T-cells 
WASP Wiskott–Aldrich Syndrome protein  
WAVE WASP-family verprolin-homologous 
WH   Wound healing assay 
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